US6165210A - Self-expandable helical intravascular stent and stent-graft - Google Patents

Self-expandable helical intravascular stent and stent-graft Download PDF

Info

Publication number
US6165210A
US6165210A US08/221,815 US22181594A US6165210A US 6165210 A US6165210 A US 6165210A US 22181594 A US22181594 A US 22181594A US 6165210 A US6165210 A US 6165210A
Authority
US
United States
Prior art keywords
stent
graft
collagen
self
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/221,815
Inventor
Lilip Lau
Charles Thomas Maroney
William M. Hartigan
Woonza Rhee
Kimberly A. McCullough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WL Gore and Associates Inc
Original Assignee
Gore Enterprise Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gore Enterprise Holdings Inc filed Critical Gore Enterprise Holdings Inc
Priority to US08/221,815 priority Critical patent/US6165210A/en
Assigned to PROGRAFT MEDICAL, INC. reassignment PROGRAFT MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARTIGAN, WILLIAM M., LAU, LILIP, MARONEY, CHARLES THOMAS
Assigned to PROGRAFT MEDICAL, INC. reassignment PROGRAFT MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCCULLOUGH, KIMBERLY A., RHEE, WOONZA
Priority to US08/411,452 priority patent/US5876432A/en
Priority to EP00101667A priority patent/EP0997115B1/en
Priority to AT95916920T priority patent/ATE244543T1/en
Priority to AU23795/95A priority patent/AU690684B2/en
Priority to DE69532049T priority patent/DE69532049T2/en
Priority to CA002261941A priority patent/CA2261941C/en
Priority to EP95916920A priority patent/EP0754016B1/en
Priority to AT00101667T priority patent/ATE252872T1/en
Priority to CA2499888A priority patent/CA2499888C/en
Priority to DE69531239T priority patent/DE69531239T2/en
Priority to PCT/US1995/004000 priority patent/WO1995026695A2/en
Priority to CA002157575A priority patent/CA2157575C/en
Priority to JP07524227A priority patent/JP3129327B2/en
Assigned to GORE ENTERPRISE HOLDINGS, INC. reassignment GORE ENTERPRISE HOLDINGS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PROGRAFT MEDICAL, INC.
Publication of US6165210A publication Critical patent/US6165210A/en
Application granted granted Critical
Assigned to W. L. GORE & ASSOCIATES, INC. reassignment W. L. GORE & ASSOCIATES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GORE ENTERPRISE HOLDINGS, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/88Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • A61F2/07Stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/92Stents in the form of a rolled-up sheet expanding after insertion into the vessel, e.g. with a spiral shape in cross-section
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/89Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/3008Properties of materials and coating materials radio-opaque, e.g. radio-opaque markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30092Properties of materials and coating materials using shape memory or superelastic materials, e.g. nitinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30316The prosthesis having different structural features at different locations within the same prosthesis; Connections between prosthetic parts; Special structural features of bone or joint prostheses not otherwise provided for
    • A61F2002/30329Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2002/30462Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements retained or tied with a rope, string, thread, wire or cable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2002/9505Instruments specially adapted for placement or removal of stents or stent-grafts having retaining means other than an outer sleeve, e.g. male-female connector between stent and instrument
    • A61F2002/9511Instruments specially adapted for placement or removal of stents or stent-grafts having retaining means other than an outer sleeve, e.g. male-female connector between stent and instrument the retaining means being filaments or wires
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0019Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at only one temperature whilst inside or touching the human body, e.g. constrained in a non-operative shape during surgery, another temperature only occurring before the operation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0075Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • A61F2230/0073Quadric-shaped
    • A61F2230/0078Quadric-shaped hyperboloidal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0096Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
    • A61F2250/0098Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers

Definitions

  • the device is a foldable stent or stent-graft which may be percutaneously delivered with (or on) an endovascular catheter or via surgical techniques or using other suitable techniques and then expanded.
  • the expandable stent structure utilizes at least one torsional member having an undulating shape which is helically deployed to form the generally cylindrical shape eventually deployed as the stent.
  • the helical winding desirably is aligned to allow those undulating shapes in adjacent turns of the helix to be in phase.
  • the adjacent undulating shapes maybe held in that phased relationship using a flexible linkage, often made of a polymeric material.
  • the stent may be flared on at least one of its ends to promote smooth blood flow at that flare and to assure that the stent will remain in the chosen position within the body.
  • the stent's configuration allows it to be folded or otherwise compressed to a very small diameter prior to deployment without changing the length of the stent.
  • the stent may be expanded with the use of an installation device such as a balloon but preferably is used as a self-expandable device.
  • the graft component cooperating with the stent is tubular and preferably is a blood-compatible collagenous material which may, if desired, be reinforced with fibers.
  • the tubular graft member may be cast onto or otherwise attached or imbedded into the stent structure to form an integral stent-graft.
  • the graft may be used to maintain the generally cylindrical shape of the stent, e.g., without the use of the flexible linkage.
  • the stent-graft may be used to reinforce vascular irregularities, to provide a smooth nonthrombogenic interior vascular surface for diseased areas in blood vessels, or to increase blood flow past a diseased area of a vessel by mechanically improving the interior surface of the vessel.
  • the inventive stent-graft is especially suitable for use within smaller vessels between 2 mm and 6 mm in diameter but is equally suitable for significantly larger vessels.
  • the invention provides a stent which is self-expanding, kink-resistant, easily bent along its longitudinal axis, does not change its length during that expansion, and is able to provide collapsible support for otherwise frangible graft material.
  • the invention involves procedures for deploying stents or stent-grafts which have been folded, bound, or otherwise collapsed to significantly smaller diameters for insertion into a human or animal body.
  • the stent When used with super-elastic alloys, the stent may be collapsed at a convenient temperature either above or, preferably, below the transition temperature of the alloy.
  • the deployment procedures may involve the use of an outer sleeve to maintain the stent or stent-graft at a reduced diameter or may involve a "slip-line” or "tether wire” to hold and then to release the device.
  • vascular aneurysms or of vessel walls which have been thinned or thickened by disease has traditionally been done via surgical bypassing with vascular grafts.
  • Shortcomings of this procedure include the morbidity and mortality associated with surgery, long recovery times after surgery, and the high incidence of repeat intervention needed due to limitations of the graft or of the procedure.
  • Vessels thickened by disease are currently sometimes treated less invasively with intraluminal stents that mechanically hold these vessels open either subsequent to or as an adjunct to a balloon angioplasty procedure.
  • Shortcomings of current stents include the use of highly thrombogenic materials (stainless steels, tantalum, ELGILOY) which are exposed to blood, the general failure of these materials to attract and support functional endothelium, the irregular stent/vessel surface that causes unnatural blood flow patterns, and the mismatch of compliance and flexibility between the vessel and the stent.
  • Important to this invention is the use of less invasive intraluminal delivery and, in a preferred aspect, placement of a nonthrombogenic blood-carrying conduit having a smooth inner lumen which will endothelize.
  • the most preferred biologic material chosen for the inner layer of the inventive stent-graft is collagen-based and, although it will fold with ease, is otherwise fairly frangible or inelastic in that it has very little ability to stretch. Mounting a collagen tube on the outside of or as a part of a balloon-expandable stent will usually cause the tube to tear. Mounting such a tube on the inside of a balloon expandable stent will yield a torn irregular surface exposed to blood flow.
  • balloon expandable devices that rely upon plastic deformation of the stent to achieve a deployed shape are subject to abrupt closure as a result of trauma when the devices are placed in a vessel near the skin surface or across a joint or ligament.
  • Those self-expanding stents which rely on the shortening of the stent upon radial expansion at deployment may cause vessel tearing problems similar to those observed with the use of balloon expandable devices.
  • stents which shorten during deployment are also subject to deployment placement inaccuracies.
  • stent-graft which is self-expanding, which does not shorten upon delivery, which has excellent longitudinal flexibility, which has high radial compliance to the vessel lumen, exposes the blood to a smooth, nonthrombogenic surface capable of supporting endothelium growth.
  • the inventive device may be delivered in a reduced diameter and expanded to maintain the patency of any conduit or lumen in the body.
  • An area in which the inventive stent and stent graft is particularly beneficial is in the scaffolding of atherosclerotic lesions in the cardiovascular system to establish vessel patency, prevention of thrombosis, and the further prevention of restenosis after angioplasty.
  • the smooth, continuous surface provided by the preferred tubular collagen-based inner conduit of our invention provides a hemodynamically superior surface for blood flow.
  • the non-thrombogenic properties of the most preferred sPEG collagen surface results in a less thrombogenic device. Clinically, this allows a more moderate anti-coagulation regimen to be used. As a result, the rate of bleeding complications, a major drawback associated with stenting, may be reduced.
  • the absence of gaps or holes in the graft structure between stent struts of our invention allows the tacking of both large and small flaps and tears in the vessel wall. These flaps disrupt blood flow and attract thrombus.
  • the disruption of the natural anti-thrombotic covering of endothelium only worsens the condition.
  • the collagen-based barrier we interpose between blood and a disrupted or injured portion of the vessel wall serves to mask injured intimal or medial layers from blood, thereby preventing thrombus formation and intimal proliferation which may lead to restenosis.
  • the presence of our inventive stent-graft acts as a mechanical barrier preventing tissue from proliferating into or impinging the lumen.
  • the nature of the bioactivity of the collagen and the smoother flow characteristics at the blood-contacting surface are conducive to endothelial cell attachment and growth thereby assuring the long-term blood compatibility of the device.
  • our inventive linked helical stent structure provides a good combination of radial strength and flexibility.
  • the structure is also radially resilient. It can be completely crushed or flattened and yet spring open again once the obstructive loading is removed. This ability is important for use in exposed portions of the body around the peripheral vasculature or around joints.
  • the stent-graft can sustain a crushing traumatic blow or compression from the bending of a joint and still return to the open configuration once the load is removed.
  • the self-expansion mechanism eliminates the need for a balloon catheter and the associated balloon rupture problems often associated with balloons.
  • the absence of the bulk of the balloon allows a smaller delivery profile to be achieved.
  • this stent-graft maintains a constant length throughout the expansion process.
  • the stent-graft would not have some of the positioning problems associated with other many self-expanding stents.
  • our self-expanding design eliminates the need for special long balloons or repositioning of the balloon between inflations in order to expand the entire length of the stent.
  • the collagen-based material supports endothelial cell growth and is incorporated into the surrounding tissue.
  • the device has several advantages.
  • the wall thickness may be made thinner than either of current stents and expanded PTFE or of tanned, reinforced biologic grafts.
  • a thin-walled graft results in a larger opening for blood flow resulting in improved hemodynamics.
  • the impermeability of the preferred stent-graft makes it suitable for shunting and thereby hydraulically isolating aneurysms.
  • the expansile properties derived from the stent structure provide a secure anchor to the vessel wall.
  • the stent reinforces the collagen-based tubular component, much as a fiber tube would, increasing the burst strength of the stent-graft.
  • the organic composition of the preferred collagen-based materials used in the inventive stent-graft provides an excellent vehicle for localized drug delivery, certainly better than metallic stents or other synthetic grafts.
  • therapeutic compounds may be linked, conjugated, or otherwise more easily bound to the organic graft material (or to its substituents, such as PEG) than to the surface of a metallic structure. Localized drug delivery is desirable in preventing thrombosis or restenosis.
  • Therapeutically effective doses may be administered to the target area without systemic concentrations being raised. This capability is of great benefit in reducing side-effects and complications associated with drug therapy.
  • Therapeutic agents may be delivered out of the collagen matrix by diffusion. Alternatively, these agents may be bound temporarily or permanently on the collagen surfaces. Different agents may be bound on the inner and outer surfaces to achieve different therapeutic ends. For example, a drug to minimize thrombus formation might be appropriate for the inside, blood-contacting surface, while a drug which would inhibit smooth muscle cell proliferation might be appropriate on the outer surface. Drugs can be chemically or physically bound to either the sPEG or the collagen molecules.
  • the stents currently described in the open literature include a wide variety of different shapes.
  • Wallsten U.S. Pat. No. 4,655,771
  • a vascular prosthesis for transluminal implantation which is made up of a flexible tubular body having a diameter that is varied by adjusting the axial separation of the two ends of the body relative to each other.
  • the body appears to be a woven device produced of various plastics or stainless steel.
  • Porter, U.S. Pat. No. 5,064,435 suggests a stent made up of two or more tubular stent segments which may be deployed together so to produce a single axial length by a provision of overlapping areas. This concept is to permit the use of segments of known length, which, when deployed, may be used together in overlapping fashion additively to provide a stent of significant length.
  • U.S. Pat. No. 5,151,105 discloses an implantable, collapsible tubular sleeve apparently of an outer band and an inner spring used to maintain the sleeve in a deployed condition.
  • Gianturco in U.S. Pat. Nos. 4,580,568 and 5,035,706, describes stents formed of stainless steel wire arranged in a closed zigzag pattern.
  • the stents are compressible to a reduced diameter for insertion into and removal from a body passageway.
  • the stents appear to be introduced into the selected sites by discharge of the collapsed zigzag wire configuration from the tip of a catheter.
  • Wiktor U.S. Pat. Nos. 4,649,992, 4,886,062, 4,969,458, and 5,133,732, shows wire stent designs using variously a zigzag design or, in the case of Wiktor '458, a helix which winds back upon itself.
  • Wiktor '062 suggests use of a wire component made of a low-memory metal such as copper, titanium or gold. These stents are to be implanted using a balloon and expanded radially for plastic deformation of the metal.
  • Wiktor '458 is similarly made of low-memory alloy and is to be plastically deformed upon its expansion on an angioplasty balloon.
  • Wiktor '732 teaches the use of a longitudinal wire welded to each turn of the helically wound zig-zag wire which is said to prevent the longitudinal expansion of the stent during deployment.
  • a further variation of the described stent includes a hook in each turn of the helix which loops over a turn in an adjacent turn.
  • Neither variation includes a flexible linkage between adjacent helices.
  • W093/13825 shows a self-expanding stent similar to the Gianturco, Wolff, and Wiktor designs, formed of stainless steel wire, which is built into an elongated zig-zag pattern, and helically wound about a central axis to form a tubular shape interconnected with a filament.
  • the bends of the helix each have small loops or "eyes" at their apexes which are inter-connected with a filament.
  • the stent appears to be a design that axially expands during compression and may tear attached grafts because of the relative change in position of the arms of the zig-zag during compression of the stent.
  • MacGregor, U.S. Pat. No. 5,015,253 shows a tubular non-woven stent made up of a pair of helical members which appear to be wound using opposite "handedness".
  • the stent helices desirably are joined or secured at the various points where they cross.
  • Pinchuk in U.S. Pat. Nos. 5,019,090, 5,092,877, and 5,163,958, suggests a spring stent which appears to circumferentially and helically wind about as it is finally deployed except, perhaps, at the very end link of the stent.
  • the Pinchuk '958 patent further suggests the use of a pyrolytic carbon layer on the surface of the stent to present a porous surface of improved antithrombogenic properties.
  • the helices are not linked to each other, however, nor is there any suggestion that the helices be maintained in a specific relationship either as deployed or as kept in the catheter prior to deployment.
  • U.S. Pat. No. 5,123,917, to Lee suggests an expandable vascular graft having a flexible cylindrical inner tubing and a number of "scaffold members" which are expandable, ring-like, and provide circumferential rigidity to the graft.
  • the scaffold members are deployed by deforming them beyond their plastic limit using, e.g., an angioplasty balloon.
  • Jervis in U.S. Pat. Nos. 4,665,906 and 5,067,957, describes the use of shape memory alloys having stress-induced martensite properties in medical devices which are implantable or, at least, introduced into the human body.
  • Ersek shows a system for deploying expandable, plastically deformable stents of metal mesh having an attached graft through the use of an expansion tool.
  • Palmaz describes a variety of expandable intraluminal vascular grafts in a sequence of patents: U.S. Pat. Nos. 4,733,665; 4,739,762; 4,776,337; and 5,102,417.
  • the Palmaz '665 patent suggests grafts (which also function as stents) that are expanded using angioplasty balloons.
  • the grafts are variously a wire mesh tube or of a plurality of thin bars fixedly secured to each other.
  • the devices are installed, e.g., using an angioplasty balloon and consequently are not seen to be self-expanding.
  • Palmaz '762 and '337 patents appear to suggest the use of thin-walled, biologically inert materials on the outer periphery of the earlier-described stents.
  • Palmaz '417 patent describes the use of multiple stent sections each flexibly connected to its neighbor.
  • the stent is a sequence of ring-like members formed of links spaced apart along the graft.
  • the graft is a sleeve of a material such as expanded a polyfluorocarbon, e.g., GORETEX or IMPRAGRAFT.
  • Schatz U.S. Pat. No. 5,195,984, shows an expandable intraluminal stent and graft related in concept to the Palmaz patents discussed above.
  • Schatz discusses, in addition, the use of flexibly-connecting vascular grafts which contain several of the Palmaz stent rings to allow flexibility of the overall structure in following curving body lumen.
  • Cragg European Patent Application 0,556,850 discloses an intraluminal stent made up of a continuous helix of zig-zag wire and having loops at each apex of the zig-zags. Those loops on the adjacent apexes are individually tied together to form diamond-shaped openings among the wires.
  • the stent may be made of a metal such as nitinol (col. 3, lines 15-25 and col. 4, lines 42+) and may be associated with a "polytetrafluoroethylene (PTFE), dacron, or any other suitable biocompatible material". Those biocompatible materials may be inside the stent (col. 3, lines 52+) or outside the stent (col. 4, lines 6+).
  • Medell U.S. Pat. No. 3,479,670, discloses a tubular prothesis adapted to be placed permanently in the human body. It is made of framework or support of a synthetic fiber such as DACRON or TEFLON. The tube is said to be made more resistant to collapse by fusing a helix of a polypropylene monofilament to its exterior. The reinforced fabric tube is then coated with a layer of collagen or gelatin to render the tubing (to be used as an esophageal graft) impermeable to bacteria or fluids.
  • DACRON DACRON
  • TEFLON synthetic fiber
  • the reinforced fabric tube is then coated with a layer of collagen or gelatin to render the tubing (to be used as an esophageal graft) impermeable to bacteria or fluids.
  • Braun in U.S. Pat. No. 3,562,820, shows a biological prosthesis manufactured by applying onto a support of a biological tissue (such as serosa taken from cattle intestine) a collagen fiber paste. The procedure is repeated using multiple layers of biological tissue and collagen fiber paste until a multi-layer structure of the desired wall thicknesses is produced. The prosthesis is then dried and removed prior to use.
  • a biological tissue such as serosa taken from cattle intestine
  • Dardik et al U.S. Pat. No. 3,974,526 shows a procedure for producing tubular prostheses for use in vascular reconstructive surgeries.
  • the prosthesis is made from the umbilical cord of a newly born infant. It is washed with a solution of 1 percent hydrogen peroxide and rinsed with Ringer's lactate solution. It is then immersed in a hyaluronidase solution to dissolve the hyaluronic acid coating found in the umbilical cord. The vessels are then separated from the cord and their natural interior valving removed by use of a tapered mandrel. The vessels are then tanned with glutaraldehyde. A polyester mesh support is applied to the graft for added support and strength.
  • Ketharanathan U.S. Pat. No. 4,319,363, shows a procedure for producing a vascular prosthesis suitable for use as a surgical graft.
  • the prosthesis is produced by implanting a rod or tube in a living host and allowing collagenous tissue to grow on the rod or tube in the form of coherent tubular wall.
  • the collagenous implant is removed from the rod or tube and tanned in glutaraldehyde. The prosthesis is then ready for use.
  • Bell, U.S. Pat. No. 4,546,500 teaches a method for making a vessel prosthesis by incorporating a contractile agent such as smooth muscle cells or platelets into a collagen lattice and contracting the lattice around a inner core. After the structure has set, additional layers are applied in a similar fashion. A plastic mesh sleeve is desirably sandwiched between the layers or imbedded within the structure to provide some measure of elasticity.
  • a contractile agent such as smooth muscle cells or platelets
  • Hoffman Jr. et al U.S. Pat. No. 4,842,575, shows a collagen impregnated synthetic vascular graft. It is made of a synthetic graft substrate and a cross-linked collagen fibril. It is formed by depositing a aqueous slurry of collagen fibrils into the lumen of the graft and massaging the slurry into the pore structure of the substrate to assure intimate admixture in the interior. Repeated applications and massaging and drying is said further to reduce the porosity of the graft.
  • Kreamer U.S. Pat. No. 4,740,207, suggests a intraluminal graft made of a semi-rigid resilient tube, open along a seam extending from one end to the other, which is expanded within the vessel and which resulting larger diameter is maintained by use of a ledge at the longitudinal seam for catching the opposite side of the seam on the expanded graft.
  • the hinge regions include torsion members allowing a significant portion of the folding displacement to be re-oriented parallel to the longitudinal axis of the stent-graft.
  • the act of folding, crushing, or otherwise elastically deforming the stent creates a significant torsional component in the torsion members which component is parallel to that longitudinal axis.
  • the hinges are positioned at least at each of the fold points around the circumference of the stent where folding is desired.
  • the length of the torsion members is increased to lower the amount of twist per length or strain imposed.
  • the orientation of the torsion members is such that their length does not increase the circumference of the device. None of the cited references suggest such a device.
  • This invention is a foldable stent or stent-graft which may be percutaneously delivered through or over an endovascular catheter or using surgical techniques or other appropriate methodologies.
  • the expandable stent structure utilizes torsional regions which allow it to be folded to a very small diameter prior to deployment.
  • the torsional members have an undulating shape which may be helically deployed to form the stent's cylindrical shape.
  • the undulating shape may be aligned to allow the shapes in adjacent turns of the helix to be in phase.
  • the undulating shapes may be generally V-shaped, U-shaped, sinusoidal, or ovoid. Adjacent undulating shapes may be held in the phased relationship using a flexible linkage, often made of a polymeric material.
  • the undulating torsional members do not have any means at (or near) the apex of the undulating shapes which would tend to constrict the movement of the flexible linkage during compression of the stent.
  • the stent may be expanded with the use of an installation device such as an angioplasty balloon but preferably is used as a self-expandable device.
  • the graft component used to complement the stent is tubular and preferably is of a collagenous material which may, if desired, be reinforced with fibers of random, woven, roving, or wound configurations.
  • the tubular member preferably is cast onto or otherwise attached or imbedded into the stent structure.
  • the stent-graft may be used to reinforce vascular irregularities and provide a smooth interior vascular surface, particularly within smaller vessels.
  • FIGS. 1A, 1B, 1C, 1D, and 1E are plan views of an unrolled stent form making up the invention.
  • FIG. 2 is a side view of the inventive stent.
  • FIG. 3 is a close-up of a portion of the inventive stent shown in FIG. 2.
  • FIG. 4 is an abstracted portion of an inventive stent and shows the concept of torsion on a portion of the stent.
  • FIG. 5 is a side view of the inventive stent showing a variation having flared ends.
  • FIGS. 6, 7, and 8 show plan views of an unrolled stent produced from flat stock.
  • FIG. 9 shows a quarter view of the rolled stent using the flat stock pattern shown in FIG. 7.
  • FIG. 10 shows a device for winding and heat treating a stent made according to the invention.
  • FIGS. 11 and 12 show end view cutaways of stent-grafts made according to the invention.
  • FIGS. 13A, 13C, and 13E show procedures for folding the stent-grafts made according to the invention.
  • FIGS. 13B, 13D, and 13F show the corresponding folded stent-grafts.
  • FIGS. 14A-14C show a schematic procedure for deploying the inventive stent-grafts using an external sleeve.
  • FIGS. 15A and 16A show front quarter views of folded stents or stent-grafts held in that folded position by a tether wire.
  • FIGS. 15B, 15C, 16B, and 16C show end views of the folded stent and of the open stent shown respectively in FIGS. 15A and 16A.
  • FIGS. 17A-17C show a schematic procedure for deploying the inventive stent-grafts (as shown in FIGS. 15A-15C and 16A-16C) using a tether wire.
  • this invention is variously an expandable stent, a stent-graft, and a fiber reinforced stent-graft.
  • the stent-graft may be a combination of several components: a thin-walled tube generally coaxial with the stent, the expandable stent structure, and an optional network of fibers used to reinforce the tubular component.
  • the stent and the optional reinforcing fibers are desirably imbedded in the wall of the thin-walled tube.
  • the expandable stent structure is a cylindrical body produced of a helically placed (wound or otherwise preformed) torsion member having an undulating or serpentine shape.
  • the undulations When the undulating torsion member is formed into the cylinder, the undulations may be aligned so that they are "in phase” with each other.
  • the undulations are desirably linked, typically with a flexible linkage of a suitable polymeric material, to maintain the phased relationship of the undulations during compression and deployment.
  • These stent configurations are exceptionally kink-resistant and flexible, particularly when flexed along the longitudinal axis of the stent.
  • the stent When the stent is used in a reinforced stent-graft, that is to say: the stent is included into a thin-walled tube having reinforcing fibers, the fibers may be formed into a network, such as a tubular mesh.
  • the stent-graft may be delivered percutaneously through the vasculature after having been folded to a reduced diameter. Once reaching the intended delivery site, it is expanded to form a lining on the vessel wall.
  • Methods of delivering the various devices using a percutaneous catheter either with or without expansion aids are also an aspect of the invention.
  • vascular grafts usually do not have the stiffness or strength by themselves both to stay open against the radial inward loads found in those vessels and to prevent their slippage from the chosen deployment site.
  • a radially rigid stent structure may be incorporated into the stent-graft.
  • Our stent is constructed of a reasonably high strength material, i.e., one which is resistant to plastic deformation when stressed.
  • the structure is typically from one of three sources: 1.) a wire form in which a wire is first formed into an undulating shape and the resulting undulating shape is helically wound to form a cylinder, 2.) an appropriate shape is formed from a flat stock and wound into a cylinder, and 3.) a length of tubing is formed into an appropriate shape.
  • These stent structures are typically oriented coaxially with the tubular graft component. The stent structures may be placed on the outer surface or the inner surface of the tubular member although it is preferable that the stent be imbedded in the graft tubing wall for ease of integration with the tubing and to prevent the stent's exposure to blood.
  • the stent structure have the strength and flexibility to tack the graft tubing firmly and conformally against the vessel wall.
  • the stent material should have a high strength-to-volume ratio.
  • a percutaneously delivered stent-graft must expand from a reduced diameter, necessary for delivery, to a larger deployed diameter.
  • the diameters of these devices obviously vary with the size of the body lumen into which they are placed.
  • the stents of this invention may range in size (for neurological applications) from 2.0 mm in diameter to 30 mm in diameter (for placement in the aorta). A range of about 2.0 mm to 6.5 mm (perhaps to 10.0 mm) is believed to be desirable.
  • expansion ratios of 2:1 or more are required.
  • These stents are capable of expansion ratios of up to 5:1 for larger diameter stents.
  • Typical expansion ratios for use with the stents and stent-grafts of the invention typically are in the range of about 2:1 to about 4:1 although the invention is not so limited.
  • the thickness of the stent materials obviously varies with the size (or diameter) of the stent and the ultimate required yield strength of the folded stent. These values are further dependent upon the selected materials of construction.
  • Wire used in these variations are typically of stronger alloys, e.g., nitinol and stronger spring stainless steels, and have diameters of about 0.002 inches to 0.005 inches.
  • the appropriate diameter for the stent wire may be somewhat larger, e.g., 0.005 to 0.020 inches.
  • thicknesses of about 0.002 inches to 0.005 inches is usually sufficient.
  • the appropriate thickness for the stent flat stock may be somewhat thicker, e.g., 0.005 to 0.020 inches.
  • the stent-graft is fabricated in the expanded configuration. In order to reduce its diameter for delivery the stent-graft would be folded along its length, similar to the way in which a PCTA balloon would be folded. It is desirable, when using super-elastic alloys which are also have temperature-memory characteristics, to reduce the diameter of the stent at a temperature below the transition-temperature of the alloys. Often the phase of the alloy at the lower temperature is somewhat more workable and easily formed. The temperature of deployment is desirably above the transition temperature to allow use of the super-elastic properties of the alloy.
  • FIG. 1A is a plan view of an isolated section of the inventive stent device and is intended both to identify a variation of the invention and to provide conventions for naming the components of the torsion member (100).
  • FIG. 1A shows, in plan view, an undulating torsion member (100) formed from a wire stock into a U-shape.
  • a torsion pair (102) is made up of an end member (104) and two adjacent torsion lengths (106).
  • each torsion length (106) will be a component to each of its adjacent torsion pairs (102).
  • the U-shaped torsion pair (102) may be characterized by the fact that the adjacent torsion lengths are generally parallel to each other prior to formation into the stent.
  • the stents of this invention use undulating torsion members which are "open” or “unconfined” at their apex or end member (104).
  • "open” or “unconfined” we mean that the apex or end member (104) does not have any means in that apex which would tend to inhibit the movement of the flexible linkage (discussed below) down between the arms or torsion lengths (106) of the torsion pair (102).
  • FIG. 1B shows another variation of the invention having a sinusoidal shaped torsion member (108).
  • the adjacent torsion lengths (110) are not parallel and the wire forms an approximate sine shape before being formed into a cylinder.
  • FIG. 1C shows a variation of the invention having an ovoid shaped torsion member (112).
  • the adjacent torsion lengths (114) are again not parallel.
  • the wire forms an approximate open-ended oval with each torsion pair (116) before being formed into a cylinder.
  • FIG. 1D shows another variation of the invention having a V-shaped torsion member (118).
  • the adjacent torsion lengths (120) form a relatively sharp angle at the torsion end (122) shape before being formed into a cylinder.
  • FIG. 1E shows a variation of the invention in which adjacent torsion members on the stent (117) have differing amplitude.
  • the peaks of the high amplitude torsion members (119) may be lined up “out of phase” or “peak to peak” with short amplitude (121) or high amplitude torsion members in the adjacent turn of the helix or may be positioned “in phase” similar to those discussed with regard to FIG. 2 below.
  • FIGS. 1A-1E are exceptionally kink-resistant and flexible when flexed along the longitudinal axis of the stent.
  • a section of the torsion member found on one of FIGS. 1A-1D would be helically wound about a form of an appropriate size so that the end members (e.g., 104 in FIG. 1A) would be centered between the end members of the torsion member on an adjacent turn of the helix. This is said to be “in phase”. "Out of phase” would be the instance in which the adjacent members meet directly, i.e., end member-to-end member. In any event, once so aligned, the phasic relationship may be stabilized by weaving a flexible linkage through the end members from one turn of the helix to the next.
  • FIG. 2 shows a side view of a typical stent (122) made according to this invention including the phased relationship of the helical turns of the stent and the flexible linkage (124).
  • FIG. 3 shows a close-up of the FIG. 2 stent and depicts the phased relationship (within box A) and shows in detail a typical way in which the flexible linkage (124) is looped through the various end members (104) to maintain the phased relationship. It may be noted that the flexible linkage (124) is free to move away from the apex at the end members (104) without constraint.
  • the stent may be folded in some fashion (as will be discussed below) for deployment. During the step of folding, the stent undergoes a transformation.
  • FIG. 4 shows an isolated torsion pair (102).
  • the end member When the torsion pair (102) undergoes a flexing in the amount of ⁇ °, the end member will flex some amount ⁇ °, torsion length (130) will undertake a twist of ⁇ °, and torsion length (132) will undertake a twist opposite of that found in torsion length (130) in the amount of ⁇ °.
  • the amounts of angular torsion found in the torsion lengths (130 and 132) will not necessarily be equal because the torsion lengths are not necessarily at the same angle to the longitudinal axis of the stent.
  • the torsion pair (102) undergoes a significant of flexing as the stent is folded or compressed in some fashion.
  • the flexing provides a twist to the torsion lengths (103 and 132), a significant portion of which is generally parallel to the longitudinal axis of the stent. It is this significant imposed longitudinal torsion which forms an important concept of the inventive stent.
  • the stent is folded longitudinally and is delivered through the lumen of the catheter in such a way that it is self-restoring once it has been introduced to the selected body lumen site.
  • This stated desire is not to rule out the use of the inventive stent or stent-graft with a balloon or expander or other shape-restoring tool if so desired, but the design of the stent is meant to eliminate the need for (or, at least to minimize the need for) such expanding tools.
  • the inventive stent uses concepts which can be thought of as widely distributing and storing the force necessary to fold the tubular stent into a configuration which will fit through a diameter smaller than its relaxed outside diameter without inducing plastic deformation of the constituent metal or plastic and yet allowing those distributed forces to expand the stent upon deployment.
  • FIG. 5 shows, in side view, a variation of the inventive stent (140) made from wire having flares (142) at one or both ends.
  • the flaring provides a secure anchoring of the stent or stent-graft (140) against the vessel wall. This prevents the implant from migrating downstream.
  • the flaring provides a tight seal against the vessel so that the blood is channelled through the lumen rather than outside the graft.
  • the undulating structure may vary in spacing to allow the helix turns to maintain its phased relationship between turns of the helix and to conform to the discussion just above.
  • a flexible linkage between the contiguous helical turns may also be applied to at least a portion of the helices.
  • the stent structure may also be made by forming a desired structural pattern out of a flat sheet.
  • the sheet may then be rolled to form a tube.
  • FIGS. 6, 7, and 8 show plan views of torsion members (respectively 200, 202, and 204) which may be then rolled about an axis (206) to form a cylinder.
  • the end caps (208) may be aligned so that they are "out of phase”.
  • the flexible linkage (210) is then included to preserve the diameter of the stent.
  • the stent shown in FIG. 9 may be machined from tubing. If the chosen material in nitinol, careful control of temperature during the machining step may be had by EDM (electro-discharge-machining), laser cutting, chemical machining, or high pressure water cutting.
  • EDM electro-discharge-machining
  • laser cutting laser cutting
  • chemical machining chemical machining
  • high pressure water cutting high pressure water cutting
  • Nitinol is especially preferred because of its "super-elastic" or "pseudo-elastic" shape recovery properties, i.e., the ability to withstand a significant amount of bending and flexing and yet return to its original form without deformation.
  • These metals are characterized by their ability to be transformed from an austenitic crystal structure to a stress-induced martensitic structure at certain temperatures, and to return elastically to the austenitic shape when the stress is released.
  • These alternating crystalline structures provide the alloy with its super-elastic properties. These alloys are well known but are described in U.S. Pat. Nos. 3,174,851, 3,351,463, and 3,753,700.
  • nitinol will be nominally 50.6% ( ⁇ 0.2%) Ni with the remainder Ti.
  • Commercially available nitinol materials usually will be sequentially mixed, cast, formed, and separately cold-worked to 30-40%, annealed, and stretched. Nominal ultimate yield strength values for commercial nitinol are in the range of 30 psi and for Young's modulus are about 700 kBar.
  • Nitinol is further suitable because it has a relatively high strength to volume ratio. This allows the torsion members to be shorter than for less elastic metals.
  • the flexibility of the stent-graft is largely dictated by the length of the torsion member components in the stent structural component. The shorter the pitch of the device, the more flexible the stent-graft structure can be made. Materials other than nitinol are suitable. Spring tempered stainless steels and cobalt-chromium alloys such as ELGILOY are also suitable as are a wide variety of other known "super-elastic" alloys.
  • nitinol is preferred in this service because of its physical properties and its significant history in implantable medical devices, we also consider it also to be suitable for use as a stent because of its overall suitability with magnetic resonance imaging (MRI) technology.
  • MRI magnetic resonance imaging
  • thermotropic liquid crystal polymers are high molecular weight materials which can exist in a so-called “liquid crystalline state” where the material has some of the properties of a liquid (in that it can flow) but retains the long range molecular order of a crystal.
  • thermotropic refers to the class of LCP's which are formed by temperature adjustment. LCP's may be prepared from monomers such as p,p'-dihydroxy-polynuclear-aromatics or dicarboxy-polynuclear-aromatics.
  • the LCP's are easily formed and retain the necessary interpolymer attraction at room temperature to act as high strength plastic artifacts as are needed as a foldable stent. They are particularly suitable when augmented or filled with fibers such as those of the metals or alloys discussed below. It is to be noted that the fibers need not be linear but may have some preforming such as corrugations which add to the physical torsion enhancing abilities of the composite.
  • FIG. 10 shows a method for producing a stent of the configuration shown in FIG. 9. It may be used, of course, for producing a variety of other configurations shown herein.
  • a preformed strip (211) (preferably nitinol) is rolled onto a mandrel (213) having a channel defined by a thread (215).
  • the pitch of the strip (211) is selected using the criteria discussed above.
  • the pitch angle (215) shown is about 20° but is not critical to the operation of the invention.
  • the strip (211) is wound onto the mandrel (213) and the assembly is introduced into the outer sleeve (217), the strip (now in the shape of the stent) may then be annealed (or at least "heat set") to assist in maintaining the resulting stent in a useful shape.
  • nitinol devices may be heat treated for five minutes or less at temperatures of 500° C. without significant lessening of the superelastic properties. Said another way, heating super-elastic alloys must carried out with some care so as not to destroy or significantly lessen the super-elastic properties.
  • the flexible linkage between adjacent turns of the helix may be of any appropriate filamentary material which is blood compatible or biocompatible and sufficiently flexible to allow the stent to flex and not deform the stent upon folding.
  • the linkage may be a single or multiple strand wire (platinum, platinum/tungsten, gold, palladium, tantalum, stainless steel, etc.), much preferred is the use of polymeric biocompatible filaments.
  • Synthetic polymers such as polyethylene, polypropylene, polyurethane, polyglycolic acid, polyesters, polyamides, their mixtures, blends, copolymers, mixtures, blends and copolymers are suitable; preferred of this class are polyesters such as polyethylene terephthalate including DACRON and MYLAR and polyaramids such as KEVLAR, polyfluorocarbons such as polytetrafluoroethylene with and without copolymerized hexafluoropropylene (TEFLON or GORETEX), and porous or nonporous polyurethanes. Natural materials or materials based on natural sources such as collagen are especially preferred is this service.
  • the tubular component or member of the stent-graft may be made up of any material which is suitable for use as a graft in the chosen body lumen.
  • Many graft materials are known, particularly known are vascular graft materials.
  • natural material may be introduced onto the inner surface of the stent and fastened into place.
  • Synthetic polymers such as polyethylene, polypropylene, polyurethane, polyglycolic acid, polyesters, polyamides, their mixtures, blends, copolymers, mixtures, blends and copolymers are suitable; preferred of this class are polyesters such as polyethylene terephthalate including DACRON and MYLAR and polyaramids such as KEVLAR, polyfluorocarbons such as polytetrafluoroethylene with and without copolymerized hexafluoropropylene (TEFLON or GORETEX), and porous or nonporous polyurethanes. Highly preferred materials are certain collagen-based materials of COLLAGEN CORPORATION of Palo Alto, Calif.
  • the graft may adhere to or partially encapsulate or be cast about the stent when appropriate materials such as castable polyurethane or collagen-based materials are employed.
  • appropriate materials such as castable polyurethane or collagen-based materials are employed.
  • a highly preferred material is a collagen-based material described in U.S. Pat. No. 5,162,430, to Rhee et al, the entirety of which is incorporated by notice, or as described below.
  • Collagen is easily formed into thin-walled tubes which are limp, compliant, flexible, uniform, and have smooth surfaces.
  • the tubing walls may have a hydrated thickness of 0.001 to 0.020 inches (or to 0.100 inches in some cases) for efficacy. Other thicknesses may be used if specific goals are to be achieved.
  • the collagen tube acts as an intravascular blood conduit to line the interior surface of the blood vessel.
  • the preferred collagen composition used in this invention is a pharmaceutically acceptable non-immunogenic composition formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates.
  • Any type of collagen may be used including extracted and purified collagen including atelopeptide collagen which can be type I, type II or type III collagen.
  • the collagen may be extracted from various sources such as bovine hide and human placenta and may be fibrillar or non-fibrillar.
  • the synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000.
  • the compositions may incorporate other components such as biologically active materials.
  • the collagen-polymer conjugates generally contain large amounts of water when formed. The extruded materials may be dehydrated, resulting in a reasonably flexible material which can be readily stored.
  • collagen refers to all forms of collagen, including those which have been extracted, processed or otherwise modified. Preferred collagens are non-immunogenic and, if extracted from animals, are treated to remove the immunogenic telopeptide regions ("atelopeptide collagen"), are soluble, and may be in the fibrillar or non-fibrillar form. Type I collagen is best suited to most applications involving bone or cartilage repair. However, other forms of collagen are also useful in the practice of the invention, and are not excluded from consideration here. Collagen crosslinked using heat, radiation, or chemical agents such as glutaraldehyde may be conjugated with polymers as described herein to form particularly rigid compositions.
  • Collagen crosslinked using glutaraldehyde or other (nonpolymer) linking agents is referred to herein as "GAX", while collagen cross-linked using heat and/or radiation is termed "HRX.”
  • GX Collagen crosslinked using glutaraldehyde or other (nonpolymer) linking agents
  • HRX collagen cross-linked using heat and/or radiation
  • Collagen used in connection with the preferred embodiments of the invention is in a pharmaceutically pure form such that it can be incorporated into a body, human or otherwise, for the intended purpose.
  • synthetic hydrophilic polymer refers to a synthetic polymer having an average molecular weight and composition which renders the polymer essentially water-soluble.
  • Preferred polymers are highly pure or are purified to a highly pure state such that the polymer is, or is treated to become, pharmaceutically pure.
  • Most hydrophilic polymers can be rendered water-soluble by incorporating a sufficient number of oxygen (or, less frequently, nitrogen) atoms available for forming hydrogen bonds in aqueous solutions.
  • Preferred polymers are hydrophilic but not soluble.
  • Preferred hydrophilic polymers used herein include polyethylene glycol, polyoxyethylene, polymethylene glycol, polytrimethylene glycols, polyvinylpyrrolidones, and derivatives thereof.
  • the polymers can be linear or multiply branched and will not be substantially crosslinked.
  • Other suitable polymers include polyoxyethylene-polyoxypropylene block polymers and copolymers. Polyoxyethylene-polyoxypropylene block polymers having an ethylene diamine nucleus (and thus having four ends) are also available and may be used in the practice of the invention. Naturally occurring and/or biologically active polymers such as proteins, starch, cellulose, heparin, and the like are not generally desirable in this definition although they may be used. All suitable polymers will be non-toxic, non-inflammatory and non-immunogenic when used to form the desired composition, and will preferably be essentially non-degradable in vivo over a period of at least several months.
  • the hydrophilic polymer may increase the hydrophilicity of the collagen, but does not render it water-soluble.
  • Presently preferred hydrophilic polymers are mono-, di-, and multi-functional polyethylene glycols (PEG).
  • Monofunctional PEG has only one reactive hydroxy group, while difunctional PEG has reactive groups at each end.
  • Monofunctional PEG preferably has a weight average molecular weight between about 100 and about 15,000, more preferably between about 200 and about 8,000, and most preferably about 4,000.
  • Difunctional PEG preferably has a molecular weight of about 400 to about 40,000, more preferably about 3,000 to about 10,000.
  • Multi-functional PEG preferably has a molecular weight between about 3,000 and 100,000.
  • PEG can be rendered monofunctional by forming an alkylene ether at one end.
  • the alkylene ether may be any suitable alkoxy radical having 1-6 carbon atoms, for example, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, hexyloxy, and the like. Methoxy is presently preferred.
  • Difunctional PEG is provided by allowing a reactive hydroxy group at each end of the linear molecule. The reactive groups are preferably at the ends of the polymer, but may be provided along the length thereof.
  • collagen-polymer refers to collagen chemically conjugated to a synthetic hydrophilic polymer, within the meaning of this invention.
  • collagen-PEG or “PEG-collagen” denotes a composition within the most preferred aspect of the invention wherein collagen is chemically conjugated to PEG.
  • Collagen-dPEG refers to collagen chemically conjugated to difunctional PEG, wherein the collagen molecules are typically crosslinked.
  • Crosslinked collagen refers to collagen in which collagen molecules are linked by covalent bonds with polyfunctional (including difunctional) polymers.
  • Terms such as “GAX-dPEG” and “HRX-dPEG” indicate collagen crosslinked by both a difunctional hydrophilic polymer and a crosslinking agent such as glutaraldehyde or heat.
  • the polymer may be "chemically conjugated" to the collagen by means of a number of different types of chemical linkages. For example, the conjugation can be via an ester or urethane linkage, but is more preferably by means of an ether linkage. An ether linkage is preferred in that it can be formed without the use of toxic chemicals and is not readily susceptible to hydrolysis in vivo.
  • molecular weight refers to the weight average molecular weight of a number of molecules in any given sample, as commonly used in the art.
  • a sample of PEG 2,000 might contain a statistical mixture of polymer molecules ranging in weight from, for example, 1,500 to 2,500 daltons with one molecule differing slightly from the next over a range.
  • Specification of a range of molecular weight indicates that the average molecular weight may be any value between the limits specified, and may include molecules outside those limits.
  • a molecular weight range of about 800 to about 20,000 indicates an average molecular weight of at least about 800, ranging up to about 20 kDa.
  • available lysine residue refers to lysine side chains exposed on the outer surface of collagen molecules, which are positioned in a manner to allow reaction with activated PEG.
  • the number of available lysine residues may be determined by reaction with sodium 2,4,6-trinitrobenzenesulfonate (TNBS).
  • growth factor is used to describe biologically active molecules and active peptides (which may be naturally occurring or synthetic) which aid in healing or regrowth of normal tissue.
  • the function of growth factors is two-fold: 1) they can incite local cells to produce new collagen or tissue, or 2) they can attract cells to the site in need of correction.
  • growth factors may serve to encourage "biological anchoring" of the collagen graft implant within the host tissue.
  • the growth factors may either be admixed with the collagen-polymer conjugate or chemically coupled to the conjugate.
  • growth factors such as epidermal growth factor (EGF), transforming growth factor (TGF) alpha, TGF.sub. ⁇ : (including any combination of TGF.sub. ⁇ s), TGF.sub. ⁇ 1, TGF.sub. ⁇ 2, platelet derived growth factor (PDGF-AA, PDGF-AB, PDGF-BB), acidic fibroblast growth factor (FGF), basic FGF, connective tissue activating peptides (CTAP), ⁇ -thrombo-globulin, insulin-like growth factors, erythropoietin (EPO), nerve growth factor (NGF), bone morphogenic protein (BMP), osteogenic factors, and the like.
  • EGF epidermal growth factor
  • TGF transforming growth factor alpha
  • TGF.sub. ⁇ including any combination of TGF.sub. ⁇ s), TGF.sub. ⁇ 1, TGF.sub. ⁇ 2, platelet derived growth factor (PDGF-AA, PDGF-AB, PDGF-BB), acidic fibroblast growth factor (FGF),
  • Incorporation of growth factors can facilitate regrowth when the tubes are used in the treatment of defective or damaged channels.
  • one may chemically link the growth factors to the collagen-polymer composition by employing a suitable amount of multi-functional polymer molecules during synthesis.
  • the growth factors may then be attached to the free polymer ends by the same method used to attach PEG to collagen, or by any other suitable method.
  • By tethering growth factors to the outer and/or inner surface of the graft material the amount of grafts needed to carry out effective treatment is substantially reduced.
  • Tubes which incorporate growth factors may provide effective controlled-release drug delivery. By varying the chemical linkage between the collagen and the synthetic polymer, it is possible to vary the effect with respect to the release of the biologic.
  • the linkage when an "ester” linkage is used, the linkage is more easily broken under physiological conditions, allowing for sustained release of the growth factor from the matrix.
  • an "ether” linkage when an “ether” linkage is used, the bonds are not easily broken and the growth factor will remain in place for longer periods of time with its active sites exposed providing a biological effect on the natural substrate for the active site of the protein. It is possible to include a mixture of conjugates with different linkages so as to obtain variations in the effect with respect to the release of the biologic, e.g., the sustained release effect can be modified to obtain the desired rate of release.
  • tissue growth-promoting amount of a composition containing a growth factor refers to the amount of growth factor needed in order to stimulate tissue growth to a detectable degree.
  • Tissue in this context, includes connective tissue, bone, cartilage, epidermis and dermis, blood, and other tissues with particular emphasis on tissues which form channels such as veins, arteries, intestines and the like.
  • the actual amount which is determined to be an effective amount will vary depending on factors such as the size, condition, sex, and age of the patient, the type of tissue or channel, the effect desired and type of growth factor, and can be more readily determined by the caregiver.
  • sufficient amount is applied to the amount of carrier used in combination with the collagen-polymer conjugates used in forming the tubes of the invention.
  • a sufficient amount is that amount which, when mixed with the conjugate, renders it in the physical form desired, for example, extrudable tubes, extrudable cylinders having any desired cross-section, and so forth.
  • Extrudable formulations may include an amount of a carrier sufficient to render the composition smoothly extrudable without significant need to interrupt the extrusion process.
  • the amount of the carrier can be varied and adjusted depending on the size and shape and thickness of the wall of the tube being extruded. Such adjustments will be apparent to those skilled in the art upon reading this disclosure.
  • collagen must be chemically bound to a synthetic hydrophilic polymer.
  • the synthetic hydrophilic polymer is activated and then reacted with the collagen.
  • the hydroxyl or amino groups present on the collagen can be activated and the activated groups will react with the polymer to form the conjugate.
  • a linking group with activated hydroxyl or amino groups thereon can be combined with the polymer and collagen in a manner so as to concurrently react with both the polymer and collagen forming the conjugate.
  • Other methods of forming the conjugates will become apparent to those skilled in the art upon reading this disclosure.
  • conjugates of the invention are to be used in the human body it is important that all of the components, including the polymer, collagen, and linking group, if used form a conjugate that is unlikely to be rejected by the body. Accordingly, toxic and/or immunoreactive components are not preferred as starting materials. Some preferred starting materials and methods of forming conjugates are described further below.
  • hydrophilic synthetic polymers can be used in connection with forming the conjugate, such polymers must be biocompatible, relatively insoluble, but hydrophilic and is preferably one or more forms of polyethylene glycol (PEG), due to its known biocompatibility.
  • PEG polyethylene glycol
  • Various forms of PEG are extensively used in the modification of biologically active molecules because PEG can be formulated to have a wide range of solubilities and because it lacks toxicity, antigenicity, immunogenicity, and does not typically interfere with the enzymatic activities and/or conformations of peptides. Further, PEG is generally non-biodegradable and is easily excreted from most living organisms including humans.
  • the first step in forming the collagen-polymer conjugates generally involves the functionalization of the PEG molecule.
  • Various functionalized polyethylene glycols have been used effectively in fields such as protein modification (see Abuchowski et al., Enzymes as Drugs, John Wiley & Sons: New York, N.Y. (1981) pp. 367-383; and Dreborg et al., Crit. Rev. Therap. Drug Carrier Syst. (1990) 6:315, both of which are incorporated herein by reference), peptide chemistry (see Mutter et al., The Peptides, Academic: New York, N.Y. 2:285-332; and Zalipsky et al., Int. J. Peptide Protein Res.
  • polyethylene glycol which has been found to be particularly useful is monomethoxy-polyethylene glycol (mPEG), which can be activated by the addition of a compound such as cyanuric chloride, then coupled to a protein (see Abuchowski et al., J. Biol. Chem. (1977) 252:3578, which is incorporated herein by reference).
  • mPEG monomethoxy-polyethylene glycol
  • cyanuric chloride cyanuric chloride
  • Activated forms of PEG can be made from reactants which can be purchased commercially.
  • One form of activated PEG which has been found to be particularly useful in connection with the present invention is mPEG-succinate-N-hydroxysuccinimide ester (SS-PEG) (see Abuchowski et al., Cancer Biochem. Biphys. (1984) 7:175, which is incorporated herein by reference).
  • SS-PEG mPEG-succinate-N-hydroxysuccinimide ester
  • ester linkages can be used in connection with the present invention, they are not particularly preferred in that they undergo hydrolysis when subjected to physiological conditions over extended periods of time (see Dreborg et al., Crit. Rev. Therap. Drug Carrier Syst. (1990) 6:315; and Ulbrich et al., J. Makromol. Chem. (1986) 187:1131, both of which are incorporated herein by reference).
  • Another means of attaching the PEG to a protein can be by means of a carbamate linkage (see Beauchamp et al., Anal. Biochem. (1983) 131:25; and Berger et al., Blood (1988) 71:1641, both of which are incorporated herein by reference).
  • the carbamate linkage is created by the use of carbonyldiimidazole-activated PEG. Although such linkages have advantages, the reactions are relatively slow and may take 2 to 3 days to complete.
  • the conjugates used in forming the grafts may be prepared by covalently binding a variety of different types of synthetic hydrophilic polymers to collagen.
  • the final product or conjugate obtained must have a number of required characteristics such as being extrudable from a nozzle, biocompatible and non-immunogenic, it has been found useful to use polyethylene glycol as the synthetic hydrophilic polymer.
  • the polyethylene glycol must be modified in order to provide activated groups on one or preferably both ends of the molecule so that covalent binding can occur between the PEG and the collagen.
  • the first functionalized PEG is difunctionalized PEG succinimidyl glutarate, referred to herein as (SG-PEG).
  • the structural formula of this molecule and the reaction product obtained by reacting it with collagen is shown in Formula 1. ##STR1##
  • PEG succinimidyl Another difunctionally activated form of PEG is referred to as PEG succinimidyl (S-PEG).
  • S-PEG PEG succinimidyl
  • the structural formula for this compound and the reaction product obtained by reacting it with collagen is shown in Formula 2.
  • the subscript 3 is replaced with an "n.”
  • the structure in Formula 2 results in a conjugate which includes an "ether” linkage which is not subject to hydrolysis. This is distinct from the first conjugate shown in Formula 1, wherein an ester linkage is provided. The ester linkage is subject to hydrolysis under physiological conditions.
  • the structural formula and resulting conjugate are shown in Formula 4. It is noted that the conjugate includes both an ether and a peptide linkage. These linkages are stable under physiological conditions.
  • the difunctionalized form is referred to as PEG succinimidyl carbonate (SC-PEG).
  • SC-PEG PEG succinimidyl carbonate
  • the structural formula of this compound and the conjugate formed by reacting SC-PEG with collagen is shown in Formula 5.
  • this conjugate includes a urethane linkage, the conjugate has been found not to have a high degree of stability under physiological conditions. The instability can be a desirable characteristic when the tubes are used in a situation where it is desirable that they dissolve over time.
  • A-PEG difunctional PEG propionaldehyde
  • E-PEG difunctional PEG glycidyl ether
  • the conjugates formed using the functionalized forms of PEG vary depending on the functionalized form of PEG which is used in the reaction. Furthermore, the final product can be varied with respect to its characteristics by changing the molecular weight of the PEG. In general, the stability of the conjugate is improved by eliminating any ester linkages between the PEG and the collagen and including ether and/or urethane linkages. These stable linkages are generally used to form tubes to replace or augment a channel as may be done with a stent-graft.
  • the grafts When the grafts are used as a temporary repair unit for a damaged channel, it may be desirable to include the weaker ester linkages so that the linkages are gradually broken by hydrolysis under physiological conditions, breaking apart the tube as it may be replaced by host tissue, or as it degrades, and releasing a component held therein, such as a growth factor.
  • the rate of sustained release can be varied.
  • Suitable collagens include all types of pharmaceutically useful collagen, preferably types I, II and III.
  • Collagens may be soluble (for example, commercially available Vitrogen® 100 collagen-in-solution), and may or may not have the telopeptide regions.
  • the collagen will be reconstituted fibrillar atelopeptide collagen, for example Zyderm® collagen implant (ZCI) or atelopeptide collagen in solution (CIS).
  • ZCI Zyderm® collagen implant
  • CIS atelopeptide collagen in solution
  • Various forms of collagen are available commercially, or may be prepared by the processes described in, for example, U.S. Pat. Nos.
  • Fibrillar, atelopeptide, reconstituted collagen is preferred in order to form tubes used for the repair or augmentation of channels.
  • compositions used in forming the invention comprise collagen chemically conjugated to a selected synthetic hydrophilic polymer or polymers.
  • Collagen contains a number of available amino and hydroxy groups which may be used to bind the synthetic hydrophilic polymer.
  • the polymer may be bound using a "linking group", as the native hydroxy or amino groups in collagen and in the polymer frequently require activation before they can be linked.
  • dicarboxylic anhydrides e.g., glutaric or succinic anhydride
  • a polymer derivative e.g., succinate
  • a convenient leaving group for example, N-hydroxy-succinimide, N,N'-disuccinimidyl oxalate, N,N'-disuccinimidyl carbonate, and the like. See also Davis, U.S. Pat. No. 4,179,337
  • Presently preferred dicarboxylic anhydrides that are used to form polymer-glutarate compositions include glutaric anhydride, adipic anhydride, 1,8-naphthalene dicarboxylic anhydride, and 1,4,5,8-naphthalenetetracarboxylic dianhydride.
  • the polymer thus activated is then allowed to react with the collagen, forming a collagen-polymer composition used to make the grafts.
  • a pharmaceutically pure form of monomethylpolyethylene glycol (mPEG) (mw 5,000) is reacted with glutaric anhydride (pure form) to create mPEG glutarate.
  • the glutarate derivative is then reacted with N-hydroxy-succinimide to form a succinimidyl monomethylpolyethylene glycol glutarate.
  • the succinimidyl ester (mPEG*, denoting the activated PEG intermediate) is then capable of reacting with free amino groups present on collagen (lysine residues) to form a collagen-PEG conjugate wherein one end of the PEG molecule is free or nonbound.
  • Other polymers may be substituted for the monomethyl PEG, as described above.
  • the coupling reaction may be carried out using any known method for derivatizing proteins and synthetic polymers.
  • the number of available lysines conjugated may vary from a single residue to 100% of the lysines, preferably 10-50%, and more preferably 20-30%.
  • the number of reactive lysine residues may be determined by standard methods, for example by reaction with TNBS.
  • the resulting product is a smooth, pliable, rubbery mass having a shiny appearance. It may be wetted, but is not water-soluble. It may be formulated as a suspension at any convenient concentration, preferably about 30-65 mg/mL, and may be extruded through a nozzle to form a tube. The consistency of the formulation may be adjusted by varying the amount of liquid used.
  • the tubular component may be reinforced using a network of small diameter fibers.
  • the fibers may be random, braided, knitted, or woven.
  • the fibers may be imbedded in the tubular component wall, may be placed in a separate layer coaxial with the tubular component, or may be used in a combination of the two.
  • FIG. 11 shows an end view, cross-section of the configuration in which the stent (220) forms the outermost layer, a fibrous layer (222) coaxial to and inside the stent (220), and the tubular component (224) of, e.g., collagen as the inner layer.
  • the fibrous material is mixed with or imbedded into the tubular layer (226) and cast or injected around the stent (220).
  • This fibrous material may extend for the length of the device or may be shorter.
  • the fibers may be wound or placed in any reasonable orientation within the device. Alternatively, randomly oriented short segments of fibers may also be imbedded in the wall of the tubing.
  • the fiber may be any suitable fibrous blood-compatible material including polyesters such as DACRON, polyamides such as NYLON, KEVLAR, polyglycolic acids, polylactic acids, polyethylene, polypropylene, silk or other strong flexible fiber which are not detrimentally affected in the medical service in which this device is placed. Specifically, polypropylene and the like will not be dissolved in blood but polyglycolic acid will dissolve. Each are suitable but work in different ways.
  • radio-opaque metallic fibers such as gold, platinum, platinum-tungsten, palladium, platinum-iridium, rhodium, tantalum, or alloys or composites of these metals like may be incorporated into the multi-strand reinforcement network to allow fluoroscopic visualization of the device.
  • the fibers carry much of the hoop stress and other loadings imposed by the vessel. This relieves the loading on the collagen and significantly increases the burst strength and fatigue properties of the tube. In addition, this makes the tube more effective in hydraulically isolating the vessel and as a result prevents the formation or worsening of aneurysms. This would be particularly beneficial in thinned weakened vessel walls resulting from de-bulking interventions or from medial thinning that has been seen to accompany stent placement. Another benefit of the fiber reinforcement is the increase in resistance to radially inward loading, especially if the loading is very focussed. Finally, fiber reinforcement may also impart some longitudinal stiffness to the stent-graft. This allows the stent-graft to maintain its strength and prevent it from kinking or sagging into the lumen.
  • the preferred method of constructing the stent-graft is to first construct the stent and then to mold or cast the collagen tubular component about the stent.
  • the stent structure and fiber reinforcement may be molded into the wall of the collagen tube.
  • a mold for such a structure desirably is a simple annular space between two cylinders having room in the annular space for placement of the stent and would have a longitudinal axis slightly longer than the length of the stent-graft to be produced.
  • the stent and fiber tubing is centered in the annular space and then the remaining space filled with collagen. If sPEG cross-linked collagen is used as the matrix material, the sPEG and collagen are mixed and introduced into the mold and allowed to cure. After curing, the mold is separated and the inventive fiber reinforced collagen tube with a stent structure produced.
  • a stent-graft having torsion members When a stent-graft having torsion members is folded, crushed, or otherwise collapsed, mechanical energy is stored in torsion in those torsion members. In this loaded state, the torsion members have a torque exerted about them and consequently have a tendency to untwist. Collectively, the torque exerted by the torsion members as folded down to a reduced diameter must be restrained from springing open.
  • the stent typically has at least one torsion member per fold to take advantage of the invention.
  • the stent-graft is folded along its longitudinal axis and restrained from springing open. The stent-graft is then deployed by removing the restraining mechanism, thus allowing the torsion members to spring open against the vessel wall.
  • inventive devices of this type are typically selected having an expanded diameter of up to about 10% greater than the diameter of the lumen to be the site of the stent deployment.
  • FIG. 13A shows a sequence of folding the device (230) of this invention about a guidewire (232) into a loose C-shaped configuration.
  • FIG. 13B shows a front quarter view of the resulting folded stent or stent-graft.
  • FIG. 13C shows a sequence of folding the device (230) of this invention about a guidewire (232) into a rolled configuration.
  • FIG. 13D shows a front quarter view of the resulting folded stent or stent-graft.
  • FIG. 13E shows a sequence of folding the device (230) of this invention about a guidewire (232) into a triple lobed configuration.
  • FIG. 13F shows a front quarter view of the resulting folded stent or stent-graft.
  • the stent-graft may be tracked through the vasculature to the intended deployment site and then unfolded against the vessel lumen.
  • the collagen tube component of the stent-graft is limp, flexible, and thus easy to fold. Folding of the stent structure in the manner discussed above allows it to return to a circular, open configuration.
  • FIGS. 14A-14C show one desired way to place the devices of the present invention and allow them to self-expand.
  • FIG. 14A shows a target site (246) having, e.g., a narrowed vessel lumen.
  • a guidewire (248) having a guide tip (250) has been directed to the site using known techniques.
  • the stent-graft (252) is mounted on guidewire tubing (254) inside outer sliding sheath (256) after having folded in the manner discussed above.
  • the outer sliding sheath (256) binds the compressed stent-graft (252) in place until released.
  • FIG. 14B shows placement of the stent-graft (252) at the selected site (246) by sliding the stent-graft (252) over the guidewire (248) all together with the guidewire tubing (254) and the outer sliding sheath (256).
  • the stent-graft (252) is deployed by holding the guidewire tubing (254) in a stationary position while withdrawing the outer sliding sheath (256).
  • the stent-graft (252) can be seen in FIG. 14B as partially deployed.
  • FIG. 14C shows the stent-graft (252) fully deployed after the guidewire tubing (254) and the outer sliding sheath (256) have been fully retracted.
  • FIGS. 15A-C, 16A-C, and 17A-C show an inventive variation of deploying a stent or stent-graft made according to this invention. These methods involve the use of a control line or tether line which maintains the stent or stent-graft in a folded configuration until release.
  • FIG. 15A is a front-quarter view of the stent (302) or stent-graft which has been folded as shown in the Figures discussed above.
  • the stent (302) is folded about guidewire (304) so that, when deployed, the guidewire (304) is within the stent (302).
  • the tether wire (306) which is passed through loops (308) associated with the various helices as they wind about the stent (302).
  • the loops (308) may be formed from the flexible link (124 in FIG. 2 or 3) or may be simply an alternating weave through appropriate apexes of the undulating helix, e.g., (104 in FIG. 3) or may be loops specifically installed for the purpose shown here.
  • the tether wire (306) is so placed that when it is removed by sliding it axially along the stent (302) and out of the loops (308), that the stent (302) unfolds into a generally cylindrical shape within the body lumen.
  • FIG. 15B shows an end-view of a folded stent (302) or stent-graft having a guidewire (304) within the inner surface of the stent (302) and with the tether wire (306) within the loops (308).
  • the end view of the folded stent (302) shows it to be folded into a form which is generally C-shaped.
  • the stent (302) in FIG. 15B assumes the form shown in end view in FIG. 15C.
  • the guidewire (304) within the lumen of the stent (302) and the loops (308) which were formerly in a generally linear relationship having a tether wire passing through them.
  • FIG. 16A shows a folded stent (310) (or stent-graft) in front quarter view which is similar in configuration to the stent (302) shown in FIG. 15A except that the stent (310) is rolled somewhat tighter than the previously discussed stent.
  • the guidewire (304) is also inside the stent (310) rather than outside of it. Loops (308) from generally opposing sides of the stent (310) are folded into an approximate line so that the tether wire may pass through the aligned loops (308).
  • FIG. 16B shows an end view of the stent (310), and in particular, emphasizes the tighter fold of the stent (310). When expanded by removal of the tether wire (306), the stent (310) in FIG.
  • FIG. 16B assumes the form shown in FIG. 16C.
  • FIGS. 17A-C show a schematic procedure for deploying the stent (312) (or stent-graft) using a percutaneous catheter assembly (314).
  • FIG. 17A may be seen a percutaneous catheter assembly (314) which has been inserted to a selected site (316) within a body lumen.
  • the stent (312) is folded about the guidewire (319) and guidewire tube (318) held axially in place prior to deployment by distal barrier (320) and proximal barrier (322).
  • the distal barrier (320) and proximal barrier (322) typically are affixed to the guidewire tube (318).
  • the tether wire (306) is shown extending through loops (308) proximally through the catheter assembly's (314) outer jacket (324) through to outside the body.
  • FIG. 17B shows the removal of the tether wire (306) from a portion of the loops (308) to partially expand the stent (312) onto the selected site (316).
  • FIG. 17C shows the final removal of the tether wire (306) from the loops (308) and the retraction of the catheter assembly (314) from the interior of the stent (312).
  • the stent (312) is shown as fully expanded.

Abstract

This invention is a medical device and a method of using it. The device is a foldable stent or stent-graft which may be percutaneously delivered with (or on) an endovascular catheter or via surgical techniques or using other suitable techniques. The expandable stent structure utilizes at least one torsional member having an undulating shape which is helically deployed to form the generally cylindrical shape used as the stent. The helical winding desirably is aligned to allow those undulating shapes in adjacent turns of the helix to be in phase. The adjacent undulating shapes may be held in phased relationship using a flexible linkage, often made of a polymeric material. The stent may be flared on at least one of its ends to promote smooth blood flow at that flare and to assure that the stent will remain in the chosen position within the body. The stent's configuration allows it to be folded or collapsed to a very small diameter prior to deployment without changing the length of the stent. The stent may be expanded with the use of an installation device such as a balloon but preferably is used as a self-expandable device.

Description

FIELD OF THE INVENTION
This invention is a medical device and a method of using it. The device is a foldable stent or stent-graft which may be percutaneously delivered with (or on) an endovascular catheter or via surgical techniques or using other suitable techniques and then expanded. The expandable stent structure utilizes at least one torsional member having an undulating shape which is helically deployed to form the generally cylindrical shape eventually deployed as the stent. The helical winding desirably is aligned to allow those undulating shapes in adjacent turns of the helix to be in phase. The adjacent undulating shapes maybe held in that phased relationship using a flexible linkage, often made of a polymeric material. The stent may be flared on at least one of its ends to promote smooth blood flow at that flare and to assure that the stent will remain in the chosen position within the body. The stent's configuration allows it to be folded or otherwise compressed to a very small diameter prior to deployment without changing the length of the stent. The stent may be expanded with the use of an installation device such as a balloon but preferably is used as a self-expandable device. The graft component cooperating with the stent is tubular and preferably is a blood-compatible collagenous material which may, if desired, be reinforced with fibers. The tubular graft member may be cast onto or otherwise attached or imbedded into the stent structure to form an integral stent-graft. Alternatively, the graft may be used to maintain the generally cylindrical shape of the stent, e.g., without the use of the flexible linkage.
The stent-graft may be used to reinforce vascular irregularities, to provide a smooth nonthrombogenic interior vascular surface for diseased areas in blood vessels, or to increase blood flow past a diseased area of a vessel by mechanically improving the interior surface of the vessel. The inventive stent-graft is especially suitable for use within smaller vessels between 2 mm and 6 mm in diameter but is equally suitable for significantly larger vessels. The invention provides a stent which is self-expanding, kink-resistant, easily bent along its longitudinal axis, does not change its length during that expansion, and is able to provide collapsible support for otherwise frangible graft material.
The invention involves procedures for deploying stents or stent-grafts which have been folded, bound, or otherwise collapsed to significantly smaller diameters for insertion into a human or animal body. When used with super-elastic alloys, the stent may be collapsed at a convenient temperature either above or, preferably, below the transition temperature of the alloy. The deployment procedures may involve the use of an outer sleeve to maintain the stent or stent-graft at a reduced diameter or may involve a "slip-line" or "tether wire" to hold and then to release the device.
BACKGROUND OF THE INVENTION
Treatment or isolation of vascular aneurysms or of vessel walls which have been thinned or thickened by disease has traditionally been done via surgical bypassing with vascular grafts. Shortcomings of this procedure include the morbidity and mortality associated with surgery, long recovery times after surgery, and the high incidence of repeat intervention needed due to limitations of the graft or of the procedure. Vessels thickened by disease are currently sometimes treated less invasively with intraluminal stents that mechanically hold these vessels open either subsequent to or as an adjunct to a balloon angioplasty procedure. Shortcomings of current stents include the use of highly thrombogenic materials (stainless steels, tantalum, ELGILOY) which are exposed to blood, the general failure of these materials to attract and support functional endothelium, the irregular stent/vessel surface that causes unnatural blood flow patterns, and the mismatch of compliance and flexibility between the vessel and the stent.
Important to this invention is the use of less invasive intraluminal delivery and, in a preferred aspect, placement of a nonthrombogenic blood-carrying conduit having a smooth inner lumen which will endothelize. The most preferred biologic material chosen for the inner layer of the inventive stent-graft is collagen-based and, although it will fold with ease, is otherwise fairly frangible or inelastic in that it has very little ability to stretch. Mounting a collagen tube on the outside of or as a part of a balloon-expandable stent will usually cause the tube to tear. Mounting such a tube on the inside of a balloon expandable stent will yield a torn irregular surface exposed to blood flow. Further, balloon expandable devices that rely upon plastic deformation of the stent to achieve a deployed shape are subject to abrupt closure as a result of trauma when the devices are placed in a vessel near the skin surface or across a joint or ligament. Those self-expanding stents which rely on the shortening of the stent upon radial expansion at deployment may cause vessel tearing problems similar to those observed with the use of balloon expandable devices. Obviously, stents which shorten during deployment are also subject to deployment placement inaccuracies.
The most desired variations of this invention involve a stent-graft which is self-expanding, which does not shorten upon delivery, which has excellent longitudinal flexibility, which has high radial compliance to the vessel lumen, exposes the blood to a smooth, nonthrombogenic surface capable of supporting endothelium growth.
The inventive device may be delivered in a reduced diameter and expanded to maintain the patency of any conduit or lumen in the body. An area in which the inventive stent and stent graft is particularly beneficial is in the scaffolding of atherosclerotic lesions in the cardiovascular system to establish vessel patency, prevention of thrombosis, and the further prevention of restenosis after angioplasty. In contrast to many of the stents discussed below having metallic struts intruding into the blood flow in the vessel lumen which generate turbulence and create blood stasis points initiating thrombus formation, the smooth, continuous surface provided by the preferred tubular collagen-based inner conduit of our invention provides a hemodynamically superior surface for blood flow.
The non-thrombogenic properties of the most preferred sPEG collagen surface results in a less thrombogenic device. Clinically, this allows a more moderate anti-coagulation regimen to be used. As a result, the rate of bleeding complications, a major drawback associated with stenting, may be reduced. The absence of gaps or holes in the graft structure between stent struts of our invention allows the tacking of both large and small flaps and tears in the vessel wall. These flaps disrupt blood flow and attract thrombus. The disruption of the natural anti-thrombotic covering of endothelium only worsens the condition. The collagen-based barrier we interpose between blood and a disrupted or injured portion of the vessel wall serves to mask injured intimal or medial layers from blood, thereby preventing thrombus formation and intimal proliferation which may lead to restenosis.
The presence of our inventive stent-graft acts as a mechanical barrier preventing tissue from proliferating into or impinging the lumen. The nature of the bioactivity of the collagen and the smoother flow characteristics at the blood-contacting surface are conducive to endothelial cell attachment and growth thereby assuring the long-term blood compatibility of the device.
Mechanically, our inventive linked helical stent structure provides a good combination of radial strength and flexibility. The structure is also radially resilient. It can be completely crushed or flattened and yet spring open again once the obstructive loading is removed. This ability is important for use in exposed portions of the body around the peripheral vasculature or around joints. The stent-graft can sustain a crushing traumatic blow or compression from the bending of a joint and still return to the open configuration once the load is removed.
With regard to delivery, the self-expansion mechanism eliminates the need for a balloon catheter and the associated balloon rupture problems often associated with balloons. In addition, the absence of the bulk of the balloon allows a smaller delivery profile to be achieved. Unlike some other self-expanding stent designs, this stent-graft maintains a constant length throughout the expansion process. Thus, the stent-graft would not have some of the positioning problems associated with other many self-expanding stents. In treating longer lesions, our self-expanding design eliminates the need for special long balloons or repositioning of the balloon between inflations in order to expand the entire length of the stent.
When used as a conventional vascular graft or intraluminal graft, our most preferred stent-grafts offer a number of advantages over existing technologies. Unlike expanded polytetrafluoroethylene (PTFE) grafts, the collagen-based material supports endothelial cell growth and is incorporated into the surrounding tissue. As an intraluminal graft, the device has several advantages. The wall thickness may be made thinner than either of current stents and expanded PTFE or of tanned, reinforced biologic grafts. When placed inside the lumen of a vessel, a thin-walled graft results in a larger opening for blood flow resulting in improved hemodynamics. Lastly, when used as an intraluminal graft, there is no anastomosis site. Anastomosis sites are thought to be a common source of problems associated with graft failures.
The impermeability of the preferred stent-graft makes it suitable for shunting and thereby hydraulically isolating aneurysms. The expansile properties derived from the stent structure provide a secure anchor to the vessel wall. The stent reinforces the collagen-based tubular component, much as a fiber tube would, increasing the burst strength of the stent-graft.
Finally, the organic composition of the preferred collagen-based materials used in the inventive stent-graft provides an excellent vehicle for localized drug delivery, certainly better than metallic stents or other synthetic grafts. In addition, therapeutic compounds may be linked, conjugated, or otherwise more easily bound to the organic graft material (or to its substituents, such as PEG) than to the surface of a metallic structure. Localized drug delivery is desirable in preventing thrombosis or restenosis. Therapeutically effective doses may be administered to the target area without systemic concentrations being raised. This capability is of great benefit in reducing side-effects and complications associated with drug therapy.
Therapeutic agents may be delivered out of the collagen matrix by diffusion. Alternatively, these agents may be bound temporarily or permanently on the collagen surfaces. Different agents may be bound on the inner and outer surfaces to achieve different therapeutic ends. For example, a drug to minimize thrombus formation might be appropriate for the inside, blood-contacting surface, while a drug which would inhibit smooth muscle cell proliferation might be appropriate on the outer surface. Drugs can be chemically or physically bound to either the sPEG or the collagen molecules.
Stents
The stents currently described in the open literature include a wide variety of different shapes.
Wallsten, U.S. Pat. No. 4,655,771, suggests a vascular prosthesis for transluminal implantation which is made up of a flexible tubular body having a diameter that is varied by adjusting the axial separation of the two ends of the body relative to each other. In general, the body appears to be a woven device produced of various plastics or stainless steel.
U.S. Pat. No. 4,760,849, to Kroph, shows the use of a ladder-shaped coil spring which additionally may be used as a filter in certain situations.
Porter, U.S. Pat. No. 5,064,435, suggests a stent made up of two or more tubular stent segments which may be deployed together so to produce a single axial length by a provision of overlapping areas. This concept is to permit the use of segments of known length, which, when deployed, may be used together in overlapping fashion additively to provide a stent of significant length.
Quan-Gett, U.S. Pat. No. 5,151,105, discloses an implantable, collapsible tubular sleeve apparently of an outer band and an inner spring used to maintain the sleeve in a deployed condition.
Wall, U.S. Pat. No. 5,192,307, suggests a stent having a number of holes therein and which is expandable using an angioplasty balloon so to allow ratchet devices or ledges to hold the stent in an open position once it is deployed.
Perhaps of more relevance are the patents using wire as the stent material.
Gianturco, in U.S. Pat. Nos. 4,580,568 and 5,035,706, describes stents formed of stainless steel wire arranged in a closed zigzag pattern. The stents are compressible to a reduced diameter for insertion into and removal from a body passageway. The stents appear to be introduced into the selected sites by discharge of the collapsed zigzag wire configuration from the tip of a catheter.
U.S. Pat. Nos. 4,830,003 and 5,104,404, to Wolff et al., shows a stent of a zigzag wire configuration very similar in overall impression to the Gianturco device. However, the stent is said to be self-expanding and therefore does not need the angioplasty balloon for its expansion.
Hillstead, U.S. Pat. No. 4,856,516, suggests a stent for reinforcing vessel walls made from a single elongated wire. The stent produced is cylindrical and is made up of a series of rings which are, in turn, linked together by half-hitch junctions produced from the single elongated wire. It is not helically wound, nor is there a second linking member tending to link the helices together.
Wiktor, U.S. Pat. Nos. 4,649,992, 4,886,062, 4,969,458, and 5,133,732, shows wire stent designs using variously a zigzag design or, in the case of Wiktor '458, a helix which winds back upon itself. Wiktor '062 suggests use of a wire component made of a low-memory metal such as copper, titanium or gold. These stents are to be implanted using a balloon and expanded radially for plastic deformation of the metal.
Wiktor '458 is similarly made of low-memory alloy and is to be plastically deformed upon its expansion on an angioplasty balloon.
Wiktor '732 teaches the use of a longitudinal wire welded to each turn of the helically wound zig-zag wire which is said to prevent the longitudinal expansion of the stent during deployment. A further variation of the described stent includes a hook in each turn of the helix which loops over a turn in an adjacent turn. Neither variation includes a flexible linkage between adjacent helices.
W093/13825, to Maeda et al, shows a self-expanding stent similar to the Gianturco, Wolff, and Wiktor designs, formed of stainless steel wire, which is built into an elongated zig-zag pattern, and helically wound about a central axis to form a tubular shape interconnected with a filament. The bends of the helix each have small loops or "eyes" at their apexes which are inter-connected with a filament. Because of the teaching to connect the eyes of the apexes, the stent appears to be a design that axially expands during compression and may tear attached grafts because of the relative change in position of the arms of the zig-zag during compression of the stent.
MacGregor, U.S. Pat. No. 5,015,253, shows a tubular non-woven stent made up of a pair of helical members which appear to be wound using opposite "handedness". The stent helices desirably are joined or secured at the various points where they cross.
Pinchuk, in U.S. Pat. Nos. 5,019,090, 5,092,877, and 5,163,958, suggests a spring stent which appears to circumferentially and helically wind about as it is finally deployed except, perhaps, at the very end link of the stent. The Pinchuk '958 patent further suggests the use of a pyrolytic carbon layer on the surface of the stent to present a porous surface of improved antithrombogenic properties. The helices are not linked to each other, however, nor is there any suggestion that the helices be maintained in a specific relationship either as deployed or as kept in the catheter prior to deployment.
U.S. Pat. No. 5,123,917, to Lee, suggests an expandable vascular graft having a flexible cylindrical inner tubing and a number of "scaffold members" which are expandable, ring-like, and provide circumferential rigidity to the graft. The scaffold members are deployed by deforming them beyond their plastic limit using, e.g., an angioplasty balloon.
Tower, in U.S. Pat. Nos. 5,161,547 and 5,217,483, shows a stent formed from a zig-zag wire wound around a mandrel in a cylindrical fashion. It is said to be made from "a soft platinum wire which has been fully annealed to remove as much spring memory as possible." A longitudinal wire is welded along the helically wound sections much in the same way as was the device of Wiktor.
There are a variety of disclosures in which super-elastic alloys such as nitinol are used in stents. See, U.S. Pat. No. 4,503,569, to Dotter; U.S. Pat. No. 4,512,338, to Balko et al.; U.S. Pat. No. 4,990,155, to Wilkoff; U.S. Pat. No. 5,037,427, to Harada, et al.; U.S. Pat. No. 5,147,370, to MacNamara et al.; U.S. Pat. No. 5,211,658, to Clouse; and U.S. Pat. No. 5,221,261, to Termin et al. None of these references suggest a device having discrete, individual, energy-storing torsional members as are required by this invention.
Jervis, in U.S. Pat. Nos. 4,665,906 and 5,067,957, describes the use of shape memory alloys having stress-induced martensite properties in medical devices which are implantable or, at least, introduced into the human body.
Stent-Grafts
A variety of stent-graft designs are shown in the following literature.
Perhaps the most widely known such device is shown in Ersek, U.S. Pat. No. 3,657,744. Ersek shows a system for deploying expandable, plastically deformable stents of metal mesh having an attached graft through the use of an expansion tool.
Palmaz describes a variety of expandable intraluminal vascular grafts in a sequence of patents: U.S. Pat. Nos. 4,733,665; 4,739,762; 4,776,337; and 5,102,417. The Palmaz '665 patent suggests grafts (which also function as stents) that are expanded using angioplasty balloons. The grafts are variously a wire mesh tube or of a plurality of thin bars fixedly secured to each other. The devices are installed, e.g., using an angioplasty balloon and consequently are not seen to be self-expanding.
The Palmaz '762 and '337 patents appear to suggest the use of thin-walled, biologically inert materials on the outer periphery of the earlier-described stents.
Finally, the Palmaz '417 patent describes the use of multiple stent sections each flexibly connected to its neighbor.
Rhodes, U.S. Pat. No. 5,122,154, shows an expandable stent-graft made to be expanded using a balloon catheter. The stent is a sequence of ring-like members formed of links spaced apart along the graft. The graft is a sleeve of a material such as expanded a polyfluorocarbon, e.g., GORETEX or IMPRAGRAFT.
Schatz, U.S. Pat. No. 5,195,984, shows an expandable intraluminal stent and graft related in concept to the Palmaz patents discussed above. Schatz discusses, in addition, the use of flexibly-connecting vascular grafts which contain several of the Palmaz stent rings to allow flexibility of the overall structure in following curving body lumen.
Cragg, "Percutaneous Femoropopliteal Graft Placement", Radiology, vol. 187, no. 3, pp. 643-648 (1993), shows a stent-graft of a self-expanding, nitinol, zig-zag, helically wound stent having a section of polytetrafluoroethylene tubing sewed to the interior of the stent.
Cragg (European Patent Application 0,556,850) discloses an intraluminal stent made up of a continuous helix of zig-zag wire and having loops at each apex of the zig-zags. Those loops on the adjacent apexes are individually tied together to form diamond-shaped openings among the wires. The stent may be made of a metal such as nitinol (col. 3, lines 15-25 and col. 4, lines 42+) and may be associated with a "polytetrafluoroethylene (PTFE), dacron, or any other suitable biocompatible material". Those biocompatible materials may be inside the stent (col. 3, lines 52+) or outside the stent (col. 4, lines 6+). There is no suggestion that the zig-zag wire helix be re-aligned to be "in phase" rather than tied in an apex-to-apex alignment. The alignment of the wire and the way in which it is tied mandates that it expand in length as it is expanded from its compressed form.
Grafts
As was noted above, the use of grafts in alleviating a variety of vascular conditions is well known. Included in such known grafting designs and procedures are the following.
Medell, U.S. Pat. No. 3,479,670, discloses a tubular prothesis adapted to be placed permanently in the human body. It is made of framework or support of a synthetic fiber such as DACRON or TEFLON. The tube is said to be made more resistant to collapse by fusing a helix of a polypropylene monofilament to its exterior. The reinforced fabric tube is then coated with a layer of collagen or gelatin to render the tubing (to be used as an esophageal graft) impermeable to bacteria or fluids.
Sparks, in U.S. Pat. Nos. 3,514,791, 3,625,198, 3,710,777, 3,866,247, and 3,866,609, teach procedures for the production of various graft structures using dies of suitable shape and a cloth reinforcing material within the die. The die and reinforcement are used to grow a graft structure using a patient's own tissues. The die is implanted within the human body for a period of time to allow the graft to be produced. The graft is in harvested and implanted in another site in the patient's body by a second surgical procedure.
Braun, in U.S. Pat. No. 3,562,820, shows a biological prosthesis manufactured by applying onto a support of a biological tissue (such as serosa taken from cattle intestine) a collagen fiber paste. The procedure is repeated using multiple layers of biological tissue and collagen fiber paste until a multi-layer structure of the desired wall thicknesses is produced. The prosthesis is then dried and removed prior to use.
Dardik et al, U.S. Pat. No. 3,974,526, shows a procedure for producing tubular prostheses for use in vascular reconstructive surgeries. The prosthesis is made from the umbilical cord of a newly born infant. It is washed with a solution of 1 percent hydrogen peroxide and rinsed with Ringer's lactate solution. It is then immersed in a hyaluronidase solution to dissolve the hyaluronic acid coating found in the umbilical cord. The vessels are then separated from the cord and their natural interior valving removed by use of a tapered mandrel. The vessels are then tanned with glutaraldehyde. A polyester mesh support is applied to the graft for added support and strength.
Whalen, U.S. Pat. No. 4,130,904, shows a prosthetic blood conduit having two concentrically associated tubes with a helical spring between them. Curved sections in the tube walls help prevent kinking of the tube.
Ketharanathan, U.S. Pat. No. 4,319,363, shows a procedure for producing a vascular prosthesis suitable for use as a surgical graft. The prosthesis is produced by implanting a rod or tube in a living host and allowing collagenous tissue to grow on the rod or tube in the form of coherent tubular wall. The collagenous implant is removed from the rod or tube and tanned in glutaraldehyde. The prosthesis is then ready for use.
Bell, U.S. Pat. No. 4,546,500, teaches a method for making a vessel prosthesis by incorporating a contractile agent such as smooth muscle cells or platelets into a collagen lattice and contracting the lattice around a inner core. After the structure has set, additional layers are applied in a similar fashion. A plastic mesh sleeve is desirably sandwiched between the layers or imbedded within the structure to provide some measure of elasticity.
Hoffman Jr. et al, U.S. Pat. No. 4,842,575, shows a collagen impregnated synthetic vascular graft. It is made of a synthetic graft substrate and a cross-linked collagen fibril. It is formed by depositing a aqueous slurry of collagen fibrils into the lumen of the graft and massaging the slurry into the pore structure of the substrate to assure intimate admixture in the interior. Repeated applications and massaging and drying is said further to reduce the porosity of the graft.
Alonoso, U.S. Pat. No. 5,037,377, is similar in overall content to the Hoffman Jr. et al patent discussed above except that, in addition to collagen fibers, soluble collagen is introduced into the fabric. A suitable cross-linking agent such as glutaraldehyde is used to bond adjacent collagen fibers to each other.
Slepian et al, U.S. Pat. No. 5,213,580, teaches a process described as "paving" or "stabilizing by sealing the interior surface of a body vessel or organ" by applying a biodegradable polymer such as a polycaprolactone. The polymer is made into a tubular substrate, placed in position, and patched into place.
Finally, there are known vascular grafts using collagenous tissue with reinforcing structure. For instance, Pinchuk, in U.S. Pat. Nos. 4,629,458 and 4,798,606, suggests the use of collagen with some other type of fibrous structure supporting the collagen as a biograft. Similarly, Sinofsky et al., U.S. Pat. No. 5,100,429, suggests a partially-cured, collagen-based material used to form a graft within a blood vessel.
Kreamer, U.S. Pat. No. 4,740,207, suggests a intraluminal graft made of a semi-rigid resilient tube, open along a seam extending from one end to the other, which is expanded within the vessel and which resulting larger diameter is maintained by use of a ledge at the longitudinal seam for catching the opposite side of the seam on the expanded graft.
We have found that elasticity, or the ability of a material to return to its original shape after a deformation, can be maintained in smaller stents by the distribution of folding deformation throughout the structure. By incorporating hinges or hinge regions into the structure, the distribution of "local" folding deformation is maximized. The hinge regions include torsion members allowing a significant portion of the folding displacement to be re-oriented parallel to the longitudinal axis of the stent-graft. The act of folding, crushing, or otherwise elastically deforming the stent creates a significant torsional component in the torsion members which component is parallel to that longitudinal axis. The hinges are positioned at least at each of the fold points around the circumference of the stent where folding is desired. The circumferentially oriented regions of the stents, which connect the torsion members, pivot about the torsion members, causing the torsion members to undergo a twisting deformation. In order to avoid exceeding the elastic limit of the material, the length of the torsion members is increased to lower the amount of twist per length or strain imposed. The orientation of the torsion members is such that their length does not increase the circumference of the device. None of the cited references suggest such a device.
SUMMARY OF THE INVENTION
This invention is a foldable stent or stent-graft which may be percutaneously delivered through or over an endovascular catheter or using surgical techniques or other appropriate methodologies. The expandable stent structure utilizes torsional regions which allow it to be folded to a very small diameter prior to deployment. The torsional members have an undulating shape which may be helically deployed to form the stent's cylindrical shape. The undulating shape may be aligned to allow the shapes in adjacent turns of the helix to be in phase. The undulating shapes may be generally V-shaped, U-shaped, sinusoidal, or ovoid. Adjacent undulating shapes may be held in the phased relationship using a flexible linkage, often made of a polymeric material. The undulating torsional members do not have any means at (or near) the apex of the undulating shapes which would tend to constrict the movement of the flexible linkage during compression of the stent. The stent may be expanded with the use of an installation device such as an angioplasty balloon but preferably is used as a self-expandable device. The graft component used to complement the stent is tubular and preferably is of a collagenous material which may, if desired, be reinforced with fibers of random, woven, roving, or wound configurations. The tubular member preferably is cast onto or otherwise attached or imbedded into the stent structure. The stent-graft may be used to reinforce vascular irregularities and provide a smooth interior vascular surface, particularly within smaller vessels.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1A, 1B, 1C, 1D, and 1E are plan views of an unrolled stent form making up the invention.
FIG. 2 is a side view of the inventive stent.
FIG. 3 is a close-up of a portion of the inventive stent shown in FIG. 2.
FIG. 4 is an abstracted portion of an inventive stent and shows the concept of torsion on a portion of the stent.
FIG. 5 is a side view of the inventive stent showing a variation having flared ends.
FIGS. 6, 7, and 8 show plan views of an unrolled stent produced from flat stock.
FIG. 9 shows a quarter view of the rolled stent using the flat stock pattern shown in FIG. 7.
FIG. 10 shows a device for winding and heat treating a stent made according to the invention.
FIGS. 11 and 12 show end view cutaways of stent-grafts made according to the invention.
FIGS. 13A, 13C, and 13E show procedures for folding the stent-grafts made according to the invention.
FIGS. 13B, 13D, and 13F show the corresponding folded stent-grafts.
FIGS. 14A-14C show a schematic procedure for deploying the inventive stent-grafts using an external sleeve.
FIGS. 15A and 16A show front quarter views of folded stents or stent-grafts held in that folded position by a tether wire. FIGS. 15B, 15C, 16B, and 16C show end views of the folded stent and of the open stent shown respectively in FIGS. 15A and 16A.
FIGS. 17A-17C show a schematic procedure for deploying the inventive stent-grafts (as shown in FIGS. 15A-15C and 16A-16C) using a tether wire.
DESCRIPTION OF THE INVENTION
As was noted above, this invention is variously an expandable stent, a stent-graft, and a fiber reinforced stent-graft. The stent-graft may be a combination of several components: a thin-walled tube generally coaxial with the stent, the expandable stent structure, and an optional network of fibers used to reinforce the tubular component. The stent and the optional reinforcing fibers are desirably imbedded in the wall of the thin-walled tube. The expandable stent structure is a cylindrical body produced of a helically placed (wound or otherwise preformed) torsion member having an undulating or serpentine shape. When the undulating torsion member is formed into the cylinder, the undulations may be aligned so that they are "in phase" with each other. The undulations are desirably linked, typically with a flexible linkage of a suitable polymeric material, to maintain the phased relationship of the undulations during compression and deployment. These stent configurations are exceptionally kink-resistant and flexible, particularly when flexed along the longitudinal axis of the stent.
When the stent is used in a reinforced stent-graft, that is to say: the stent is included into a thin-walled tube having reinforcing fibers, the fibers may be formed into a network, such as a tubular mesh. The stent-graft may be delivered percutaneously through the vasculature after having been folded to a reduced diameter. Once reaching the intended delivery site, it is expanded to form a lining on the vessel wall.
Methods of delivering the various devices using a percutaneous catheter either with or without expansion aids are also an aspect of the invention.
Stent Component
The materials typically used for vascular grafts, e.g., collagen, usually do not have the stiffness or strength by themselves both to stay open against the radial inward loads found in those vessels and to prevent their slippage from the chosen deployment site. In order to provide the strength required, a radially rigid stent structure may be incorporated into the stent-graft. Our stent is constructed of a reasonably high strength material, i.e., one which is resistant to plastic deformation when stressed. The structure is typically from one of three sources: 1.) a wire form in which a wire is first formed into an undulating shape and the resulting undulating shape is helically wound to form a cylinder, 2.) an appropriate shape is formed from a flat stock and wound into a cylinder, and 3.) a length of tubing is formed into an appropriate shape. These stent structures are typically oriented coaxially with the tubular graft component. The stent structures may be placed on the outer surface or the inner surface of the tubular member although it is preferable that the stent be imbedded in the graft tubing wall for ease of integration with the tubing and to prevent the stent's exposure to blood. It is desired that the stent structure have the strength and flexibility to tack the graft tubing firmly and conformally against the vessel wall. In order to minimize the wall thickness of the stent-graft, the stent material should have a high strength-to-volume ratio. Use of designs according to this invention provides stents which are shorter in length than those often used in the prior art. Additionally, the designs do not suffer from a tendency to twist (or helically unwind) or to shorten as the stent is deployed. As will be discussed below, materials suitable in these stents and meeting these criteria include various metals and some polymers.
A percutaneously delivered stent-graft must expand from a reduced diameter, necessary for delivery, to a larger deployed diameter. The diameters of these devices obviously vary with the size of the body lumen into which they are placed. For instance, the stents of this invention may range in size (for neurological applications) from 2.0 mm in diameter to 30 mm in diameter (for placement in the aorta). A range of about 2.0 mm to 6.5 mm (perhaps to 10.0 mm) is believed to be desirable. Typically, expansion ratios of 2:1 or more are required. These stents are capable of expansion ratios of up to 5:1 for larger diameter stents. Typical expansion ratios for use with the stents and stent-grafts of the invention typically are in the range of about 2:1 to about 4:1 although the invention is not so limited. The thickness of the stent materials obviously varies with the size (or diameter) of the stent and the ultimate required yield strength of the folded stent. These values are further dependent upon the selected materials of construction. Wire used in these variations are typically of stronger alloys, e.g., nitinol and stronger spring stainless steels, and have diameters of about 0.002 inches to 0.005 inches. For the larger stents, the appropriate diameter for the stent wire may be somewhat larger, e.g., 0.005 to 0.020 inches. For flat stock metallic stents, thicknesses of about 0.002 inches to 0.005 inches is usually sufficient. For the larger stents, the appropriate thickness for the stent flat stock may be somewhat thicker, e.g., 0.005 to 0.020 inches.
The stent-graft is fabricated in the expanded configuration. In order to reduce its diameter for delivery the stent-graft would be folded along its length, similar to the way in which a PCTA balloon would be folded. It is desirable, when using super-elastic alloys which are also have temperature-memory characteristics, to reduce the diameter of the stent at a temperature below the transition-temperature of the alloys. Often the phase of the alloy at the lower temperature is somewhat more workable and easily formed. The temperature of deployment is desirably above the transition temperature to allow use of the super-elastic properties of the alloy.
As a generic explanation of the mechanical theory of the inventive stent, reference is made to FIGS. 1A, 1B, 1C, 1D, 1E, 2, 3, and 4. FIG. 1A is a plan view of an isolated section of the inventive stent device and is intended both to identify a variation of the invention and to provide conventions for naming the components of the torsion member (100). FIG. 1A shows, in plan view, an undulating torsion member (100) formed from a wire stock into a U-shape. A torsion pair (102) is made up of an end member (104) and two adjacent torsion lengths (106). Typically, then, each torsion length (106) will be a component to each of its adjacent torsion pairs (102). The U-shaped torsion pair (102) may be characterized by the fact that the adjacent torsion lengths are generally parallel to each other prior to formation into the stent.
Generically speaking, the stents of this invention use undulating torsion members which are "open" or "unconfined" at their apex or end member (104). By "open" or "unconfined" we mean that the apex or end member (104) does not have any means in that apex which would tend to inhibit the movement of the flexible linkage (discussed below) down between the arms or torsion lengths (106) of the torsion pair (102).
FIG. 1B shows another variation of the invention having a sinusoidal shaped torsion member (108). In this variation, the adjacent torsion lengths (110) are not parallel and the wire forms an approximate sine shape before being formed into a cylinder.
FIG. 1C shows a variation of the invention having an ovoid shaped torsion member (112). In this variation, the adjacent torsion lengths (114) are again not parallel. The wire forms an approximate open-ended oval with each torsion pair (116) before being formed into a cylinder.
FIG. 1D shows another variation of the invention having a V-shaped torsion member (118). In this variation, the adjacent torsion lengths (120) form a relatively sharp angle at the torsion end (122) shape before being formed into a cylinder.
FIG. 1E shows a variation of the invention in which adjacent torsion members on the stent (117) have differing amplitude. The peaks of the high amplitude torsion members (119) may be lined up "out of phase" or "peak to peak" with short amplitude (121) or high amplitude torsion members in the adjacent turn of the helix or may be positioned "in phase" similar to those discussed with regard to FIG. 2 below.
The configurations shown in FIGS. 1A-1E are exceptionally kink-resistant and flexible when flexed along the longitudinal axis of the stent.
As ultimately deployed, a section of the torsion member found on one of FIGS. 1A-1D would be helically wound about a form of an appropriate size so that the end members (e.g., 104 in FIG. 1A) would be centered between the end members of the torsion member on an adjacent turn of the helix. This is said to be "in phase". "Out of phase" would be the instance in which the adjacent members meet directly, i.e., end member-to-end member. In any event, once so aligned, the phasic relationship may be stabilized by weaving a flexible linkage through the end members from one turn of the helix to the next.
FIG. 2 shows a side view of a typical stent (122) made according to this invention including the phased relationship of the helical turns of the stent and the flexible linkage (124). FIG. 3 shows a close-up of the FIG. 2 stent and depicts the phased relationship (within box A) and shows in detail a typical way in which the flexible linkage (124) is looped through the various end members (104) to maintain the phased relationship. It may be noted that the flexible linkage (124) is free to move away from the apex at the end members (104) without constraint.
The stent may be folded in some fashion (as will be discussed below) for deployment. During the step of folding, the stent undergoes a transformation. FIG. 4 shows an isolated torsion pair (102). When the torsion pair (102) undergoes a flexing in the amount of α°, the end member will flex some amount β°, torsion length (130) will undertake a twist of γ°, and torsion length (132) will undertake a twist opposite of that found in torsion length (130) in the amount of δ°. The amounts of angular torsion found in the torsion lengths (130 and 132) will not necessarily be equal because the torsion lengths are not necessarily at the same angle to the longitudinal axis of the stent. Nevertheless, the sum of β°+γ°+δ°will equal α°. When a value of α° is chosen, as by selection of the shape and size of the stent upon folding, the values of the other three angles (β°, γ°, δ°) are chosen by virtue of selection of number of torsion pairs around the stent, size and physical characteristics of the wire, and length of the torsion lengths (103 and 132). Each of the noted angles must not be so large as to exceed the values at which the chosen material of construction plastically deforms at the chosen value of α°.
To further explain the invention: it should understood that the torsion pair (102) undergoes a significant of flexing as the stent is folded or compressed in some fashion. The flexing provides a twist to the torsion lengths (103 and 132), a significant portion of which is generally parallel to the longitudinal axis of the stent. It is this significant imposed longitudinal torsion which forms an important concept of the inventive stent.
As noted elsewhere, in one very desirable variation of the inventive stent, as deployed in FIGS. 2 and 3, the stent is folded longitudinally and is delivered through the lumen of the catheter in such a way that it is self-restoring once it has been introduced to the selected body lumen site. This stated desire is not to rule out the use of the inventive stent or stent-graft with a balloon or expander or other shape-restoring tool if so desired, but the design of the stent is meant to eliminate the need for (or, at least to minimize the need for) such expanding tools.
With that preliminary background in place, it should be apparent that a simple tube of metal will undergo plastic deformation when sufficient force is applied radially to the outside of the tube. The amount of force needed to cause that plastic deformation will depend on a wide variety of factors, e.g., the type of metal utilized in the tube, the width of the tube, the circumference of the tube, the thickness of the material making up the band, etc. The act of attempting to fold a tube along its centered axis in such a way to allow it to pass through a lumen having the same or smaller diameter and yet maintain the axis of the folded stent parallel to the axis of the lumen invites plastic deformation in and of the stent.
The inventive stent uses concepts which can be thought of as widely distributing and storing the force necessary to fold the tubular stent into a configuration which will fit through a diameter smaller than its relaxed outside diameter without inducing plastic deformation of the constituent metal or plastic and yet allowing those distributed forces to expand the stent upon deployment.
Once the concept of distributing the folding or compression stresses both into a bending component (as typified by angle β° in FIG. 4) and to twisting components (as typified by angle γ° and δ° in FIG. 4), and determining the overall size of a desired stent, determination of the optimum materials as well as the sizes of the various integral components making up the stent becomes straightforward. Specifically, the diameter and length of torsion lengths (130 and 132) and end sector (104), the number of torsion pairs (102) around the stent may then be determined.
FIG. 5 shows, in side view, a variation of the inventive stent (140) made from wire having flares (142) at one or both ends. The flaring provides a secure anchoring of the stent or stent-graft (140) against the vessel wall. This prevents the implant from migrating downstream. In addition, the flaring provides a tight seal against the vessel so that the blood is channelled through the lumen rather than outside the graft. The undulating structure may vary in spacing to allow the helix turns to maintain its phased relationship between turns of the helix and to conform to the discussion just above. A flexible linkage between the contiguous helical turns may also be applied to at least a portion of the helices.
The stent structure may also be made by forming a desired structural pattern out of a flat sheet. The sheet may then be rolled to form a tube. FIGS. 6, 7, and 8 show plan views of torsion members (respectively 200, 202, and 204) which may be then rolled about an axis (206) to form a cylinder. As is shown in FIG. 9, the end caps (208) may be aligned so that they are "out of phase". The flexible linkage (210) is then included to preserve the diameter of the stent.
The stent shown in FIG. 9 may be machined from tubing. If the chosen material in nitinol, careful control of temperature during the machining step may be had by EDM (electro-discharge-machining), laser cutting, chemical machining, or high pressure water cutting.
It should be clear that a variety of materials variously metallic, super elastic alloys, and preferably nitinol, are suitable for use in these stents. Primary requirements of the materials are that they be suitably springy even when fashioned into very thin sheets or small diameter wires. Various stainless steels which have been physically, chemically, and otherwise treated to produce high springiness are suitable as are other metal alloys such as cobalt chrome alloys (e.g., ELGILOY), platinum/tungsten alloys, and especially the nickel-titanium alloys generically known as "nitinol".
Nitinol is especially preferred because of its "super-elastic" or "pseudo-elastic" shape recovery properties, i.e., the ability to withstand a significant amount of bending and flexing and yet return to its original form without deformation. These metals are characterized by their ability to be transformed from an austenitic crystal structure to a stress-induced martensitic structure at certain temperatures, and to return elastically to the austenitic shape when the stress is released. These alternating crystalline structures provide the alloy with its super-elastic properties. These alloys are well known but are described in U.S. Pat. Nos. 3,174,851, 3,351,463, and 3,753,700. Typically, nitinol will be nominally 50.6% (±0.2%) Ni with the remainder Ti. Commercially available nitinol materials usually will be sequentially mixed, cast, formed, and separately cold-worked to 30-40%, annealed, and stretched. Nominal ultimate yield strength values for commercial nitinol are in the range of 30 psi and for Young's modulus are about 700 kBar.
The '700 patent describes an alloy containing a higher iron content and consequently has a higher modulus than the Ni--Ti alloys. Nitinol is further suitable because it has a relatively high strength to volume ratio. This allows the torsion members to be shorter than for less elastic metals. The flexibility of the stent-graft is largely dictated by the length of the torsion member components in the stent structural component. The shorter the pitch of the device, the more flexible the stent-graft structure can be made. Materials other than nitinol are suitable. Spring tempered stainless steels and cobalt-chromium alloys such as ELGILOY are also suitable as are a wide variety of other known "super-elastic" alloys.
Although nitinol is preferred in this service because of its physical properties and its significant history in implantable medical devices, we also consider it also to be suitable for use as a stent because of its overall suitability with magnetic resonance imaging (MRI) technology. Many other alloys, particularly those based on iron, are an anathema to the practice of MRI causing exceptionally poor images in the region of the alloy implant. Nitinol does not cause such problems.
Other materials suitable as the stent include certain polymeric materials, particularly engineering plastics such as thermotropic liquid crystal polymers ("LCP's"). These polymers are high molecular weight materials which can exist in a so-called "liquid crystalline state" where the material has some of the properties of a liquid (in that it can flow) but retains the long range molecular order of a crystal. The term "thermotropic" refers to the class of LCP's which are formed by temperature adjustment. LCP's may be prepared from monomers such as p,p'-dihydroxy-polynuclear-aromatics or dicarboxy-polynuclear-aromatics. The LCP's are easily formed and retain the necessary interpolymer attraction at room temperature to act as high strength plastic artifacts as are needed as a foldable stent. They are particularly suitable when augmented or filled with fibers such as those of the metals or alloys discussed below. It is to be noted that the fibers need not be linear but may have some preforming such as corrugations which add to the physical torsion enhancing abilities of the composite.
FIG. 10 shows a method for producing a stent of the configuration shown in FIG. 9. It may be used, of course, for producing a variety of other configurations shown herein. In this procedure, a preformed strip (211) (preferably nitinol) is rolled onto a mandrel (213) having a channel defined by a thread (215). The pitch of the strip (211) is selected using the criteria discussed above. The pitch angle (215) shown is about 20° but is not critical to the operation of the invention. Once the strip (211) is wound onto the mandrel (213) and the assembly is introduced into the outer sleeve (217), the strip (now in the shape of the stent) may then be annealed (or at least "heat set") to assist in maintaining the resulting stent in a useful shape. For use in stents of the sizes mentioned elsewhere, we have found that nitinol devices may be heat treated for five minutes or less at temperatures of 500° C. without significant lessening of the superelastic properties. Said another way, heating super-elastic alloys must carried out with some care so as not to destroy or significantly lessen the super-elastic properties.
The flexible linkage between adjacent turns of the helix (124 in FIGS. 2 and 3) may be of any appropriate filamentary material which is blood compatible or biocompatible and sufficiently flexible to allow the stent to flex and not deform the stent upon folding. Although the linkage may be a single or multiple strand wire (platinum, platinum/tungsten, gold, palladium, tantalum, stainless steel, etc.), much preferred is the use of polymeric biocompatible filaments. Synthetic polymers such as polyethylene, polypropylene, polyurethane, polyglycolic acid, polyesters, polyamides, their mixtures, blends, copolymers, mixtures, blends and copolymers are suitable; preferred of this class are polyesters such as polyethylene terephthalate including DACRON and MYLAR and polyaramids such as KEVLAR, polyfluorocarbons such as polytetrafluoroethylene with and without copolymerized hexafluoropropylene (TEFLON or GORETEX), and porous or nonporous polyurethanes. Natural materials or materials based on natural sources such as collagen are especially preferred is this service.
Tubular Component
The tubular component or member of the stent-graft may be made up of any material which is suitable for use as a graft in the chosen body lumen. Many graft materials are known, particularly known are vascular graft materials. For instance, natural material may be introduced onto the inner surface of the stent and fastened into place. Synthetic polymers such as polyethylene, polypropylene, polyurethane, polyglycolic acid, polyesters, polyamides, their mixtures, blends, copolymers, mixtures, blends and copolymers are suitable; preferred of this class are polyesters such as polyethylene terephthalate including DACRON and MYLAR and polyaramids such as KEVLAR, polyfluorocarbons such as polytetrafluoroethylene with and without copolymerized hexafluoropropylene (TEFLON or GORETEX), and porous or nonporous polyurethanes. Highly preferred materials are certain collagen-based materials of COLLAGEN CORPORATION of Palo Alto, Calif. The graft may adhere to or partially encapsulate or be cast about the stent when appropriate materials such as castable polyurethane or collagen-based materials are employed. When the stent-graft is produced in such a way that the openings in the stent contain graft material (as by casting), then we refer to such a stent-graft as an "integral stent-graft".
A highly preferred material is a collagen-based material described in U.S. Pat. No. 5,162,430, to Rhee et al, the entirety of which is incorporated by notice, or as described below. Collagen is easily formed into thin-walled tubes which are limp, compliant, flexible, uniform, and have smooth surfaces. The tubing walls may have a hydrated thickness of 0.001 to 0.020 inches (or to 0.100 inches in some cases) for efficacy. Other thicknesses may be used if specific goals are to be achieved. In a stent-graft, the collagen tube acts as an intravascular blood conduit to line the interior surface of the blood vessel. It isolates the lined segment of the vessel from direct contact with blood flow, tacks any tears or dissections, helps reinforce the vessel wall to protect against or isolate aneurysms, and provides a smooth, relatively thin, conformal surface for the blood flow. Of most importance (at least from the perspective of the most preferred aspects of our invention), specific collagenous materials, such as the collagen-hydrophilic polymer conjugate described in U.S. Pat. No. 5,162,430 and as described below, are very desirable as the tubular component in this stent-graft in that they form non-thrombogenic surfaces which will support the growth of endothelium.
The preferred collagen composition used in this invention is a pharmaceutically acceptable non-immunogenic composition formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. Any type of collagen may be used including extracted and purified collagen including atelopeptide collagen which can be type I, type II or type III collagen. The collagen may be extracted from various sources such as bovine hide and human placenta and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may incorporate other components such as biologically active materials. The collagen-polymer conjugates generally contain large amounts of water when formed. The extruded materials may be dehydrated, resulting in a reasonably flexible material which can be readily stored.
The term "collagen" as used herein refers to all forms of collagen, including those which have been extracted, processed or otherwise modified. Preferred collagens are non-immunogenic and, if extracted from animals, are treated to remove the immunogenic telopeptide regions ("atelopeptide collagen"), are soluble, and may be in the fibrillar or non-fibrillar form. Type I collagen is best suited to most applications involving bone or cartilage repair. However, other forms of collagen are also useful in the practice of the invention, and are not excluded from consideration here. Collagen crosslinked using heat, radiation, or chemical agents such as glutaraldehyde may be conjugated with polymers as described herein to form particularly rigid compositions. Collagen crosslinked using glutaraldehyde or other (nonpolymer) linking agents is referred to herein as "GAX", while collagen cross-linked using heat and/or radiation is termed "HRX." Collagen used in connection with the preferred embodiments of the invention is in a pharmaceutically pure form such that it can be incorporated into a body, human or otherwise, for the intended purpose.
The term "synthetic hydrophilic polymer" as used herein refers to a synthetic polymer having an average molecular weight and composition which renders the polymer essentially water-soluble. Preferred polymers are highly pure or are purified to a highly pure state such that the polymer is, or is treated to become, pharmaceutically pure. Most hydrophilic polymers can be rendered water-soluble by incorporating a sufficient number of oxygen (or, less frequently, nitrogen) atoms available for forming hydrogen bonds in aqueous solutions. Preferred polymers are hydrophilic but not soluble. Preferred hydrophilic polymers used herein include polyethylene glycol, polyoxyethylene, polymethylene glycol, polytrimethylene glycols, polyvinylpyrrolidones, and derivatives thereof. The polymers can be linear or multiply branched and will not be substantially crosslinked. Other suitable polymers include polyoxyethylene-polyoxypropylene block polymers and copolymers. Polyoxyethylene-polyoxypropylene block polymers having an ethylene diamine nucleus (and thus having four ends) are also available and may be used in the practice of the invention. Naturally occurring and/or biologically active polymers such as proteins, starch, cellulose, heparin, and the like are not generally desirable in this definition although they may be used. All suitable polymers will be non-toxic, non-inflammatory and non-immunogenic when used to form the desired composition, and will preferably be essentially non-degradable in vivo over a period of at least several months. The hydrophilic polymer may increase the hydrophilicity of the collagen, but does not render it water-soluble. Presently preferred hydrophilic polymers are mono-, di-, and multi-functional polyethylene glycols (PEG). Monofunctional PEG has only one reactive hydroxy group, while difunctional PEG has reactive groups at each end. Monofunctional PEG preferably has a weight average molecular weight between about 100 and about 15,000, more preferably between about 200 and about 8,000, and most preferably about 4,000. Difunctional PEG preferably has a molecular weight of about 400 to about 40,000, more preferably about 3,000 to about 10,000. Multi-functional PEG preferably has a molecular weight between about 3,000 and 100,000.
PEG can be rendered monofunctional by forming an alkylene ether at one end. The alkylene ether may be any suitable alkoxy radical having 1-6 carbon atoms, for example, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, hexyloxy, and the like. Methoxy is presently preferred. Difunctional PEG is provided by allowing a reactive hydroxy group at each end of the linear molecule. The reactive groups are preferably at the ends of the polymer, but may be provided along the length thereof.
The term "chemically conjugated" as used herein means attached through a covalent chemical bond. In the practice of the invention, a synthetic hydrophilic polymer and collagen may be chemically conjugated by using a linking radical, so that the polymer and collagen are each bound to the radical, but not directly to each other. The term "collagen-polymer" refers to collagen chemically conjugated to a synthetic hydrophilic polymer, within the meaning of this invention. Thus, "collagen-PEG" (or "PEG-collagen) denotes a composition within the most preferred aspect of the invention wherein collagen is chemically conjugated to PEG. "Collagen-dPEG" refers to collagen chemically conjugated to difunctional PEG, wherein the collagen molecules are typically crosslinked. "Crosslinked collagen" refers to collagen in which collagen molecules are linked by covalent bonds with polyfunctional (including difunctional) polymers. Terms such as "GAX-dPEG" and "HRX-dPEG" indicate collagen crosslinked by both a difunctional hydrophilic polymer and a crosslinking agent such as glutaraldehyde or heat. The polymer may be "chemically conjugated" to the collagen by means of a number of different types of chemical linkages. For example, the conjugation can be via an ester or urethane linkage, but is more preferably by means of an ether linkage. An ether linkage is preferred in that it can be formed without the use of toxic chemicals and is not readily susceptible to hydrolysis in vivo.
Those of ordinary skill in the art will appreciate that synthetic polymers such as polyethylene glycol cannot be prepared practically to have exact molecular weights, and that the term "molecular weight" as used herein refers to the weight average molecular weight of a number of molecules in any given sample, as commonly used in the art. Thus, a sample of PEG 2,000 might contain a statistical mixture of polymer molecules ranging in weight from, for example, 1,500 to 2,500 daltons with one molecule differing slightly from the next over a range. Specification of a range of molecular weight indicates that the average molecular weight may be any value between the limits specified, and may include molecules outside those limits. Thus, a molecular weight range of about 800 to about 20,000 indicates an average molecular weight of at least about 800, ranging up to about 20 kDa.
The term "available lysine residue" as used herein refers to lysine side chains exposed on the outer surface of collagen molecules, which are positioned in a manner to allow reaction with activated PEG. The number of available lysine residues may be determined by reaction with sodium 2,4,6-trinitrobenzenesulfonate (TNBS).
The term "growth factor" is used to describe biologically active molecules and active peptides (which may be naturally occurring or synthetic) which aid in healing or regrowth of normal tissue. The function of growth factors is two-fold: 1) they can incite local cells to produce new collagen or tissue, or 2) they can attract cells to the site in need of correction. As such, growth factors may serve to encourage "biological anchoring" of the collagen graft implant within the host tissue. As previously described, the growth factors may either be admixed with the collagen-polymer conjugate or chemically coupled to the conjugate. For example, one may incorporate growth factors such as epidermal growth factor (EGF), transforming growth factor (TGF) alpha, TGF.sub.β : (including any combination of TGF.sub.β s), TGF.sub.β1, TGF.sub.β2, platelet derived growth factor (PDGF-AA, PDGF-AB, PDGF-BB), acidic fibroblast growth factor (FGF), basic FGF, connective tissue activating peptides (CTAP), β-thrombo-globulin, insulin-like growth factors, erythropoietin (EPO), nerve growth factor (NGF), bone morphogenic protein (BMP), osteogenic factors, and the like. Incorporation of growth factors can facilitate regrowth when the tubes are used in the treatment of defective or damaged channels. Furthermore, one may chemically link the growth factors to the collagen-polymer composition by employing a suitable amount of multi-functional polymer molecules during synthesis. The growth factors may then be attached to the free polymer ends by the same method used to attach PEG to collagen, or by any other suitable method. By tethering growth factors to the outer and/or inner surface of the graft material, the amount of grafts needed to carry out effective treatment is substantially reduced. Tubes which incorporate growth factors may provide effective controlled-release drug delivery. By varying the chemical linkage between the collagen and the synthetic polymer, it is possible to vary the effect with respect to the release of the biologic. For example, when an "ester" linkage is used, the linkage is more easily broken under physiological conditions, allowing for sustained release of the growth factor from the matrix. However, when an "ether" linkage is used, the bonds are not easily broken and the growth factor will remain in place for longer periods of time with its active sites exposed providing a biological effect on the natural substrate for the active site of the protein. It is possible to include a mixture of conjugates with different linkages so as to obtain variations in the effect with respect to the release of the biologic, e.g., the sustained release effect can be modified to obtain the desired rate of release.
The terms "effective amount" or "amount effective to treat" refer to the amount of composition required in order to obtain the effect desired. Thus, a "tissue growth-promoting amount" of a composition containing a growth factor refers to the amount of growth factor needed in order to stimulate tissue growth to a detectable degree. Tissue, in this context, includes connective tissue, bone, cartilage, epidermis and dermis, blood, and other tissues with particular emphasis on tissues which form channels such as veins, arteries, intestines and the like. The actual amount which is determined to be an effective amount will vary depending on factors such as the size, condition, sex, and age of the patient, the type of tissue or channel, the effect desired and type of growth factor, and can be more readily determined by the caregiver.
The term "sufficient amount" as used herein is applied to the amount of carrier used in combination with the collagen-polymer conjugates used in forming the tubes of the invention. A sufficient amount is that amount which, when mixed with the conjugate, renders it in the physical form desired, for example, extrudable tubes, extrudable cylinders having any desired cross-section, and so forth. Extrudable formulations may include an amount of a carrier sufficient to render the composition smoothly extrudable without significant need to interrupt the extrusion process. The amount of the carrier can be varied and adjusted depending on the size and shape and thickness of the wall of the tube being extruded. Such adjustments will be apparent to those skilled in the art upon reading this disclosure.
Conjugates
To form the most desired collagen-conjugates used in the inventive stent-grafts, collagen must be chemically bound to a synthetic hydrophilic polymer. This can be carried out in a variety of ways. In accordance with the preferred method, the synthetic hydrophilic polymer is activated and then reacted with the collagen. Alternatively, the hydroxyl or amino groups present on the collagen can be activated and the activated groups will react with the polymer to form the conjugate. In accordance with a less preferred method, a linking group with activated hydroxyl or amino groups thereon can be combined with the polymer and collagen in a manner so as to concurrently react with both the polymer and collagen forming the conjugate. Other methods of forming the conjugates will become apparent to those skilled in the art upon reading this disclosure. Since the conjugates of the invention are to be used in the human body it is important that all of the components, including the polymer, collagen, and linking group, if used form a conjugate that is unlikely to be rejected by the body. Accordingly, toxic and/or immunoreactive components are not preferred as starting materials. Some preferred starting materials and methods of forming conjugates are described further below.
Although different hydrophilic synthetic polymers can be used in connection with forming the conjugate, such polymers must be biocompatible, relatively insoluble, but hydrophilic and is preferably one or more forms of polyethylene glycol (PEG), due to its known biocompatibility. Various forms of PEG are extensively used in the modification of biologically active molecules because PEG can be formulated to have a wide range of solubilities and because it lacks toxicity, antigenicity, immunogenicity, and does not typically interfere with the enzymatic activities and/or conformations of peptides. Further, PEG is generally non-biodegradable and is easily excreted from most living organisms including humans.
The first step in forming the collagen-polymer conjugates generally involves the functionalization of the PEG molecule. Various functionalized polyethylene glycols have been used effectively in fields such as protein modification (see Abuchowski et al., Enzymes as Drugs, John Wiley & Sons: New York, N.Y. (1981) pp. 367-383; and Dreborg et al., Crit. Rev. Therap. Drug Carrier Syst. (1990) 6:315, both of which are incorporated herein by reference), peptide chemistry (see Mutter et al., The Peptides, Academic: New York, N.Y. 2:285-332; and Zalipsky et al., Int. J. Peptide Protein Res. (1987) 30:740, both of which are incorporated herein by reference), and the synthesis of polymeric drugs (see Zalipsky et al., Eur. Polym. J. (1983) 19:1177; and Ouchi et al., J. Macromol. Sci. -Chem. (1987) A24:1011, both of which are incorporated herein by reference). Various types of conjugates formed by the binding of polyethylene glycol with specific pharmaceutically active proteins have been disclosed and found to have useful medical applications in part due to the stability of such conjugates with respect to proteolytic digestion, reduced immunogenicity and longer half-lives within living organisms.
One form of polyethylene glycol which has been found to be particularly useful is monomethoxy-polyethylene glycol (mPEG), which can be activated by the addition of a compound such as cyanuric chloride, then coupled to a protein (see Abuchowski et al., J. Biol. Chem. (1977) 252:3578, which is incorporated herein by reference). Although such methods of activating polyethylene glycol can be used in connection with the present invention, they are not particularly desirable in that the cyanuric chloride is relatively toxic and must be completely removed from any resulting product in order to provide a pharmaceutically acceptable composition.
Activated forms of PEG can be made from reactants which can be purchased commercially. One form of activated PEG which has been found to be particularly useful in connection with the present invention is mPEG-succinate-N-hydroxysuccinimide ester (SS-PEG) (see Abuchowski et al., Cancer Biochem. Biphys. (1984) 7:175, which is incorporated herein by reference). Activated forms of PEG such as SS-PEG react with the proteins under relatively mild conditions and produce conjugates without destroying the specific biological activity and specificity of the protein attached to the PEG. However, when such activated PEGs are reacted with proteins, they react and form linkages by means of ester bonds. Although ester linkages can be used in connection with the present invention, they are not particularly preferred in that they undergo hydrolysis when subjected to physiological conditions over extended periods of time (see Dreborg et al., Crit. Rev. Therap. Drug Carrier Syst. (1990) 6:315; and Ulbrich et al., J. Makromol. Chem. (1986) 187:1131, both of which are incorporated herein by reference).
It is possible to link PEG to proteins via urethane linkages, thereby providing a more stable attachment which is more resistant to hydrolytic digestion than the ester linkages (see Zalipsky et al., Polymeric Drug and Drug Delivery Systems, Chapter 10, "Succinimidyl Carbonates of Polyethylene Glycol" (1991) incorporated herein by reference to disclose the chemistry involved in linking various forms of PEG to specific biologically active proteins). The stability of urethane linkages has been demonstrated under physiological conditions (see Veronese et al., Appl. Biochem. Biotechnol. (1985) 11:141; and Larwood et al., J. Labelled Compounds Radiopharm. (1984) 21:603, both of which are incorporated herein by reference). Another means of attaching the PEG to a protein can be by means of a carbamate linkage (see Beauchamp et al., Anal. Biochem. (1983) 131:25; and Berger et al., Blood (1988) 71:1641, both of which are incorporated herein by reference). The carbamate linkage is created by the use of carbonyldiimidazole-activated PEG. Although such linkages have advantages, the reactions are relatively slow and may take 2 to 3 days to complete.
The various means of activating PEG described above and publications (all of which are incorporated herein by reference) cited in connection with the activation means are described in connection with linking the PEG to specific biologically active proteins and not collagen. However, the present invention now discloses that such activated PEG compounds can be used in connection with the formation of collagen-PEG conjugates. Such conjugates provide a range of improved characteristics and as such can be used to form the various compositions used in forming the tubes of the present invention. [Polymeric Drug and Drug Delivery Systems, Chapter 10, "Succinimidyl Carbonates of Polyethylene Glycol" (1991), incorporated herein by reference to disclose the chemistry involved in linking various forms of PEG to specific biologically active proteins.]
As indicated above, the conjugates used in forming the grafts may be prepared by covalently binding a variety of different types of synthetic hydrophilic polymers to collagen. However, because the final product or conjugate obtained must have a number of required characteristics such as being extrudable from a nozzle, biocompatible and non-immunogenic, it has been found useful to use polyethylene glycol as the synthetic hydrophilic polymer. The polyethylene glycol must be modified in order to provide activated groups on one or preferably both ends of the molecule so that covalent binding can occur between the PEG and the collagen. Some specific functionalized forms of PEG are shown structurally below, as are the products obtained by reacting these functionalized forms of PEG with collagen.
The first functionalized PEG is difunctionalized PEG succinimidyl glutarate, referred to herein as (SG-PEG). The structural formula of this molecule and the reaction product obtained by reacting it with collagen is shown in Formula 1. ##STR1##
Another difunctionally activated form of PEG is referred to as PEG succinimidyl (S-PEG). The structural formula for this compound and the reaction product obtained by reacting it with collagen is shown in Formula 2. In a general structural formula for the compound of Formula 2, the subscript 3 is replaced with an "n." In the embodiment shown in Formula 1, n=3, in that there are three repeating CH2 groups on each side of the PEG. The structure in Formula 2 results in a conjugate which includes an "ether" linkage which is not subject to hydrolysis. This is distinct from the first conjugate shown in Formula 1, wherein an ester linkage is provided. The ester linkage is subject to hydrolysis under physiological conditions.
S-PEG. n=3: Difunctional PEG Succinimidyl ##STR2##
Yet another derivatized form of polyethylene glycol, wherein n=2 is shown in Formula 3, as is the conjugate formed by reacting the derivatized PEG with collagen.
S-PEG. n=2: Difunctional PEG Succinimidyl ##STR3## Another preferred embodiment of the invention similar to the compounds of Formula 2 and Formula 3, is provided when n=1. The structural formula and resulting conjugate are shown in Formula 4. It is noted that the conjugate includes both an ether and a peptide linkage. These linkages are stable under physiological conditions.
S-PEG, n=1: Difunctional PEG Succinimidyl ##STR4## Yet another derivatized form of PEG is provided when n=0. The difunctionalized form is referred to as PEG succinimidyl carbonate (SC-PEG). The structural formula of this compound and the conjugate formed by reacting SC-PEG with collagen is shown in Formula 5. Although this conjugate includes a urethane linkage, the conjugate has been found not to have a high degree of stability under physiological conditions. The instability can be a desirable characteristic when the tubes are used in a situation where it is desirable that they dissolve over time.
SC-PEG, n=0: Difunctional PEG Succinimidyl Carbonate ##STR5##
All of the derivatives depicted in Formulas 1-5 involve the inclusion of the succinimidyl group. However, different activating groups can be attached to one or both ends of the PEG. For example, the PEG can be derivatized to form difunctional PEG propionaldehyde (A-PEG), which is shown in Formula 6, as is the conjugate formed by the reaction of A-PEG with collagen.
A-PEG. Difunctional PEG Propion Aldehyde ##STR6##
Yet another functionalized form of polyethylene glycol is difunctional PEG glycidyl ether (E-PEG), which is shown in Formula 7, as ##STR7##
The conjugates formed using the functionalized forms of PEG vary depending on the functionalized form of PEG which is used in the reaction. Furthermore, the final product can be varied with respect to its characteristics by changing the molecular weight of the PEG. In general, the stability of the conjugate is improved by eliminating any ester linkages between the PEG and the collagen and including ether and/or urethane linkages. These stable linkages are generally used to form tubes to replace or augment a channel as may be done with a stent-graft. When the grafts are used as a temporary repair unit for a damaged channel, it may be desirable to include the weaker ester linkages so that the linkages are gradually broken by hydrolysis under physiological conditions, breaking apart the tube as it may be replaced by host tissue, or as it degrades, and releasing a component held therein, such as a growth factor. By varying the chemical structure of the linkage, the rate of sustained release can be varied.
Suitable collagens include all types of pharmaceutically useful collagen, preferably types I, II and III. Collagens may be soluble (for example, commercially available Vitrogen® 100 collagen-in-solution), and may or may not have the telopeptide regions. Preferably, the collagen will be reconstituted fibrillar atelopeptide collagen, for example Zyderm® collagen implant (ZCI) or atelopeptide collagen in solution (CIS). Various forms of collagen are available commercially, or may be prepared by the processes described in, for example, U.S. Pat. Nos. 3,949,073; 4,488,911; 4,424,208; 4,582,640; 4,642,117; 4,557,764; and 4,689,399, all incorporated herein by reference. Fibrillar, atelopeptide, reconstituted collagen is preferred in order to form tubes used for the repair or augmentation of channels.
Compositions used in forming the invention comprise collagen chemically conjugated to a selected synthetic hydrophilic polymer or polymers. Collagen contains a number of available amino and hydroxy groups which may be used to bind the synthetic hydrophilic polymer. The polymer may be bound using a "linking group", as the native hydroxy or amino groups in collagen and in the polymer frequently require activation before they can be linked. For example, one may employ compounds such as dicarboxylic anhydrides (e.g., glutaric or succinic anhydride) to form a polymer derivative (e.g., succinate), which may then be activated by esterification with a convenient leaving group, for example, N-hydroxy-succinimide, N,N'-disuccinimidyl oxalate, N,N'-disuccinimidyl carbonate, and the like. See also Davis, U.S. Pat. No. 4,179,337 for additional linking groups. Presently preferred dicarboxylic anhydrides that are used to form polymer-glutarate compositions include glutaric anhydride, adipic anhydride, 1,8-naphthalene dicarboxylic anhydride, and 1,4,5,8-naphthalenetetracarboxylic dianhydride. The polymer thus activated is then allowed to react with the collagen, forming a collagen-polymer composition used to make the grafts.
In one highly desirable embodiment having ester linkages, a pharmaceutically pure form of monomethylpolyethylene glycol (mPEG) (mw 5,000) is reacted with glutaric anhydride (pure form) to create mPEG glutarate. The glutarate derivative is then reacted with N-hydroxy-succinimide to form a succinimidyl monomethylpolyethylene glycol glutarate. The succinimidyl ester (mPEG*, denoting the activated PEG intermediate) is then capable of reacting with free amino groups present on collagen (lysine residues) to form a collagen-PEG conjugate wherein one end of the PEG molecule is free or nonbound. Other polymers may be substituted for the monomethyl PEG, as described above. Similarly, the coupling reaction may be carried out using any known method for derivatizing proteins and synthetic polymers. The number of available lysines conjugated may vary from a single residue to 100% of the lysines, preferably 10-50%, and more preferably 20-30%. The number of reactive lysine residues may be determined by standard methods, for example by reaction with TNBS.
The resulting product is a smooth, pliable, rubbery mass having a shiny appearance. It may be wetted, but is not water-soluble. It may be formulated as a suspension at any convenient concentration, preferably about 30-65 mg/mL, and may be extruded through a nozzle to form a tube. The consistency of the formulation may be adjusted by varying the amount of liquid used.
The tubular component, whether collagen-based or not, may be reinforced using a network of small diameter fibers. The fibers may be random, braided, knitted, or woven. The fibers may be imbedded in the tubular component wall, may be placed in a separate layer coaxial with the tubular component, or may be used in a combination of the two. FIG. 11 shows an end view, cross-section of the configuration in which the stent (220) forms the outermost layer, a fibrous layer (222) coaxial to and inside the stent (220), and the tubular component (224) of, e.g., collagen as the inner layer.
Particularly desirable is the variation shown in FIG. 12 in which the fibrous material is mixed with or imbedded into the tubular layer (226) and cast or injected around the stent (220). This fibrous material may extend for the length of the device or may be shorter. The fibers may be wound or placed in any reasonable orientation within the device. Alternatively, randomly oriented short segments of fibers may also be imbedded in the wall of the tubing. The fiber may be any suitable fibrous blood-compatible material including polyesters such as DACRON, polyamides such as NYLON, KEVLAR, polyglycolic acids, polylactic acids, polyethylene, polypropylene, silk or other strong flexible fiber which are not detrimentally affected in the medical service in which this device is placed. Specifically, polypropylene and the like will not be dissolved in blood but polyglycolic acid will dissolve. Each are suitable but work in different ways.
In addition, one or more radio-opaque metallic fibers, such as gold, platinum, platinum-tungsten, palladium, platinum-iridium, rhodium, tantalum, or alloys or composites of these metals like may be incorporated into the multi-strand reinforcement network to allow fluoroscopic visualization of the device.
In the collagen-fiber composite tube, the fibers carry much of the hoop stress and other loadings imposed by the vessel. This relieves the loading on the collagen and significantly increases the burst strength and fatigue properties of the tube. In addition, this makes the tube more effective in hydraulically isolating the vessel and as a result prevents the formation or worsening of aneurysms. This would be particularly beneficial in thinned weakened vessel walls resulting from de-bulking interventions or from medial thinning that has been seen to accompany stent placement. Another benefit of the fiber reinforcement is the increase in resistance to radially inward loading, especially if the loading is very focussed. Finally, fiber reinforcement may also impart some longitudinal stiffness to the stent-graft. This allows the stent-graft to maintain its strength and prevent it from kinking or sagging into the lumen.
Production of the Stent-Graft
The preferred method of constructing the stent-graft is to first construct the stent and then to mold or cast the collagen tubular component about the stent.
The stent structure and fiber reinforcement may be molded into the wall of the collagen tube. A mold for such a structure desirably is a simple annular space between two cylinders having room in the annular space for placement of the stent and would have a longitudinal axis slightly longer than the length of the stent-graft to be produced. The stent and fiber tubing is centered in the annular space and then the remaining space filled with collagen. If sPEG cross-linked collagen is used as the matrix material, the sPEG and collagen are mixed and introduced into the mold and allowed to cure. After curing, the mold is separated and the inventive fiber reinforced collagen tube with a stent structure produced.
Deployment of the Invention
When a stent-graft having torsion members is folded, crushed, or otherwise collapsed, mechanical energy is stored in torsion in those torsion members. In this loaded state, the torsion members have a torque exerted about them and consequently have a tendency to untwist. Collectively, the torque exerted by the torsion members as folded down to a reduced diameter must be restrained from springing open. The stent typically has at least one torsion member per fold to take advantage of the invention. The stent-graft is folded along its longitudinal axis and restrained from springing open. The stent-graft is then deployed by removing the restraining mechanism, thus allowing the torsion members to spring open against the vessel wall.
The attending surgeon will choose a stent or stent-graft having an appropriate diameter. However, inventive devices of this type are typically selected having an expanded diameter of up to about 10% greater than the diameter of the lumen to be the site of the stent deployment.
FIG. 13A shows a sequence of folding the device (230) of this invention about a guidewire (232) into a loose C-shaped configuration. FIG. 13B shows a front quarter view of the resulting folded stent or stent-graft.
FIG. 13C shows a sequence of folding the device (230) of this invention about a guidewire (232) into a rolled configuration. FIG. 13D shows a front quarter view of the resulting folded stent or stent-graft.
FIG. 13E shows a sequence of folding the device (230) of this invention about a guidewire (232) into a triple lobed configuration. FIG. 13F shows a front quarter view of the resulting folded stent or stent-graft.
The stent-graft may be tracked through the vasculature to the intended deployment site and then unfolded against the vessel lumen. The collagen tube component of the stent-graft is limp, flexible, and thus easy to fold. Folding of the stent structure in the manner discussed above allows it to return to a circular, open configuration.
FIGS. 14A-14C show one desired way to place the devices of the present invention and allow them to self-expand. FIG. 14A shows a target site (246) having, e.g., a narrowed vessel lumen. A guidewire (248) having a guide tip (250) has been directed to the site using known techniques. The stent-graft (252) is mounted on guidewire tubing (254) inside outer sliding sheath (256) after having folded in the manner discussed above. The outer sliding sheath (256) binds the compressed stent-graft (252) in place until released.
FIG. 14B shows placement of the stent-graft (252) at the selected site (246) by sliding the stent-graft (252) over the guidewire (248) all together with the guidewire tubing (254) and the outer sliding sheath (256). The stent-graft (252) is deployed by holding the guidewire tubing (254) in a stationary position while withdrawing the outer sliding sheath (256). The stent-graft (252) can be seen in FIG. 14B as partially deployed.
FIG. 14C shows the stent-graft (252) fully deployed after the guidewire tubing (254) and the outer sliding sheath (256) have been fully retracted.
FIGS. 15A-C, 16A-C, and 17A-C show an inventive variation of deploying a stent or stent-graft made according to this invention. These methods involve the use of a control line or tether line which maintains the stent or stent-graft in a folded configuration until release.
FIG. 15A is a front-quarter view of the stent (302) or stent-graft which has been folded as shown in the Figures discussed above. The stent (302) is folded about guidewire (304) so that, when deployed, the guidewire (304) is within the stent (302). Central to the variation shown here is the tether wire (306) which is passed through loops (308) associated with the various helices as they wind about the stent (302). The loops (308) may be formed from the flexible link (124 in FIG. 2 or 3) or may be simply an alternating weave through appropriate apexes of the undulating helix, e.g., (104 in FIG. 3) or may be loops specifically installed for the purpose shown here. It should be clear that the tether wire (306) is so placed that when it is removed by sliding it axially along the stent (302) and out of the loops (308), that the stent (302) unfolds into a generally cylindrical shape within the body lumen.
FIG. 15B shows an end-view of a folded stent (302) or stent-graft having a guidewire (304) within the inner surface of the stent (302) and with the tether wire (306) within the loops (308). The end view of the folded stent (302) shows it to be folded into a form which is generally C-shaped. When expanded by removal of the tether wire (306), the stent (302) in FIG. 15B assumes the form shown in end view in FIG. 15C. There may be seen the guidewire (304) within the lumen of the stent (302) and the loops (308) which were formerly in a generally linear relationship having a tether wire passing through them.
FIG. 16A shows a folded stent (310) (or stent-graft) in front quarter view which is similar in configuration to the stent (302) shown in FIG. 15A except that the stent (310) is rolled somewhat tighter than the previously discussed stent. The guidewire (304) is also inside the stent (310) rather than outside of it. Loops (308) from generally opposing sides of the stent (310) are folded into an approximate line so that the tether wire may pass through the aligned loops (308). FIG. 16B shows an end view of the stent (310), and in particular, emphasizes the tighter fold of the stent (310). When expanded by removal of the tether wire (306), the stent (310) in FIG. 16B assumes the form shown in FIG. 16C. In FIG. 16C may be seen the guidewire (304) within the lumen of the stent (310) and the loops (308) which were formerly in a generally linear relationship having a tether wire passing through them.
FIGS. 17A-C show a schematic procedure for deploying the stent (312) (or stent-graft) using a percutaneous catheter assembly (314).
In FIG. 17A may be seen a percutaneous catheter assembly (314) which has been inserted to a selected site (316) within a body lumen. The stent (312) is folded about the guidewire (319) and guidewire tube (318) held axially in place prior to deployment by distal barrier (320) and proximal barrier (322). The distal barrier (320) and proximal barrier (322) typically are affixed to the guidewire tube (318). The tether wire (306) is shown extending through loops (308) proximally through the catheter assembly's (314) outer jacket (324) through to outside the body.
FIG. 17B shows the removal of the tether wire (306) from a portion of the loops (308) to partially expand the stent (312) onto the selected site (316).
FIG. 17C shows the final removal of the tether wire (306) from the loops (308) and the retraction of the catheter assembly (314) from the interior of the stent (312). The stent (312) is shown as fully expanded.
Many alterations and modifications may be made by those of ordinary skill in the art without departing from the spirit and scope of the invention. The illustrated embodiments have been shown only for purposes of clarity and examples, and should not be taken as limiting the invention as defined by the following claims, which include all equivalents, whether now or later devised.

Claims (18)

What is claimed is:
1. A method for introducing a stent to a desired site in a body lumen comprising the steps of:
providing a generally tubular stent which is self-expandable from a collapsed state toward an uncollapsed state and which includes a member arranged in a helical configuration with multiple helical turns coupled with a flexible link and having multiple undulations, each having an unconfined apex;
introducing said self-expanding stent to a selected site in a body lumen with said stent in said collapsed state; and
releasing the collapsed self-expanding stent at the selected site so as to allow the collapsed stent to expand toward said uncollapsed state with undulations in adjacent turns being maintained generally in phase with one another with said flexible link and allowing said flexible link to move between any location within a substantial portion of a respective undulation and its corresponding apex in an unconfined manner.
2. The method of claim 1 wherein the stent is delivered to a vascular site.
3. The method of claim 1 in which the introducing step includes introducing the self-expanding stent to the site with the stent in a folded state.
4. The method of claim 3 in which the self-expanding stent is held in said folded state prior to release by an exterior sliding sheath.
5. The method of claim 3 in which the stent is held in said folded state prior to release by a slip line coupled to said stent.
6. The method of claim 1 in which the stent is metallic.
7. The method of claim 1 in which the stent is a super-elastic alloy.
8. The method of claim 1 in which the stent is nitinol.
9. The method of claim 1 in which at least one end of the stent is flared.
10. The method of claim 8 in which at least one end of the stent is flared.
11. The method of claim 1 wherein the introducing step includes introducing a stent-graft having unconfined apexes in said collapsed and expanded states.
12. The method of claim 1 wherein the introducing step includes introducing said stent with a frangible graft coupled thereto, both in a collapsed state, and the releasing step includes releasing the stent and graft to asume expanded states without fracturing the frangible graft member.
13. The method of claim 12 wherein said stent and graft member are generally coaxial.
14. The method of claim 1 wherein apexes in one turn are allowed to move into undulations in an adjacent turn in an unrestricted manner.
15. The method of claim 1 wherein said introducing step includes introducing said stent with a graft coupled thereto, and the releasing step includes releasing the collapsed self-expanding stent without changing the length of said stent.
16. The method of claim 15 wherein said stent and graft are generally coaxial after said releasing step.
17. A method for delivering a prosthetic device in a mammal comprising the steps of:
providing a generally tubular stent which is self-expandable from a collapsed state toward an uncollapsed state and which includes a member which is arranged in a helical configuration with multiple helical turns coupled with a flexible link and which has multiple undulations, each having an unconfined apex:
delivering said stent to a selected site in a body lumen with the stent in said collapsed state; and
bending the stent along its longitudinal axis as it is being delivered to the selected site, while maintaining undulations in adjacent turns generally in-phase with one another with said flexible link and allowing said flexible link to move between any location within a substantial portion of a respective undulation and its corresponding apex in an unconfined manner.
18. A method for delivering a prosthetic device in a mammal comprising the steps of:
providing a generally tubular stent which is self-expandable from a collapsed state toward an uncollapsed state and which includes a member which is arranged in a helical configuration with multiple helical turns, said member having multiple undulations, each having an unconfined apex;
delivering the stent to a selected site in a body lumen with the stent in said collapsed state; and
bending the stent along its longitudinal axis as it is being delivered to the selected site, and allowing apexes in one turn to move toward apexes in an adjacent turn in a substantially unrestricted manner.
US08/221,815 1994-04-01 1994-04-01 Self-expandable helical intravascular stent and stent-graft Expired - Lifetime US6165210A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US08/221,815 US6165210A (en) 1994-04-01 1994-04-01 Self-expandable helical intravascular stent and stent-graft
US08/411,452 US5876432A (en) 1994-04-01 1995-03-28 Self-expandable helical intravascular stent and stent-graft
JP07524227A JP3129327B2 (en) 1994-04-01 1995-04-03 Self-expandable stents and stent-grafts and methods of using them
EP95916920A EP0754016B1 (en) 1994-04-01 1995-04-03 Self-expandable stent and stent-graft
PCT/US1995/004000 WO1995026695A2 (en) 1994-04-01 1995-04-03 Self-expandable stent and stent-graft and method of using them
AU23795/95A AU690684B2 (en) 1994-04-01 1995-04-03 Self-expandable stent and stent-graft and method of using them
DE69532049T DE69532049T2 (en) 1994-04-01 1995-04-03 Self-expanding stent or stent graft and method for its preparation
CA002261941A CA2261941C (en) 1994-04-01 1995-04-03 Self-expandable stent and stent-graft and method of using them
EP00101667A EP0997115B1 (en) 1994-04-01 1995-04-03 Self-expandable stent and stent-graft and method of preparing them
AT00101667T ATE252872T1 (en) 1994-04-01 1995-04-03 SELF-EXPANDABLE STENT OR STENT TRANSPLANT AND METHOD FOR PREPARING SAME
CA2499888A CA2499888C (en) 1994-04-01 1995-04-03 Self-expandable stent and stent-graft and method of using them
DE69531239T DE69531239T2 (en) 1994-04-01 1995-04-03 SELF-EXPANDABLE STENT AND STENT-GRAFT TRANSPLANT
AT95916920T ATE244543T1 (en) 1994-04-01 1995-04-03 SELF-EXPANDABLE STENT AND STENT-GRAFT TRANSPLANT
CA002157575A CA2157575C (en) 1994-04-01 1995-04-03 Self-expandable stent and stent-graft and method of using them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/221,815 US6165210A (en) 1994-04-01 1994-04-01 Self-expandable helical intravascular stent and stent-graft

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/411,452 Division US5876432A (en) 1994-04-01 1995-03-28 Self-expandable helical intravascular stent and stent-graft

Publications (1)

Publication Number Publication Date
US6165210A true US6165210A (en) 2000-12-26

Family

ID=22829513

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/221,815 Expired - Lifetime US6165210A (en) 1994-04-01 1994-04-01 Self-expandable helical intravascular stent and stent-graft
US08/411,452 Expired - Lifetime US5876432A (en) 1994-04-01 1995-03-28 Self-expandable helical intravascular stent and stent-graft

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/411,452 Expired - Lifetime US5876432A (en) 1994-04-01 1995-03-28 Self-expandable helical intravascular stent and stent-graft

Country Status (1)

Country Link
US (2) US6165210A (en)

Cited By (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331188B1 (en) 1994-08-31 2001-12-18 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US6352561B1 (en) 1996-12-23 2002-03-05 W. L. Gore & Associates Implant deployment apparatus
US6352553B1 (en) 1995-12-14 2002-03-05 Gore Enterprise Holdings, Inc. Stent-graft deployment apparatus and method
US6361637B2 (en) 1995-12-14 2002-03-26 Gore Enterprise Holdings, Inc. Method of making a kink resistant stent-graft
US20020040238A1 (en) * 1994-08-12 2002-04-04 Meadox Medicals, Inc. High strength and high density intraluminal wire stent
US6451050B1 (en) * 2000-04-28 2002-09-17 Cardiovasc, Inc. Stent graft and method
WO2002089706A1 (en) * 2001-05-03 2002-11-14 Bionx Implants, Inc. Method for attaching axial filaments to a self expanding stent
US20020177890A1 (en) * 1996-01-05 2002-11-28 Lenker Jay A. Stent graft loading and deployment device and method
US6497671B2 (en) * 1997-12-05 2002-12-24 Micrus Corporation Coated superelastic stent
US6533807B2 (en) 1998-02-05 2003-03-18 Medtronic, Inc. Radially-expandable stent and delivery system
US6544249B1 (en) * 1996-11-29 2003-04-08 The Lions Eye Institute Of Western Australia Incorporated Biological microfistula tube and implantation method and apparatus
US6551350B1 (en) 1996-12-23 2003-04-22 Gore Enterprise Holdings, Inc. Kink resistant bifurcated prosthesis
WO2003057077A1 (en) * 2001-12-28 2003-07-17 Advanced Cardiovascular Systems, Inc. Hybrid stent
US6599319B2 (en) * 2001-12-14 2003-07-29 Celanese Advanced Materials, Inc. Prosthetic ligament
US6602280B2 (en) 2000-02-02 2003-08-05 Trivascular, Inc. Delivery system and method for expandable intracorporeal device
US6613072B2 (en) 1994-09-08 2003-09-02 Gore Enterprise Holdings, Inc. Procedures for introducing stents and stent-grafts
US20030181848A1 (en) * 2000-04-14 2003-09-25 Bergheim Olav B. Implant with drug coating
US20040024446A1 (en) * 1999-07-02 2004-02-05 Scimed Life Systems, Inc. Helically formed stent/graft assembly
US6723120B2 (en) 1997-04-15 2004-04-20 Advanced Cardiovascular Systems, Inc. Medicated porous metal prosthesis
US6733521B2 (en) 2001-04-11 2004-05-11 Trivascular, Inc. Delivery system and method for endovascular graft
US6758858B2 (en) 1995-03-10 2004-07-06 Bard Peripheral Vascular, Inc. Diametrically adaptable encapsulated stent and methods for deployment thereof
US6761733B2 (en) 2001-04-11 2004-07-13 Trivascular, Inc. Delivery system and method for bifurcated endovascular graft
US6770089B1 (en) * 2000-12-28 2004-08-03 Advanced Cardiovascular Systems, Inc. Hybrid stent fabrication using metal rings and polymeric links
US6783438B2 (en) 2002-04-18 2004-08-31 Ormco Corporation Method of manufacturing an endodontic instrument
US6790226B2 (en) 1995-03-10 2004-09-14 Bard Peripheral Vascular, Inc. Endoluminal prosthesis with support wire
US6790223B2 (en) 2001-09-21 2004-09-14 Scimed Life Systems, Inc. Delivering a uretheral stent
US6805706B2 (en) 2002-08-15 2004-10-19 Gmp Cardiac Care, Inc. Stent-graft with rails
US6805898B1 (en) 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
US20040215320A1 (en) * 2003-04-25 2004-10-28 James Machek Integral stent graft
US20040216814A1 (en) * 2003-05-02 2004-11-04 Dooley Bret A. Shape memory alloy articles with improved fatigue performance and methods therefore
US20040243215A1 (en) * 2003-05-27 2004-12-02 Kristoff Nelson Staged deployment endograft
EP1518518A2 (en) * 2003-09-25 2005-03-30 Karel Volenec Stent designed to stop esophageal variceal bleeding
US20050085898A1 (en) * 2003-10-21 2005-04-21 Cook Incorporated. Natural tissue stent
US6887215B2 (en) 2001-06-01 2005-05-03 Boston Scientific Scimed, Inc. Compressible ureteral stent for comfort
WO2005039445A2 (en) * 2003-10-23 2005-05-06 Peacock James C Iii Stent-graft assembly formed insitu
US20050118344A1 (en) * 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050171595A1 (en) * 2001-03-06 2005-08-04 Feldman Marc D. Method and apparatus for stent deployment with enhanced delivery of bioactive agents
US20060014480A1 (en) * 2002-04-18 2006-01-19 Ormco Corporation Method of manufacturing a dental instrument
US20060052861A1 (en) * 2002-12-24 2006-03-09 Novostent Corporation Vascular prothesis having interdigitating edges and methods of use
US20060142840A1 (en) * 2004-12-28 2006-06-29 Scimed Life Systems, Inc. Low profile stent-graft attachment
US20060149364A1 (en) * 2004-12-31 2006-07-06 Steven Walak Low profile vascular graft
WO2007002392A2 (en) * 2005-06-24 2007-01-04 Power Ten, Llc Expandable surgical site access system
US20070073375A1 (en) * 2005-09-23 2007-03-29 Boston Scientific Scimed, Inc. Secured stent delivery system
US7225518B2 (en) 2004-02-23 2007-06-05 Boston Scientific Scimed, Inc. Apparatus for crimping a stent assembly
US20070129786A1 (en) * 2005-10-14 2007-06-07 Bradley Beach Helical stent
US20070149690A1 (en) * 2005-12-23 2007-06-28 Boston Scientific Scimed, Inc. Functionalized block copolymers
US7314480B2 (en) 2003-02-27 2008-01-01 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery
US7367989B2 (en) 2003-02-27 2008-05-06 Scimed Life Systems, Inc. Rotating balloon expandable sheath bifurcation delivery
US20080262630A1 (en) * 2005-10-13 2008-10-23 Synthes (U.S.A. Drug-Impregnated Encasement
US20090143760A1 (en) * 2007-11-30 2009-06-04 Jacques Van Dam Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder
US7637936B2 (en) 2001-04-06 2009-12-29 Boston Scientific Scimed, Inc. Stent design
US7651529B2 (en) 2003-05-09 2010-01-26 Boston Scientific Scimed, Inc. Stricture retractor
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
US7686841B2 (en) 2003-12-29 2010-03-30 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery system
US7691078B2 (en) 2001-05-22 2010-04-06 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20100094394A1 (en) * 2008-10-06 2010-04-15 Bradley Beach Reconstrainable stent delivery system
US20100094447A1 (en) * 2008-10-09 2010-04-15 Seiko Epson Corporation Operation sequence creating apparatus, method for controlling same, and program
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20100119696A1 (en) * 2006-06-30 2010-05-13 Aquesys, Inc. Manufacture of an organ implant
US7744619B2 (en) 2004-02-24 2010-06-29 Boston Scientific Scimed, Inc. Rotatable catheter assembly
US7766954B2 (en) 2001-12-20 2010-08-03 Trivascular2, Inc. Advanced endovascular graft
US7803180B2 (en) 2005-04-04 2010-09-28 Flexible Stenting Solutions, Inc. Flexible stent
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
US20100286760A1 (en) * 2009-04-24 2010-11-11 Bradley Beach Flexible devices
US7850637B2 (en) 1999-04-26 2010-12-14 Glaukos Corporation Shunt device and method for treating glaucoma
US7857782B2 (en) 2001-04-07 2010-12-28 Glaukos Corporation Ocular implant delivery system and method thereof
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US20110015721A1 (en) * 1998-03-05 2011-01-20 Boston Scientific Scimed, Inc. Intraluminal Stent
US7879079B2 (en) 2001-08-28 2011-02-01 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US7892274B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US7918881B2 (en) 2003-06-09 2011-04-05 Xtent, Inc. Stent deployment systems and methods
US7922753B2 (en) 2004-01-13 2011-04-12 Boston Scientific Scimed, Inc. Bifurcated stent delivery system
US7922740B2 (en) 2004-02-24 2011-04-12 Boston Scientific Scimed, Inc. Rotatable catheter assembly
US7938852B2 (en) 2001-12-03 2011-05-10 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US8007459B2 (en) 2002-09-21 2011-08-30 Glaukos Corporation Ocular implant with anchoring mechanism and multiple outlets
US8012192B2 (en) 2004-02-18 2011-09-06 Boston Scientific Scimed, Inc. Multi-stent delivery system
US8016871B2 (en) 2001-12-03 2011-09-13 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US8016870B2 (en) 2001-12-03 2011-09-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US8066755B2 (en) 2007-09-26 2011-11-29 Trivascular, Inc. System and method of pivoted stent deployment
US8080048B2 (en) 2001-12-03 2011-12-20 Xtent, Inc. Stent delivery for bifurcated vessels
US8083789B2 (en) 2007-11-16 2011-12-27 Trivascular, Inc. Securement assembly and method for expandable endovascular device
US8083788B2 (en) 2001-12-03 2011-12-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US8118768B2 (en) 2001-04-07 2012-02-21 Dose Medical Corporation Drug eluting ocular implant with anchor and methods thereof
US8133199B2 (en) 2008-08-27 2012-03-13 Boston Scientific Scimed, Inc. Electroactive polymer activation system for a medical device
US8172897B2 (en) 1997-04-15 2012-05-08 Advanced Cardiovascular Systems, Inc. Polymer and metal composite implantable medical devices
US8177831B2 (en) 2001-12-03 2012-05-15 Xtent, Inc. Stent delivery apparatus and method
US8196279B2 (en) 2008-02-27 2012-06-12 C. R. Bard, Inc. Stent-graft covering process
US8226701B2 (en) 2007-09-26 2012-07-24 Trivascular, Inc. Stent and delivery system for deployment thereof
US8241346B2 (en) 2001-12-20 2012-08-14 Trivascular, Inc. Endovascular graft and method of delivery
US8257427B2 (en) 2001-09-11 2012-09-04 J.W. Medical Systems, Ltd. Expandable stent
US8282680B2 (en) 2003-01-17 2012-10-09 J. W. Medical Systems Ltd. Multiple independent nested stent structures and methods for their preparation and deployment
US8308701B2 (en) 2010-11-15 2012-11-13 Aquesys, Inc. Methods for deploying intraocular shunts
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8328861B2 (en) 2007-11-16 2012-12-11 Trivascular, Inc. Delivery system and method for bifurcated graft
US8333003B2 (en) 2008-05-19 2012-12-18 Boston Scientific Scimed, Inc. Bifurcation stent crimping systems and methods
US8337445B2 (en) 2001-05-03 2012-12-25 Glaukos Corporation Ocular implant with double anchor mechanism
US8361136B2 (en) 1998-02-09 2013-01-29 Trivascular, Inc. Endovascular graft
US8372131B2 (en) 2007-07-16 2013-02-12 Power Ten , LLC Surgical site access system and deployment device for same
US8414635B2 (en) 1999-02-01 2013-04-09 Idev Technologies, Inc. Plain woven stents
US8419788B2 (en) 2006-10-22 2013-04-16 Idev Technologies, Inc. Secured strand end devices
US8460358B2 (en) 2004-03-30 2013-06-11 J.W. Medical Systems, Ltd. Rapid exchange interventional devices and methods
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8500794B2 (en) 2007-08-02 2013-08-06 Flexible Stenting Solutions, Inc. Flexible stent
US8506515B2 (en) 2006-11-10 2013-08-13 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US20130211501A1 (en) * 2012-02-14 2013-08-15 W. L. Gore & Associates, Inc. Endoprosthesis having aligned legs for ease of cannulation
US8585629B2 (en) 2010-11-15 2013-11-19 Aquesys, Inc. Systems for deploying intraocular shunts
US8585747B2 (en) 2003-12-23 2013-11-19 J.W. Medical Systems Ltd. Devices and methods for controlling and indicating the length of an interventional element
US8586125B2 (en) 1999-09-03 2013-11-19 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US8617234B2 (en) 2004-05-25 2013-12-31 Covidien Lp Flexible vascular occluding device
US8617094B2 (en) 2002-03-07 2013-12-31 Glaukos Corporation Fluid infusion methods for glaucoma treatment
US8617337B2 (en) 1999-02-02 2013-12-31 Bard Peripheral Vascular, Inc. Partial encapsulation of stents
US8623067B2 (en) 2004-05-25 2014-01-07 Covidien Lp Methods and apparatus for luminal stenting
US8623070B2 (en) 2007-03-08 2014-01-07 Thomas O. Bales Tapered helical stent and method for manufacturing the stent
US8652198B2 (en) 2006-03-20 2014-02-18 J.W. Medical Systems Ltd. Apparatus and methods for deployment of linked prosthetic segments
US8652193B2 (en) 2005-05-09 2014-02-18 Angiomed Gmbh & Co. Medizintechnik Kg Implant delivery device
US8663309B2 (en) 2007-09-26 2014-03-04 Trivascular, Inc. Asymmetric stent apparatus and method
US8663303B2 (en) 2010-11-15 2014-03-04 Aquesys, Inc. Methods for deploying an intraocular shunt from a deployment device and into an eye
US8702781B2 (en) 2001-12-03 2014-04-22 J.W. Medical Systems Ltd. Apparatus and methods for delivery of multiple distributed stents
US8721702B2 (en) 2010-11-15 2014-05-13 Aquesys, Inc. Intraocular shunt deployment devices
US8758290B2 (en) 2010-11-15 2014-06-24 Aquesys, Inc. Devices and methods for implanting a shunt in the suprachoroidal space
US8765210B2 (en) 2011-12-08 2014-07-01 Aquesys, Inc. Systems and methods for making gelatin shunts
US8769796B2 (en) 2008-09-25 2014-07-08 Advanced Bifurcation Systems, Inc. Selective stent crimping
US8784472B2 (en) 2003-08-15 2014-07-22 Boston Scientific Scimed, Inc. Clutch driven stent delivery system
US8795347B2 (en) 2008-09-25 2014-08-05 Advanced Bifurcation Systems, Inc. Methods and systems for treating a bifurcation with provisional side branch stenting
US8801766B2 (en) 2010-11-15 2014-08-12 Aquesys, Inc. Devices for deploying intraocular shunts
US8808347B2 (en) 2008-09-25 2014-08-19 Advanced Bifurcation Systems, Inc. Stent alignment during treatment of a bifurcation
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
US8828070B2 (en) 2010-11-15 2014-09-09 Aquesys, Inc. Devices for deploying intraocular shunts
US8852137B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for implanting a soft gel shunt in the suprachoroidal space
US8852256B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for intraocular shunt placement
US8852136B2 (en) 2011-12-08 2014-10-07 Aquesys, Inc. Methods for placing a shunt into the intra-scleral space
US20140324164A1 (en) * 2011-08-05 2014-10-30 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US8926688B2 (en) 2008-01-11 2015-01-06 W. L. Gore & Assoc. Inc. Stent having adjacent elements connected by flexible webs
USD723165S1 (en) 2013-03-12 2015-02-24 C. R. Bard, Inc. Stent
US8974511B2 (en) 2010-11-15 2015-03-10 Aquesys, Inc. Methods for treating closed angle glaucoma
US8980297B2 (en) 2007-02-20 2015-03-17 J.W. Medical Systems Ltd. Thermo-mechanically controlled implants and methods of use
US8979917B2 (en) 2008-09-25 2015-03-17 Advanced Bifurcation Systems, Inc. System and methods for treating a bifurcation
US8986362B2 (en) 2004-06-28 2015-03-24 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9017276B2 (en) 2010-11-15 2015-04-28 Aquesys, Inc. Shunt placement through the sclera
US9066825B2 (en) 2012-05-14 2015-06-30 C.R. Bard, Inc. Uniformly expandable stent
US9095411B2 (en) 2010-11-15 2015-08-04 Aquesys, Inc. Devices for deploying intraocular shunts
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
US9114001B2 (en) 2012-10-30 2015-08-25 Covidien Lp Systems for attaining a predetermined porosity of a vascular device
US9125659B2 (en) 2004-05-25 2015-09-08 Covidien Lp Flexible vascular occluding device
US9125723B2 (en) 2013-02-19 2015-09-08 Aquesys, Inc. Adjustable glaucoma implant
US9157174B2 (en) 2013-02-05 2015-10-13 Covidien Lp Vascular device for aneurysm treatment and providing blood flow into a perforator vessel
US9254210B2 (en) 2011-02-08 2016-02-09 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US9320590B2 (en) 2006-02-22 2016-04-26 Covidien Lp Stents having radiopaque mesh
US9364356B2 (en) 2011-02-08 2016-06-14 Advanced Bifurcation System, Inc. System and methods for treating a bifurcation with a fully crimped stent
US20160184116A1 (en) * 2014-12-29 2016-06-30 Cook Medical Technologies Llc Trigger wire arrangements for endografts
US9381683B2 (en) 2011-12-28 2016-07-05 DePuy Synthes Products, Inc. Films and methods of manufacture
US9387078B2 (en) 2011-08-05 2016-07-12 Mitraltech Ltd. Percutaneous mitral valve replacement and sealing
US9393021B2 (en) 2004-05-25 2016-07-19 Covidien Lp Flexible vascular occluding device
US9452070B2 (en) 2012-10-31 2016-09-27 Covidien Lp Methods and systems for increasing a density of a region of a vascular device
US9480594B2 (en) 2013-02-27 2016-11-01 Spirox, Inc. Nasal implants and systems and methods of use
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
US9498332B2 (en) 2012-11-13 2016-11-22 Mitraltech Ltd. Percutaneously-deliverable mechanical valve
US9585790B2 (en) 2013-11-14 2017-03-07 Aquesys, Inc. Intraocular shunt inserter
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US9597220B2 (en) 2008-11-19 2017-03-21 Spirox, Inc. Apparatus and methods for correcting nasal valve collapse
US9610195B2 (en) 2013-02-27 2017-04-04 Aquesys, Inc. Intraocular shunt implantation methods and devices
US9622888B2 (en) 2006-11-16 2017-04-18 W. L. Gore & Associates, Inc. Stent having flexibly connected adjacent stent elements
US9681952B2 (en) 2013-01-24 2017-06-20 Mitraltech Ltd. Anchoring of prosthetic valve supports
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US9737424B2 (en) 2008-09-25 2017-08-22 Advanced Bifurcation Systems, Inc. Partially crimped stent
US9763657B2 (en) 2010-07-21 2017-09-19 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US9788941B2 (en) 2010-03-10 2017-10-17 Mitraltech Ltd. Axially-shortening prosthetic valve
USD800908S1 (en) 2016-08-10 2017-10-24 Mitraltech Ltd. Prosthetic valve element
US9808373B2 (en) 2013-06-28 2017-11-07 Aquesys, Inc. Intraocular shunt implantation
US9901347B2 (en) 2009-05-29 2018-02-27 Terus Medical, Inc. Biliary shunts, delivery systems, and methods of using the same
US9943427B2 (en) 2012-11-06 2018-04-17 Covidien Lp Shaped occluding devices and methods of using the same
US9974651B2 (en) 2015-02-05 2018-05-22 Mitral Tech Ltd. Prosthetic valve with axially-sliding frames
US10004618B2 (en) 2004-05-25 2018-06-26 Covidien Lp Methods and apparatus for luminal stenting
US10028851B2 (en) 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US10080682B2 (en) 2011-12-08 2018-09-25 Aquesys, Inc. Intrascleral shunt placement
US10085884B2 (en) 2006-06-30 2018-10-02 Aquesys, Inc. Intraocular devices
US10159557B2 (en) 2007-10-04 2018-12-25 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
US10159600B2 (en) 2013-02-19 2018-12-25 Aquesys, Inc. Adjustable intraocular flow regulation
USD841813S1 (en) 2017-08-03 2019-02-26 Cardiovalve Ltd. Prosthetic heart valve element
US10271989B2 (en) 2012-03-26 2019-04-30 Glaukos Corporation System and method for delivering multiple ocular implants
US10299948B2 (en) 2014-11-26 2019-05-28 W. L. Gore & Associates, Inc. Balloon expandable endoprosthesis
US10335264B2 (en) * 2017-03-10 2019-07-02 Byung Choo Moon Vascular graft
US10376361B2 (en) 2011-08-05 2019-08-13 Cardiovalve Ltd. Techniques for percutaneous mitral valve replacement and sealing
US10390952B2 (en) 2015-02-05 2019-08-27 Cardiovalve Ltd. Prosthetic valve with flexible tissue anchor portions
US10398545B2 (en) 2014-08-26 2019-09-03 Spirox, Inc. Nasal implants and systems and method of use
US10463537B2 (en) 2015-06-03 2019-11-05 Aquesys Inc. Ab externo intraocular shunt placement
US10492908B2 (en) 2014-07-30 2019-12-03 Cardiovalve Ltd. Anchoring of a prosthetic valve
US10500304B2 (en) 2013-06-21 2019-12-10 DePuy Synthes Products, Inc. Films and methods of manufacture
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10531866B2 (en) 2016-02-16 2020-01-14 Cardiovalve Ltd. Techniques for providing a replacement valve and transseptal communication
US10548726B2 (en) 2009-12-08 2020-02-04 Cardiovalve Ltd. Rotation-based anchoring of an implant
US10568752B2 (en) 2016-05-25 2020-02-25 W. L. Gore & Associates, Inc. Controlled endoprosthesis balloon expansion
US10575948B2 (en) 2017-08-03 2020-03-03 Cardiovalve Ltd. Prosthetic heart valve
EP3622922A1 (en) 2018-09-13 2020-03-18 ETH Zürich Self-expandable stent, method and device to produce the self-expandable stent
US10603163B2 (en) 2006-09-25 2020-03-31 Spirox, Inc. Nasal implant introduced through a non-surgical injection technique
US10654230B2 (en) 2017-08-28 2020-05-19 The Boeing Company Methods of forming a cored composite laminate
US10667947B2 (en) 2016-06-02 2020-06-02 Aquesys, Inc. Intraocular drug delivery
US10842671B2 (en) 2010-11-15 2020-11-24 Aquesys, Inc. Intraocular shunt placement in the suprachoroidal space
US10856975B2 (en) 2016-08-10 2020-12-08 Cardiovalve Ltd. Prosthetic valve with concentric frames
US10888421B2 (en) 2017-09-19 2021-01-12 Cardiovalve Ltd. Prosthetic heart valve with pouch
US10952898B2 (en) 2018-03-09 2021-03-23 Aquesys, Inc. Intraocular shunt inserter
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10987133B2 (en) 2016-05-02 2021-04-27 Entellus Medical, Inc. Nasal valve implants and methods of implanting the same
US10993800B2 (en) 2015-09-25 2021-05-04 Spirox, Inc. Nasal implants and systems and method of use
US11116625B2 (en) 2017-09-28 2021-09-14 Glaukos Corporation Apparatus and method for controlling placement of intraocular implants
US11135089B2 (en) 2018-03-09 2021-10-05 Aquesys, Inc. Intraocular shunt inserter
US11246704B2 (en) 2017-08-03 2022-02-15 Cardiovalve Ltd. Prosthetic heart valve
US11246753B2 (en) 2017-11-08 2022-02-15 Aquesys, Inc. Manually adjustable intraocular flow regulation
US11291547B2 (en) 2011-08-05 2022-04-05 Cardiovalve Ltd. Leaflet clip with collars
US11298252B2 (en) 2008-09-25 2022-04-12 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
US11382746B2 (en) 2017-12-13 2022-07-12 Cardiovalve Ltd. Prosthetic valve and delivery tool therefor
US11633277B2 (en) 2018-01-10 2023-04-25 Cardiovalve Ltd. Temperature-control during crimping of an implant
US11653910B2 (en) 2010-07-21 2023-05-23 Cardiovalve Ltd. Helical anchor implantation
US11793633B2 (en) 2017-08-03 2023-10-24 Cardiovalve Ltd. Prosthetic heart valve
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11931071B2 (en) 2021-03-28 2024-03-19 Entellus Medical, Inc. Nasal valve implants and methods of implanting the same

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019259A1 (en) * 1992-11-17 2004-01-29 Brown Stephen J. Remote monitoring and data management platform
US6051020A (en) * 1994-02-09 2000-04-18 Boston Scientific Technology, Inc. Bifurcated endoluminal prosthesis
US5609627A (en) * 1994-02-09 1997-03-11 Boston Scientific Technology, Inc. Method for delivering a bifurcated endoluminal prosthesis
US6736843B1 (en) 1994-07-25 2004-05-18 Advanced Cardiovascular Systems, Inc. Cylindrically-shaped balloon-expandable stent
US5636641A (en) 1994-07-25 1997-06-10 Advanced Cardiovascular Systems, Inc. High strength member for intracorporeal use
US5683449A (en) * 1995-02-24 1997-11-04 Marcade; Jean Paul Modular bifurcated intraluminal grafts and methods for delivering and assembling same
US20070073384A1 (en) * 1995-03-01 2007-03-29 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
ATE220308T1 (en) * 1995-03-01 2002-07-15 Scimed Life Systems Inc LONGITUDONLY FLEXIBLE AND EXPANDABLE STENT
US6818014B2 (en) 1995-03-01 2004-11-16 Scimed Life Systems, Inc. Longitudinally flexible expandable stent
US7204848B1 (en) 1995-03-01 2007-04-17 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
US6007573A (en) * 1996-09-18 1999-12-28 Microtherapeutics, Inc. Intracranial stent and method of use
US6086610A (en) * 1996-10-22 2000-07-11 Nitinol Devices & Components Composite self expanding stent device having a restraining element
US6159165A (en) * 1997-12-05 2000-12-12 Micrus Corporation Three dimensional spherical micro-coils manufactured from radiopaque nickel-titanium microstrand
US7520890B2 (en) * 1998-01-26 2009-04-21 Phillips Peter W Reinforced graft and method of deployment
US20050154446A1 (en) * 1998-01-26 2005-07-14 Peter Phillips Reinforced graft
US5984926A (en) * 1998-02-24 1999-11-16 Jones; A. Alexander M. Bone screw shimming and bone graft containment system and method
US6280467B1 (en) * 1998-02-26 2001-08-28 World Medical Manufacturing Corporation Delivery system for deployment and endovascular assembly of a multi-stage stented graft
US7491232B2 (en) 1998-09-18 2009-02-17 Aptus Endosystems, Inc. Catheter-based fastener implantation apparatus and methods with implantation force resolution
US6520983B1 (en) 1998-03-31 2003-02-18 Scimed Life Systems, Inc. Stent delivery system
US6264689B1 (en) * 1998-03-31 2001-07-24 Scimed Life Systems, Incorporated Low profile medical stent
US7294144B1 (en) * 1998-08-10 2007-11-13 Schneider James R Preserved implantable vessel derived from a human umbilical cord or placenta
US6159239A (en) * 1998-08-14 2000-12-12 Prodesco, Inc. Woven stent/graft structure
US6733523B2 (en) * 1998-12-11 2004-05-11 Endologix, Inc. Implantable vascular graft
US6660030B2 (en) * 1998-12-11 2003-12-09 Endologix, Inc. Bifurcation graft deployment catheter
AU2004200062B2 (en) * 1999-02-01 2007-09-06 Board Of Regents, The University Of Texas System Woven intravascular devices and methods for making the same and apparatus for delivery of the same
WO2000044309A2 (en) 1999-02-01 2000-08-03 Board Of Regents, The University Of Texas System Woven bifurcated and trifurcated stents and methods for making the same
US6368346B1 (en) * 1999-06-03 2002-04-09 American Medical Systems, Inc. Bioresorbable stent
US6365734B1 (en) * 1999-10-21 2002-04-02 Pohang University Of Science And Technology Foundation Cucurbituril derivatives, their preparation methods and uses
US6733513B2 (en) 1999-11-04 2004-05-11 Advanced Bioprosthetic Surfaces, Ltd. Balloon catheter having metal balloon and method of making same
US6379383B1 (en) 1999-11-19 2002-04-30 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal device exhibiting improved endothelialization and method of manufacture thereof
US7300457B2 (en) 1999-11-19 2007-11-27 Advanced Bio Prosthetic Surfaces, Ltd. Self-supporting metallic implantable grafts, compliant implantable medical devices and methods of making same
US6936066B2 (en) * 1999-11-19 2005-08-30 Advanced Bio Prosthetic Surfaces, Ltd. Complaint implantable medical devices and methods of making same
US8458879B2 (en) * 2001-07-03 2013-06-11 Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. Method of fabricating an implantable medical device
US7736687B2 (en) 2006-01-31 2010-06-15 Advance Bio Prosthetic Surfaces, Ltd. Methods of making medical devices
US10172730B2 (en) * 1999-11-19 2019-01-08 Vactronix Scientific, Llc Stents with metallic covers and methods of making same
US7235092B2 (en) * 1999-11-19 2007-06-26 Advanced Bio Prosthetic Surfaces, Ltd. Guidewires and thin film catheter-sheaths and method of making same
US6849085B2 (en) 1999-11-19 2005-02-01 Advanced Bio Prosthetic Surfaces, Ltd. Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same
US6537310B1 (en) 1999-11-19 2003-03-25 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal implantable devices and method of making same
US7195641B2 (en) 1999-11-19 2007-03-27 Advanced Bio Prosthetic Surfaces, Ltd. Valvular prostheses having metal or pseudometallic construction and methods of manufacture
US6423090B1 (en) * 2000-02-11 2002-07-23 Advanced Cardiovascular Systems, Inc. Stent pattern with staged expansion
GB0003387D0 (en) * 2000-02-14 2000-04-05 Angiomed Ag Stent matrix
EP1261294B1 (en) * 2000-03-10 2006-11-29 Paracor Medical, Inc. Expandable cardiac harness for treating congestive heart failure
US6290722B1 (en) 2000-03-13 2001-09-18 Endovascular Technologies, Inc. Tacky attachment method of covered materials on stents
US6379382B1 (en) 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
US6613082B2 (en) 2000-03-13 2003-09-02 Jun Yang Stent having cover with drug delivery capability
US6695865B2 (en) 2000-03-20 2004-02-24 Advanced Bio Prosthetic Surfaces, Ltd. Embolic protection device
US6632241B1 (en) 2000-03-22 2003-10-14 Endovascular Technologies, Inc. Self-expanding, pseudo-braided intravascular device
US7250058B1 (en) 2000-03-24 2007-07-31 Abbott Cardiovascular Systems Inc. Radiopaque intraluminal stent
GB2369575A (en) * 2000-04-20 2002-06-05 Salviac Ltd An embolic protection system
US6425856B1 (en) * 2000-05-10 2002-07-30 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
US9566148B2 (en) 2000-05-12 2017-02-14 Vactronix Scientific, Inc. Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US7006858B2 (en) * 2000-05-15 2006-02-28 Silver James H Implantable, retrievable sensors and immunosensors
US7181261B2 (en) 2000-05-15 2007-02-20 Silver James H Implantable, retrievable, thrombus minimizing sensors
US7769420B2 (en) * 2000-05-15 2010-08-03 Silver James H Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction
US8133698B2 (en) * 2000-05-15 2012-03-13 Silver James H Sensors for detecting substances indicative of stroke, ischemia, infection or inflammation
US6800089B1 (en) 2000-05-31 2004-10-05 Advanced Cardiovascular Systems, Inc. Mechanical attachment method of cover materials on stents
US6805704B1 (en) 2000-06-26 2004-10-19 C. R. Bard, Inc. Intraluminal stents
US20020144757A1 (en) * 2000-07-07 2002-10-10 Craig Charles Horace Stainless steel alloy with improved radiopaque characteristics
US6773454B2 (en) * 2000-08-02 2004-08-10 Michael H. Wholey Tapered endovascular stent graft and method of treating abdominal aortic aneurysms and distal iliac aneurysms
US20020087176A1 (en) * 2000-10-10 2002-07-04 Greenhalgh E. Skott Anastomosis device
AU2002233936A1 (en) * 2000-11-07 2002-05-21 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal stent, self-fupporting endoluminal graft and methods of making same
WO2002039888A2 (en) * 2000-11-15 2002-05-23 Endologix, Inc. Implantable vascular graft
US6648911B1 (en) 2000-11-20 2003-11-18 Avantec Vascular Corporation Method and device for the treatment of vulnerable tissue site
CA2441061A1 (en) * 2001-03-20 2002-09-26 Gmp Cardiac Care, Inc. Rail stent
US6613077B2 (en) * 2001-03-27 2003-09-02 Scimed Life Systems, Inc. Stent with controlled expansion
WO2002092783A2 (en) * 2001-05-15 2002-11-21 Children's Medical Center Corporation Methods and apparatus for application of micro-mechanical forces to tissues
US20020188342A1 (en) * 2001-06-01 2002-12-12 Rykhus Robert L. Short-term bioresorbable stents
US7547322B2 (en) * 2001-07-19 2009-06-16 The Cleveland Clinic Foundation Prosthetic valve and method for making same
US6579307B2 (en) 2001-07-19 2003-06-17 The Cleveland Clinic Foundation Endovascular prosthesis having a layer of biological tissue
WO2003022176A2 (en) * 2001-09-10 2003-03-20 Paracor Medical, Inc. Cardiac harness
EP1446069A1 (en) * 2001-10-31 2004-08-18 Paracor Surgical, Inc. Heart failure treatment device
US9320503B2 (en) 2001-11-28 2016-04-26 Medtronic Vascular, Inc. Devices, system, and methods for guiding an operative tool into an interior body region
US7147657B2 (en) * 2003-10-23 2006-12-12 Aptus Endosystems, Inc. Prosthesis delivery systems and methods
US20070073389A1 (en) * 2001-11-28 2007-03-29 Aptus Endosystems, Inc. Endovascular aneurysm devices, systems, and methods
US20050177180A1 (en) * 2001-11-28 2005-08-11 Aptus Endosystems, Inc. Devices, systems, and methods for supporting tissue and/or structures within a hollow body organ
US20090099650A1 (en) * 2001-11-28 2009-04-16 Lee Bolduc Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
EP1448117B1 (en) * 2001-11-28 2013-05-22 Aptus Endosystems, Inc. Endovascular aneurysm repair system
US20090138072A1 (en) * 2001-11-28 2009-05-28 Michael William Gendreau Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
US8231639B2 (en) 2001-11-28 2012-07-31 Aptus Endosystems, Inc. Systems and methods for attaching a prosthesis within a body lumen or hollow organ
JP4331610B2 (en) * 2001-12-20 2009-09-16 トリバスキュラー2,インコーポレイティド Advanced endovascular graft
US7022063B2 (en) 2002-01-07 2006-04-04 Paracor Medical, Inc. Cardiac harness
US7174896B1 (en) 2002-01-07 2007-02-13 Paracor Medical, Inc. Method and apparatus for supporting a heart
US7485089B2 (en) * 2002-09-05 2009-02-03 Paracor Medical, Inc. Cardiac harness
JP4995420B2 (en) * 2002-09-26 2012-08-08 アドヴァンスド バイオ プロスセティック サーフェシーズ リミテッド High strength vacuum deposited Nitinol alloy film, medical thin film graft material, and method of making same.
US7794494B2 (en) * 2002-10-11 2010-09-14 Boston Scientific Scimed, Inc. Implantable medical devices
US7976936B2 (en) * 2002-10-11 2011-07-12 University Of Connecticut Endoprostheses
EP2260882B1 (en) * 2002-10-11 2020-03-04 Boston Scientific Limited Implantable medical devices
US7736299B2 (en) 2002-11-15 2010-06-15 Paracor Medical, Inc. Introducer for a cardiac harness delivery
AU2003290881A1 (en) * 2002-11-15 2004-06-15 Gmp Cardiac Care, Inc. Rail stent
CA2504555C (en) * 2002-11-15 2012-09-04 Paracor Medical, Inc. Cardiac harness delivery device
EP1560548A2 (en) * 2002-11-15 2005-08-10 GMP Cardiac Care, Inc. Rail stent-graft for repairing abdominal aortic aneurysm
US20070255093A1 (en) * 2002-11-15 2007-11-01 Lilip Lau Cardiac harness delivery device and method
US20050059855A1 (en) * 2002-11-15 2005-03-17 Lilip Lau Cardiac harness delivery device and method
US20050165469A1 (en) * 2002-12-24 2005-07-28 Michael Hogendijk Vascular prosthesis including torsional stabilizer and methods of use
US7846198B2 (en) * 2002-12-24 2010-12-07 Novostent Corporation Vascular prosthesis and methods of use
US7455687B2 (en) * 2002-12-30 2008-11-25 Advanced Cardiovascular Systems, Inc. Polymer link hybrid stent
US20040181186A1 (en) * 2003-03-13 2004-09-16 Scimed Life Systems, Inc. Medical device
US7122049B2 (en) 2003-03-19 2006-10-17 Advanced Bio Prosthetic Surfaces, Ltd. Endoluminal stent having mid-strut interconnecting members
US20040249242A1 (en) * 2003-03-28 2004-12-09 Lilip Lau Multi-panel cardiac harness
US20050283042A1 (en) * 2003-03-28 2005-12-22 Steve Meyer Cardiac harness having radiopaque coating and method of use
US20040254628A1 (en) 2003-06-13 2004-12-16 Patrice Nazzaro One-branch stent-graft for bifurcated lumens
US7316711B2 (en) * 2003-10-29 2008-01-08 Medtronic Vascular, Inc. Intralumenal stent device for use in body lumens of various diameters
US7158839B2 (en) * 2003-11-07 2007-01-02 Paracor Medical, Inc. Cardiac harness for treating heart disease
US7155295B2 (en) * 2003-11-07 2006-12-26 Paracor Medical, Inc. Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
US20050288715A1 (en) * 2003-11-07 2005-12-29 Lilip Lau Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
US20070106336A1 (en) * 2003-11-07 2007-05-10 Alan Schaer Cardiac harness assembly for treating congestive heart failure and for pacing/sensing
US20050137673A1 (en) * 2003-11-07 2005-06-23 Lilip Lau Cardiac harness having electrodes and epicardial leads
US20070055091A1 (en) * 2004-12-02 2007-03-08 Lilip Lau Cardiac harness for treating congestive heart failure and for defibrillating and/or pacing/sensing
US20050171589A1 (en) * 2003-11-07 2005-08-04 Lilip Lau Cardiac harness and method of delivery by minimally invasive access
US20070106359A1 (en) * 2003-11-07 2007-05-10 Alan Schaer Cardiac harness assembly for treating congestive heart failure and for pacing/sensing
US20060009831A1 (en) * 2003-11-07 2006-01-12 Lilip Lau Cardiac harness having leadless electrodes for pacing and sensing therapy
US7056286B2 (en) 2003-11-12 2006-06-06 Adrian Ravenscroft Medical device anchor and delivery system
US20050131515A1 (en) 2003-12-16 2005-06-16 Cully Edward H. Removable stent-graft
US7530994B2 (en) * 2003-12-30 2009-05-12 Scimed Life Systems, Inc. Non-porous graft with fastening elements
CA2553185A1 (en) * 2004-01-12 2005-08-04 Paracor Medical, Inc. Cardiac harness having interconnected strands
WO2005079339A2 (en) * 2004-02-12 2005-09-01 The University Of Akron Improved stent for use in arteries
US20060009675A1 (en) * 2004-07-08 2006-01-12 Steven Meyer Self-anchoring cardiac harness for treating the heart and for defibrillating and/or pacing/sensing
US9051411B2 (en) * 2004-08-16 2015-06-09 Lawrence Livermore National Security, Llc Shape memory polymers
US11820852B2 (en) 2004-08-16 2023-11-21 Lawrence Livermore National Security, Llc Shape memory polymers
US7237272B2 (en) * 2004-10-29 2007-07-03 Boetcher Ewald Protective clothing and flexible mesh from interwoven metal rings for production of protective clothing
US20060116602A1 (en) * 2004-12-01 2006-06-01 Alden Dana A Medical sensing device and system
US20060127442A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles
US8043361B2 (en) * 2004-12-10 2011-10-25 Boston Scientific Scimed, Inc. Implantable medical devices, and methods of delivering the same
US20060129026A1 (en) * 2004-12-15 2006-06-15 Joshua Wallin Apparatus and method for mounting a cardiac harness on the heart
US20070005103A1 (en) * 2005-06-30 2007-01-04 Cook Incorporated Emboli capturing device having a netted outer surface
KR100633020B1 (en) * 2005-07-15 2006-10-11 주식회사 스텐다드싸이텍 Stent and method for manufacturing the same
US20070032696A1 (en) * 2005-07-22 2007-02-08 Sieu Duong Cardiac harness delivery device
US20070026039A1 (en) 2005-07-29 2007-02-01 Drumheller Paul D Composite self-cohered web materials
US20070027551A1 (en) * 2005-07-29 2007-02-01 Farnsworth Ted R Composite self-cohered web materials
US7850810B2 (en) * 2005-07-29 2010-12-14 Gore Enterprise Holdings, Inc. Method of making porous self-cohered web materials
US7604668B2 (en) * 2005-07-29 2009-10-20 Gore Enterprise Holdings, Inc. Composite self-cohered web materials
US20070026040A1 (en) * 2005-07-29 2007-02-01 Crawley Jerald M Composite self-cohered web materials
US20070155010A1 (en) * 2005-07-29 2007-07-05 Farnsworth Ted R Highly porous self-cohered fibrous tissue engineering scaffold
US8048503B2 (en) * 2005-07-29 2011-11-01 Gore Enterprise Holdings, Inc. Highly porous self-cohered web materials
US20070073218A1 (en) * 2005-09-26 2007-03-29 Lilip Lau Inflatable cardiac device for treating and preventing ventricular remodeling
CN101466316B (en) 2005-10-20 2012-06-27 阿普特斯内系统公司 Devices systems and methods for prosthesis delivery and implantation including the use of a fastener tool
US8025693B2 (en) * 2006-03-01 2011-09-27 Boston Scientific Scimed, Inc. Stent-graft having flexible geometries and methods of producing the same
US9155641B2 (en) * 2006-03-09 2015-10-13 Cook Medical Technologies Llc Expandable stent grafts
US20070219618A1 (en) * 2006-03-17 2007-09-20 Cully Edward H Endoprosthesis having multiple helically wound flexible framework elements
US20070287883A1 (en) * 2006-06-07 2007-12-13 Lilip Lau Apparatus and method for pulling a cardiac harness onto a heart
US7988720B2 (en) 2006-09-12 2011-08-02 Boston Scientific Scimed, Inc. Longitudinally flexible expandable stent
MX344492B (en) 2006-10-22 2016-12-16 Idev Tech Inc * Devices and methods for stent advancement.
US20100070019A1 (en) * 2006-10-29 2010-03-18 Aneuwrap Ltd. extra-vascular wrapping for treating aneurysmatic aorta and methods thereof
CN101715329B (en) 2007-03-05 2012-11-14 恩多斯潘有限公司 Multi-component expandable supportive bifurcated endoluminal grafts and methods for using same
US8974514B2 (en) * 2007-03-13 2015-03-10 Abbott Cardiovascular Systems Inc. Intravascular stent with integrated link and ring strut
KR100847432B1 (en) * 2007-03-14 2008-07-21 주식회사 에스앤지바이오텍 Stent for expending intra luminal
EP2144580B1 (en) * 2007-04-09 2015-08-12 Covidien LP Stent delivery system
JP2010525873A (en) * 2007-05-01 2010-07-29 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド Wound healing device
DE102007022060A1 (en) * 2007-05-11 2008-11-13 Rubenstein, Nicola M., Dr. Device for connecting two blood vessels
US8133268B2 (en) * 2007-05-30 2012-03-13 Cordis Corporation Stent/fiber structural combinations
US8192351B2 (en) 2007-08-13 2012-06-05 Paracor Medical, Inc. Medical device delivery system having integrated introducer
US20090048480A1 (en) * 2007-08-13 2009-02-19 Paracor Medical, Inc. Cardiac harness delivery device
US8486131B2 (en) 2007-12-15 2013-07-16 Endospan Ltd. Extra-vascular wrapping for treating aneurysmatic aorta in conjunction with endovascular stent-graft and methods thereof
US8236040B2 (en) 2008-04-11 2012-08-07 Endologix, Inc. Bifurcated graft deployment systems and methods
US20090281372A1 (en) * 2008-05-06 2009-11-12 Paracor Medical, Inc. Cardiac harness assembly for treating congestive heart failure and for defibrillation and/or pacing/sensing
EP2520320B1 (en) 2008-07-01 2016-11-02 Endologix, Inc. Catheter system
WO2010044854A1 (en) * 2008-10-16 2010-04-22 Aptus Endosystems, Inc. Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
CA2740867C (en) 2008-10-16 2018-06-12 Aptus Endosystems, Inc. Devices, systems, and methods for endovascular staple and/or prosthesis delivery and implantation
DE102009003890A1 (en) 2009-01-02 2010-07-08 Bioregeneration Gmbh Apparatus comprising a device and a liner implantable in a vessel of the body of a patient, and methods of making same
EP2403438B1 (en) * 2009-03-04 2021-04-21 Peytant Solutions, Inc. Stents modified with material comprising amnion tissue and corresponding processes
EP2445444B1 (en) 2009-06-23 2018-09-26 Endospan Ltd. Vascular prostheses for treating aneurysms
CA2767596C (en) 2009-07-09 2015-11-24 Endospan Ltd. Apparatus for closure of a lumen and methods of using the same
EP2475336A1 (en) * 2009-09-10 2012-07-18 NovoStent Corporation Vascular prosthesis assembly with retention mechanism and method
US8366765B2 (en) * 2009-09-18 2013-02-05 Medtronic Vascular, Inc. Helical stent with connections
US20110071614A1 (en) * 2009-09-24 2011-03-24 David Christopher Majercak Stent - graft suture locks
US10092427B2 (en) 2009-11-04 2018-10-09 Confluent Medical Technologies, Inc. Alternating circumferential bridge stent design and methods for use thereof
US9649211B2 (en) 2009-11-04 2017-05-16 Confluent Medical Technologies, Inc. Alternating circumferential bridge stent design and methods for use thereof
WO2011064782A2 (en) 2009-11-30 2011-06-03 Endospan Ltd. Multi-component stent-graft system for implantation in a blood vessel with multiple branches
WO2011070576A1 (en) 2009-12-08 2011-06-16 Endospan Ltd. Endovascular stent-graft system with fenestrated and crossing stent-grafts
CA2785953C (en) 2009-12-31 2016-02-16 Endospan Ltd. Endovascular flow direction indicator
CA2789304C (en) 2010-02-08 2018-01-02 Endospan Ltd. Thermal energy application for prevention and management of endoleaks in stent-grafts
US9023095B2 (en) 2010-05-27 2015-05-05 Idev Technologies, Inc. Stent delivery system with pusher assembly
US9566147B2 (en) 2010-11-17 2017-02-14 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys containing one or more platinum group metals, refractory metals, or combinations thereof
US11298251B2 (en) 2010-11-17 2022-04-12 Abbott Cardiovascular Systems, Inc. Radiopaque intraluminal stents comprising cobalt-based alloys with primarily single-phase supersaturated tungsten content
AU2011265361B9 (en) * 2010-12-30 2014-03-20 Cook Medical Technologies Llc Woven fabric having composite yarns for endoluminal devices
EP2658484A1 (en) 2010-12-30 2013-11-06 Boston Scientific Scimed, Inc. Multi stage opening stent designs
US9526638B2 (en) 2011-02-03 2016-12-27 Endospan Ltd. Implantable medical devices constructed of shape memory material
US9855046B2 (en) 2011-02-17 2018-01-02 Endospan Ltd. Vascular bands and delivery systems therefor
CN105232195B (en) 2011-03-01 2018-06-08 恩朵罗杰克斯股份有限公司 Delivery catheter system
WO2012117395A1 (en) 2011-03-02 2012-09-07 Endospan Ltd. Reduced-strain extra- vascular ring for treating aortic aneurysm
US8790388B2 (en) 2011-03-03 2014-07-29 Boston Scientific Scimed, Inc. Stent with reduced profile
CN103391757B (en) 2011-03-03 2016-01-20 波士顿科学国际有限公司 Low strain dynamic high strength support
US8574287B2 (en) 2011-06-14 2013-11-05 Endospan Ltd. Stents incorporating a plurality of strain-distribution locations
EP2579811B1 (en) 2011-06-21 2016-03-16 Endospan Ltd Endovascular system with circumferentially-overlapping stent-grafts
US9724494B2 (en) 2011-06-29 2017-08-08 Abbott Cardiovascular Systems, Inc. Guide wire device including a solderable linear elastic nickel-titanium distal end section and methods of preparation therefor
US9254209B2 (en) 2011-07-07 2016-02-09 Endospan Ltd. Stent fixation with reduced plastic deformation
WO2013030818A2 (en) 2011-08-28 2013-03-07 Endospan Ltd. Stent-grafts with post-deployment variable axial and radial displacement
US9427339B2 (en) 2011-10-30 2016-08-30 Endospan Ltd. Triple-collar stent-graft
WO2013084235A2 (en) 2011-12-04 2013-06-13 Endospan Ltd. Branched stent-graft system
US9770350B2 (en) 2012-05-15 2017-09-26 Endospan Ltd. Stent-graft with fixation elements that are radially confined for delivery
US9993360B2 (en) 2013-01-08 2018-06-12 Endospan Ltd. Minimization of stent-graft migration during implantation
US9668892B2 (en) 2013-03-11 2017-06-06 Endospan Ltd. Multi-component stent-graft system for aortic dissections
US10271975B2 (en) 2013-03-15 2019-04-30 Atrium Medical Corporation Stent device having reduced foreshortening and recoil and method of making same
CN104586536B (en) 2013-10-31 2017-05-03 微创心脉医疗科技(上海)有限公司 Covered stent
US10603197B2 (en) 2013-11-19 2020-03-31 Endospan Ltd. Stent system with radial-expansion locking
US11839698B2 (en) 2014-03-13 2023-12-12 W. L. Gore & Associates, Inc. Drug composition and coating
US10064745B2 (en) * 2014-03-18 2018-09-04 Abbott Cardiovascular Systems Inc. Tapered scaffolds
US9907593B2 (en) 2014-08-05 2018-03-06 Woven Orthopedic Technologies, Llc Woven retention devices, systems and methods
US8956394B1 (en) 2014-08-05 2015-02-17 Woven Orthopedic Technologies, Llc Woven retention devices, systems and methods
US9943351B2 (en) 2014-09-16 2018-04-17 Woven Orthopedic Technologies, Llc Woven retention devices, systems, packaging, and related methods
BR112017012425A2 (en) 2014-12-18 2018-01-02 Endospan Ltd endovascular stent graft with fatigue resistant lateral tube
US11129737B2 (en) 2015-06-30 2021-09-28 Endologix Llc Locking assembly for coupling guidewire to delivery system
US10555758B2 (en) 2015-08-05 2020-02-11 Woven Orthopedic Technologies, Llc Tapping devices, systems and methods for use in bone tissue
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
WO2018107114A1 (en) 2016-12-09 2018-06-14 Woven Orthopedic Technologies, LLC. Retention devices, lattices and related systems and methods
US11154410B2 (en) 2018-06-29 2021-10-26 Monarch Biosciences, Inc. Spiral-based thin-film mesh systems and related methods
BR202020020329U2 (en) 2020-10-02 2022-04-19 Braile Biomédica Indústria Comércio E Representações Ltda. Constructive arrangement introduced in endoprosthesis
WO2023201067A2 (en) 2022-04-14 2023-10-19 W. L. Gore & Associates, Inc. Chemical entities

Citations (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152618A (en) * 1959-03-30 1964-10-13 Dayco Corp Flexible conduit
US3174851A (en) * 1961-12-01 1965-03-23 William J Buehler Nickel-base alloys
US3351463A (en) * 1965-08-20 1967-11-07 Alexander G Rozner High strength nickel-base alloys
US3479670A (en) * 1966-10-19 1969-11-25 Ethicon Inc Tubular prosthetic implant having helical thermoplastic wrapping therearound
US3514791A (en) * 1967-07-25 1970-06-02 Charles H Sparks Tissue grafts
US3562820A (en) * 1966-08-22 1971-02-16 Bernhard Braun Tubular sheet and strip form prostheses on a basis of biological tissue
US3625198A (en) * 1969-05-09 1971-12-07 Charles H Sparks Die and holder for implanting in a living body to grow tissue grafts
US3657744A (en) * 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US3710777A (en) * 1970-12-23 1973-01-16 C Sparks Method and apparatus for growing graft tubes in place
US3753700A (en) * 1970-07-02 1973-08-21 Raychem Corp Heat recoverable alloy
US3774596A (en) * 1971-06-29 1973-11-27 G Cook Compliable cavity speculum
GB1355373A (en) 1970-05-21 1974-06-05 Gore & Ass Porous materials derived from tetrafluoroethylene and process for their production
US3866609A (en) * 1972-04-05 1975-02-18 Charles Howard Sparks Apparatus for growing graft tubes in place
US3866247A (en) * 1972-04-05 1975-02-18 Charles Howard Sparks Graft tubes
US3868956A (en) * 1972-06-05 1975-03-04 Ralph J Alfidi Vessel implantable appliance and method of implanting it
US3927422A (en) * 1973-12-12 1975-12-23 Philip Nicholas Sawyer Prosthesis and method for making same
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US3974526A (en) * 1973-07-06 1976-08-17 Dardik Irving I Vascular prostheses and process for producing the same
GB1506432A (en) 1974-04-02 1978-04-05 Gore & Ass Prosthetic device
US4130904A (en) * 1977-06-06 1978-12-26 Thermo Electron Corporation Prosthetic blood conduit
US4164045A (en) * 1977-08-03 1979-08-14 Carbomedics, Inc. Artificial vascular and patch grafts
GB1567122A (en) 1977-03-31 1980-05-08 Gore & Ass Tubular flixible instruments
US4319363A (en) * 1978-05-23 1982-03-16 Vettivetpillai Ketharanathan Vascular prostheses
US4411655A (en) * 1981-11-30 1983-10-25 Schreck David M Apparatus and method for percutaneous catheterization
US4424208A (en) * 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
US4425908A (en) * 1981-10-22 1984-01-17 Beth Israel Hospital Blood clot filter
US4488911A (en) * 1975-10-22 1984-12-18 Luck Edward E Non-antigenic collagen and articles of manufacture
US4494531A (en) * 1982-12-06 1985-01-22 Cook, Incorporated Expandable blood clot filter
US4503569A (en) * 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US4512338A (en) * 1983-01-25 1985-04-23 Balko Alexander B Process for restoring patency to body vessels
US4546500A (en) * 1981-05-08 1985-10-15 Massachusetts Institute Of Technology Fabrication of living blood vessels and glandular tissues
US4553545A (en) * 1981-09-16 1985-11-19 Medinvent S.A. Device for application in blood vessels or other difficultly accessible locations and its use
US4557764A (en) * 1984-09-05 1985-12-10 Collagen Corporation Process for preparing malleable collagen and the product thereof
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US4582640A (en) * 1982-03-08 1986-04-15 Collagen Corporation Injectable cross-linked collagen implant material
US4604762A (en) * 1981-02-13 1986-08-12 Thoratec Laboratories Corporation Arterial graft prosthesis
US4629458A (en) * 1985-02-26 1986-12-16 Cordis Corporation Reinforcing structure for cardiovascular graft
US4642117A (en) * 1985-03-22 1987-02-10 Collagen Corporation Mechanically sheared collagen implant material and method
US4641653A (en) * 1978-06-02 1987-02-10 Rockey Arthur G Medical sleeve
US4647416A (en) * 1983-08-03 1987-03-03 Shiley Incorporated Method of preparing a vascular graft prosthesis
US4649922A (en) * 1986-01-23 1987-03-17 Wiktor Donimik M Catheter arrangement having a variable diameter tip and spring prosthesis
US4655771A (en) * 1982-04-30 1987-04-07 Shepherd Patents S.A. Prosthesis comprising an expansible or contractile tubular body
US4665906A (en) * 1983-10-14 1987-05-19 Raychem Corporation Medical devices incorporating sim alloy elements
US4689399A (en) * 1984-12-24 1987-08-25 Collagen Corporation Collagen membranes for medical use
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4738666A (en) * 1985-06-11 1988-04-19 Genus Catheter Technologies, Inc. Variable diameter catheter
US4740207A (en) * 1986-09-10 1988-04-26 Kreamer Jeffry W Intralumenal graft
US4760849A (en) * 1985-04-10 1988-08-02 Medinvent S.A. Planar blank and a coil spring manufactured therefrom
US4787899A (en) * 1983-12-09 1988-11-29 Lazarus Harrison M Intraluminal graft device, system and method
US4798606A (en) * 1985-02-26 1989-01-17 Corvita Corporation Reinforcing structure for cardiovascular graft
US4816339A (en) * 1987-04-28 1989-03-28 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US4820298A (en) * 1987-11-20 1989-04-11 Leveen Eric G Internal vascular prosthesis
US4830003A (en) * 1988-06-17 1989-05-16 Wolff Rodney G Compressive stent and delivery system
US4842575A (en) * 1984-01-30 1989-06-27 Meadox Medicals, Inc. Method for forming impregnated synthetic vascular grafts
US4856516A (en) * 1989-01-09 1989-08-15 Cordis Corporation Endovascular stent apparatus and method
US4878906A (en) * 1986-03-25 1989-11-07 Servetus Partnership Endoprosthesis for repairing a damaged vessel
US4886500A (en) * 1988-11-07 1989-12-12 Lazarus Harrison M External guide wire
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4913141A (en) * 1988-10-25 1990-04-03 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US4957508A (en) * 1986-10-31 1990-09-18 Ube Industries, Ltd. Medical tubes
US4969458A (en) * 1987-07-06 1990-11-13 Medtronic, Inc. Intracoronary stent and method of simultaneous angioplasty and stent implant
US4990151A (en) * 1988-09-28 1991-02-05 Medinvent S.A. Device for transluminal implantation or extraction
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5015253A (en) * 1989-06-15 1991-05-14 Cordis Corporation Non-woven endoprosthesis
US5019085A (en) * 1988-10-25 1991-05-28 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US5019090A (en) * 1988-09-01 1991-05-28 Corvita Corporation Radially expandable endoprosthesis and the like
US5035706A (en) * 1989-10-17 1991-07-30 Cook Incorporated Percutaneous stent and method for retrieval thereof
US5037377A (en) * 1984-11-28 1991-08-06 Medtronic, Inc. Means for improving biocompatibility of implants, particularly of vascular grafts
US5037427A (en) * 1987-03-25 1991-08-06 Terumo Kabushiki Kaisha Method of implanting a stent within a tubular organ of a living body and of removing same
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5067957A (en) * 1983-10-14 1991-11-26 Raychem Corporation Method of inserting medical devices incorporating SIM alloy elements
US5092877A (en) * 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US5102417A (en) * 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5104404A (en) * 1989-10-02 1992-04-14 Medtronic, Inc. Articulated stent
US5122154A (en) * 1990-08-15 1992-06-16 Rhodes Valentine J Endovascular bypass graft
US5123917A (en) * 1990-04-27 1992-06-23 Lee Peter Y Expandable intraluminal vascular graft
US5133732A (en) * 1987-10-19 1992-07-28 Medtronic, Inc. Intravascular stent
US5139480A (en) * 1990-08-22 1992-08-18 Biotech Laboratories, Inc. Necking stents
US5147370A (en) * 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
US5151105A (en) * 1991-10-07 1992-09-29 Kwan Gett Clifford Collapsible vessel sleeve implant
US5161547A (en) * 1990-11-28 1992-11-10 Numed, Inc. Method of forming an intravascular radially expandable stent
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5163958A (en) * 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US5171262A (en) * 1989-06-15 1992-12-15 Cordis Corporation Non-woven endoprosthesis
US5192307A (en) * 1987-12-08 1993-03-09 Wall W Henry Angioplasty stent
US5195984A (en) * 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
US5197978A (en) * 1991-04-26 1993-03-30 Advanced Coronary Technology, Inc. Removable heat-recoverable tissue supporting device
US5201757A (en) * 1992-04-03 1993-04-13 Schneider (Usa) Inc. Medial region deployment of radially self-expanding stents
US5209735A (en) * 1988-11-07 1993-05-11 Lazarus Harrison M External guide wire and enlargement means
US5211658A (en) * 1991-11-05 1993-05-18 New England Deaconess Hospital Corporation Method and device for performing endovascular repair of aneurysms
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5217483A (en) * 1990-11-28 1993-06-08 Numed, Inc. Intravascular radially expandable stent
US5221261A (en) * 1990-04-12 1993-06-22 Schneider (Usa) Inc. Radially expandable fixation member
US5236447A (en) * 1990-06-29 1993-08-17 Nissho Corporation Artificial tubular organ
US5242451A (en) * 1987-09-24 1993-09-07 Terumo Kabushiki Kaisha Instrument for retaining inner diameter of tubular organ lumen
US5264276A (en) * 1992-04-06 1993-11-23 W. L. Gore & Associates, Inc. Chemically protective laminate
US5282847A (en) 1991-02-28 1994-02-01 Medtronic, Inc. Prosthetic vascular grafts with a pleated structure
US5282824A (en) * 1990-10-09 1994-02-01 Cook, Incorporated Percutaneous stent assembly
EP0408245B1 (en) 1989-07-13 1994-03-02 American Medical Systems, Inc. Stent placement instrument
US5306261A (en) 1993-01-22 1994-04-26 Misonix, Inc. Catheter with collapsible wire guide
US5306294A (en) 1992-08-05 1994-04-26 Ultrasonic Sensing And Monitoring Systems, Inc. Stent construction of rolled configuration
US5314472A (en) 1991-10-01 1994-05-24 Cook Incorporated Vascular stent
US5324304A (en) 1992-06-18 1994-06-28 William Cook Europe A/S Introduction catheter set for a collapsible self-expandable implant
US5342348A (en) 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5344426A (en) 1990-04-25 1994-09-06 Advanced Cardiovascular Systems, Inc. Method and system for stent delivery
US5354309A (en) 1991-10-11 1994-10-11 Angiomed Ag Apparatus for widening a stenosis in a body cavity
US5354308A (en) 1992-05-01 1994-10-11 Beth Israel Hospital Association Metal wire stent
US5356423A (en) 1991-01-04 1994-10-18 American Medical Systems, Inc. Resectable self-expanding stent
US5360443A (en) 1990-06-11 1994-11-01 Barone Hector D Aortic graft for repairing an abdominal aortic aneurysm
US5366473A (en) 1992-08-18 1994-11-22 Ultrasonic Sensing And Monitoring Systems, Inc. Method and apparatus for applying vascular grafts
US5372600A (en) 1991-10-31 1994-12-13 Instent Inc. Stent delivery systems
EP0382014B1 (en) 1989-01-26 1994-12-14 Advanced Cardiovascular Systems, Inc. Intravascular endoprothesis
US5382261A (en) 1992-09-01 1995-01-17 Expandable Grafts Partnership Method and apparatus for occluding vessels
US5405377A (en) 1992-02-21 1995-04-11 Endotech Ltd. Intraluminal stent
US5405378A (en) 1992-05-20 1995-04-11 Strecker; Ernst P. Device with a prosthesis implantable in the body of a patient
US5421955A (en) 1991-10-28 1995-06-06 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
US5423849A (en) 1993-01-15 1995-06-13 Target Therapeutics, Inc. Vasoocclusion device containing radiopaque fibers
EP0472731B1 (en) 1990-02-15 1995-09-06 Kanji Inoue Resilient and bendable instrument inserted into human organ
US5449373A (en) 1994-03-17 1995-09-12 Medinol Ltd. Articulated stent
US5458605A (en) 1994-04-04 1995-10-17 Advanced Cardiovascular Systems, Inc. Coiled reinforced retractable sleeve for stent delivery catheter
US5480423A (en) 1993-05-20 1996-01-02 Boston Scientific Corporation Prosthesis delivery
US5484444A (en) 1992-10-31 1996-01-16 Schneider (Europe) A.G. Device for the implantation of self-expanding endoprostheses
US5496365A (en) 1992-07-02 1996-03-05 Sgro; Jean-Claude Autoexpandable vascular endoprosthesis
US5507767A (en) 1992-01-15 1996-04-16 Cook Incorporated Spiral stent
US5509902A (en) 1994-07-25 1996-04-23 Raulerson; J. Daniel Subcutaneous catheter stabilizing devices and methods for securing a catheter using the same
US5522881A (en) 1994-06-28 1996-06-04 Meadox Medicals, Inc. Implantable tubular prosthesis having integral cuffs
US5540712A (en) 1992-05-01 1996-07-30 Nitinol Medical Technologies, Inc. Stent and method and apparatus for forming and delivering the same
US5540701A (en) 1994-05-20 1996-07-30 Hugh Sharkey Passive fixation anastomosis method and device
US5545210A (en) 1994-09-22 1996-08-13 Advanced Coronary Technology, Inc. Method of implanting a permanent shape memory alloy stent
US5549635A (en) 1994-01-24 1996-08-27 Solar, Rita & Gaterud, Ltd. Non-deformable self-expanding parallel flow endovascular stent and deployment apparatus therefore
US5549663A (en) 1994-03-09 1996-08-27 Cordis Corporation Endoprosthesis having graft member and exposed welded end junctions, method and procedure
US5554180A (en) 1995-07-07 1996-09-10 Aeroquip Corporation Intraluminal stenting graft
US5556413A (en) 1994-03-11 1996-09-17 Advanced Cardiovascular Systems, Inc. Coiled stent with locking ends
US5562726A (en) 1991-10-25 1996-10-08 Cook Incorporated Expandable transluminal graft prosthesis for repair of aneurysm and method for implanting
US5571173A (en) 1990-06-11 1996-11-05 Parodi; Juan C. Graft to repair a body passageway
US5575816A (en) 1994-08-12 1996-11-19 Meadox Medicals, Inc. High strength and high density intraluminal wire stent
US5591197A (en) 1995-03-14 1997-01-07 Advanced Cardiovascular Systems, Inc. Expandable stent forming projecting barbs and method for deploying
US5607442A (en) 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
US5662713A (en) 1991-10-09 1997-09-02 Boston Scientific Corporation Medical stents for body lumens exhibiting peristaltic motion
DE19617823A1 (en) 1996-05-03 1997-11-13 Sitomed Medizintechnik Vertrie Vascular prosthesis for coronary use
EP0565251B1 (en) 1992-03-25 1998-05-20 Cook Incorporated Vascular stent
EP0686379B1 (en) 1994-06-08 2000-08-09 Cardiovascular Concepts, Inc. Vascular graft

Patent Citations (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152618A (en) * 1959-03-30 1964-10-13 Dayco Corp Flexible conduit
US3174851A (en) * 1961-12-01 1965-03-23 William J Buehler Nickel-base alloys
US3351463A (en) * 1965-08-20 1967-11-07 Alexander G Rozner High strength nickel-base alloys
US3562820A (en) * 1966-08-22 1971-02-16 Bernhard Braun Tubular sheet and strip form prostheses on a basis of biological tissue
US3479670A (en) * 1966-10-19 1969-11-25 Ethicon Inc Tubular prosthetic implant having helical thermoplastic wrapping therearound
US3514791A (en) * 1967-07-25 1970-06-02 Charles H Sparks Tissue grafts
US3625198A (en) * 1969-05-09 1971-12-07 Charles H Sparks Die and holder for implanting in a living body to grow tissue grafts
US3657744A (en) * 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4187390A (en) * 1970-05-21 1980-02-05 W. L. Gore & Associates, Inc. Porous products and process therefor
GB1355373A (en) 1970-05-21 1974-06-05 Gore & Ass Porous materials derived from tetrafluoroethylene and process for their production
US3953566A (en) * 1970-05-21 1976-04-27 W. L. Gore & Associates, Inc. Process for producing porous products
US3753700A (en) * 1970-07-02 1973-08-21 Raychem Corp Heat recoverable alloy
US3710777A (en) * 1970-12-23 1973-01-16 C Sparks Method and apparatus for growing graft tubes in place
US3774596A (en) * 1971-06-29 1973-11-27 G Cook Compliable cavity speculum
US3866247A (en) * 1972-04-05 1975-02-18 Charles Howard Sparks Graft tubes
US3866609A (en) * 1972-04-05 1975-02-18 Charles Howard Sparks Apparatus for growing graft tubes in place
US3868956A (en) * 1972-06-05 1975-03-04 Ralph J Alfidi Vessel implantable appliance and method of implanting it
US3974526A (en) * 1973-07-06 1976-08-17 Dardik Irving I Vascular prostheses and process for producing the same
US3927422A (en) * 1973-12-12 1975-12-23 Philip Nicholas Sawyer Prosthesis and method for making same
GB1506432A (en) 1974-04-02 1978-04-05 Gore & Ass Prosthetic device
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US4488911A (en) * 1975-10-22 1984-12-18 Luck Edward E Non-antigenic collagen and articles of manufacture
GB1567122A (en) 1977-03-31 1980-05-08 Gore & Ass Tubular flixible instruments
US4130904A (en) * 1977-06-06 1978-12-26 Thermo Electron Corporation Prosthetic blood conduit
US4164045A (en) * 1977-08-03 1979-08-14 Carbomedics, Inc. Artificial vascular and patch grafts
US4319363A (en) * 1978-05-23 1982-03-16 Vettivetpillai Ketharanathan Vascular prostheses
US4641653A (en) * 1978-06-02 1987-02-10 Rockey Arthur G Medical sleeve
US4604762A (en) * 1981-02-13 1986-08-12 Thoratec Laboratories Corporation Arterial graft prosthesis
US4546500A (en) * 1981-05-08 1985-10-15 Massachusetts Institute Of Technology Fabrication of living blood vessels and glandular tissues
US4553545A (en) * 1981-09-16 1985-11-19 Medinvent S.A. Device for application in blood vessels or other difficultly accessible locations and its use
US4425908A (en) * 1981-10-22 1984-01-17 Beth Israel Hospital Blood clot filter
US4411655A (en) * 1981-11-30 1983-10-25 Schreck David M Apparatus and method for percutaneous catheterization
US4424208A (en) * 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
US4582640A (en) * 1982-03-08 1986-04-15 Collagen Corporation Injectable cross-linked collagen implant material
US4655771B1 (en) * 1982-04-30 1996-09-10 Medinvent Ams Sa Prosthesis comprising an expansible or contractile tubular body
US4655771A (en) * 1982-04-30 1987-04-07 Shepherd Patents S.A. Prosthesis comprising an expansible or contractile tubular body
US4494531A (en) * 1982-12-06 1985-01-22 Cook, Incorporated Expandable blood clot filter
US4512338A (en) * 1983-01-25 1985-04-23 Balko Alexander B Process for restoring patency to body vessels
US4503569A (en) * 1983-03-03 1985-03-12 Dotter Charles T Transluminally placed expandable graft prosthesis
US4647416A (en) * 1983-08-03 1987-03-03 Shiley Incorporated Method of preparing a vascular graft prosthesis
US4665906A (en) * 1983-10-14 1987-05-19 Raychem Corporation Medical devices incorporating sim alloy elements
US5067957A (en) * 1983-10-14 1991-11-26 Raychem Corporation Method of inserting medical devices incorporating SIM alloy elements
US4787899A (en) * 1983-12-09 1988-11-29 Lazarus Harrison M Intraluminal graft device, system and method
US4842575A (en) * 1984-01-30 1989-06-27 Meadox Medicals, Inc. Method for forming impregnated synthetic vascular grafts
US4557764A (en) * 1984-09-05 1985-12-10 Collagen Corporation Process for preparing malleable collagen and the product thereof
US4580568A (en) * 1984-10-01 1986-04-08 Cook, Incorporated Percutaneous endovascular stent and method for insertion thereof
US5037377A (en) * 1984-11-28 1991-08-06 Medtronic, Inc. Means for improving biocompatibility of implants, particularly of vascular grafts
US4689399A (en) * 1984-12-24 1987-08-25 Collagen Corporation Collagen membranes for medical use
US4798606A (en) * 1985-02-26 1989-01-17 Corvita Corporation Reinforcing structure for cardiovascular graft
US4629458A (en) * 1985-02-26 1986-12-16 Cordis Corporation Reinforcing structure for cardiovascular graft
US4642117A (en) * 1985-03-22 1987-02-10 Collagen Corporation Mechanically sheared collagen implant material and method
US4760849A (en) * 1985-04-10 1988-08-02 Medinvent S.A. Planar blank and a coil spring manufactured therefrom
US4738666A (en) * 1985-06-11 1988-04-19 Genus Catheter Technologies, Inc. Variable diameter catheter
US4733665A (en) * 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5102417A (en) * 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4776337A (en) * 1985-11-07 1988-10-11 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4739762A (en) * 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) * 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4739762B1 (en) * 1985-11-07 1998-10-27 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4776337B1 (en) * 1985-11-07 2000-12-05 Cordis Corp Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4649922A (en) * 1986-01-23 1987-03-17 Wiktor Donimik M Catheter arrangement having a variable diameter tip and spring prosthesis
US4878906A (en) * 1986-03-25 1989-11-07 Servetus Partnership Endoprosthesis for repairing a damaged vessel
US4740207A (en) * 1986-09-10 1988-04-26 Kreamer Jeffry W Intralumenal graft
US4957508A (en) * 1986-10-31 1990-09-18 Ube Industries, Ltd. Medical tubes
US5037427A (en) * 1987-03-25 1991-08-06 Terumo Kabushiki Kaisha Method of implanting a stent within a tubular organ of a living body and of removing same
US4816339A (en) * 1987-04-28 1989-03-28 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US4969458A (en) * 1987-07-06 1990-11-13 Medtronic, Inc. Intracoronary stent and method of simultaneous angioplasty and stent implant
US5242451A (en) * 1987-09-24 1993-09-07 Terumo Kabushiki Kaisha Instrument for retaining inner diameter of tubular organ lumen
US4886062A (en) * 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5133732A (en) * 1987-10-19 1992-07-28 Medtronic, Inc. Intravascular stent
US4820298A (en) * 1987-11-20 1989-04-11 Leveen Eric G Internal vascular prosthesis
US5192307A (en) * 1987-12-08 1993-03-09 Wall W Henry Angioplasty stent
US4830003A (en) * 1988-06-17 1989-05-16 Wolff Rodney G Compressive stent and delivery system
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5019090A (en) * 1988-09-01 1991-05-28 Corvita Corporation Radially expandable endoprosthesis and the like
US5092877A (en) * 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US4990151A (en) * 1988-09-28 1991-02-05 Medinvent S.A. Device for transluminal implantation or extraction
US5195984A (en) * 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
US5019085A (en) * 1988-10-25 1991-05-28 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US4913141A (en) * 1988-10-25 1990-04-03 Cordis Corporation Apparatus and method for placement of a stent within a subject vessel
US4886500A (en) * 1988-11-07 1989-12-12 Lazarus Harrison M External guide wire
US5209735A (en) * 1988-11-07 1993-05-11 Lazarus Harrison M External guide wire and enlargement means
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US4856516A (en) * 1989-01-09 1989-08-15 Cordis Corporation Endovascular stent apparatus and method
US5443500A (en) 1989-01-26 1995-08-22 Advanced Cardiovascular Systems, Inc. Intravascular stent
EP0382014B1 (en) 1989-01-26 1994-12-14 Advanced Cardiovascular Systems, Inc. Intravascular endoprothesis
US5163958A (en) * 1989-02-02 1992-11-17 Cordis Corporation Carbon coated tubular endoprosthesis
US5100429A (en) * 1989-04-28 1992-03-31 C. R. Bard, Inc. Endovascular stent and delivery system
US4990155A (en) * 1989-05-19 1991-02-05 Wilkoff Howard M Surgical stent method and apparatus
US4994071A (en) * 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5015253A (en) * 1989-06-15 1991-05-14 Cordis Corporation Non-woven endoprosthesis
US5171262A (en) * 1989-06-15 1992-12-15 Cordis Corporation Non-woven endoprosthesis
EP0408245B1 (en) 1989-07-13 1994-03-02 American Medical Systems, Inc. Stent placement instrument
US5104404A (en) * 1989-10-02 1992-04-14 Medtronic, Inc. Articulated stent
US5035706A (en) * 1989-10-17 1991-07-30 Cook Incorporated Percutaneous stent and method for retrieval thereof
EP0472731B1 (en) 1990-02-15 1995-09-06 Kanji Inoue Resilient and bendable instrument inserted into human organ
US5221261A (en) * 1990-04-12 1993-06-22 Schneider (Usa) Inc. Radially expandable fixation member
US5344426A (en) 1990-04-25 1994-09-06 Advanced Cardiovascular Systems, Inc. Method and system for stent delivery
US5123917A (en) * 1990-04-27 1992-06-23 Lee Peter Y Expandable intraluminal vascular graft
US5571173A (en) 1990-06-11 1996-11-05 Parodi; Juan C. Graft to repair a body passageway
US5360443A (en) 1990-06-11 1994-11-01 Barone Hector D Aortic graft for repairing an abdominal aortic aneurysm
US5064435A (en) * 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5236447A (en) * 1990-06-29 1993-08-17 Nissho Corporation Artificial tubular organ
US5122154A (en) * 1990-08-15 1992-06-16 Rhodes Valentine J Endovascular bypass graft
US5139480A (en) * 1990-08-22 1992-08-18 Biotech Laboratories, Inc. Necking stents
US5282824A (en) * 1990-10-09 1994-02-01 Cook, Incorporated Percutaneous stent assembly
US5161547A (en) * 1990-11-28 1992-11-10 Numed, Inc. Method of forming an intravascular radially expandable stent
US5217483A (en) * 1990-11-28 1993-06-08 Numed, Inc. Intravascular radially expandable stent
US5356423A (en) 1991-01-04 1994-10-18 American Medical Systems, Inc. Resectable self-expanding stent
US5282847A (en) 1991-02-28 1994-02-01 Medtronic, Inc. Prosthetic vascular grafts with a pleated structure
US5197978B1 (en) * 1991-04-26 1996-05-28 Advanced Coronary Tech Removable heat-recoverable tissue supporting device
US5197978A (en) * 1991-04-26 1993-03-30 Advanced Coronary Technology, Inc. Removable heat-recoverable tissue supporting device
US5147370A (en) * 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
US5314472A (en) 1991-10-01 1994-05-24 Cook Incorporated Vascular stent
US5151105A (en) * 1991-10-07 1992-09-29 Kwan Gett Clifford Collapsible vessel sleeve implant
US5662713A (en) 1991-10-09 1997-09-02 Boston Scientific Corporation Medical stents for body lumens exhibiting peristaltic motion
US5354309A (en) 1991-10-11 1994-10-11 Angiomed Ag Apparatus for widening a stenosis in a body cavity
US5562726A (en) 1991-10-25 1996-10-08 Cook Incorporated Expandable transluminal graft prosthesis for repair of aneurysm and method for implanting
US5514154A (en) 1991-10-28 1996-05-07 Advanced Cardiovascular Systems, Inc. Expandable stents
US5421955B1 (en) 1991-10-28 1998-01-20 Advanced Cardiovascular System Expandable stents and method for making same
US5421955A (en) 1991-10-28 1995-06-06 Advanced Cardiovascular Systems, Inc. Expandable stents and method for making same
EP0540290B1 (en) 1991-10-28 1998-01-28 Advanced Cardiovascular Systems, Inc. Expandable stents
US5372600A (en) 1991-10-31 1994-12-13 Instent Inc. Stent delivery systems
US5211658A (en) * 1991-11-05 1993-05-18 New England Deaconess Hospital Corporation Method and device for performing endovascular repair of aneurysms
US5507767A (en) 1992-01-15 1996-04-16 Cook Incorporated Spiral stent
EP0556850B1 (en) 1992-02-21 1997-03-26 Boston Scientific Ireland Limited Intraluminal stent
US5405377A (en) 1992-02-21 1995-04-11 Endotech Ltd. Intraluminal stent
EP0565251B1 (en) 1992-03-25 1998-05-20 Cook Incorporated Vascular stent
US5201757A (en) * 1992-04-03 1993-04-13 Schneider (Usa) Inc. Medial region deployment of radially self-expanding stents
US5264276A (en) * 1992-04-06 1993-11-23 W. L. Gore & Associates, Inc. Chemically protective laminate
US5354308A (en) 1992-05-01 1994-10-11 Beth Israel Hospital Association Metal wire stent
US5540712A (en) 1992-05-01 1996-07-30 Nitinol Medical Technologies, Inc. Stent and method and apparatus for forming and delivering the same
US5405378A (en) 1992-05-20 1995-04-11 Strecker; Ernst P. Device with a prosthesis implantable in the body of a patient
US5324304A (en) 1992-06-18 1994-06-28 William Cook Europe A/S Introduction catheter set for a collapsible self-expandable implant
US5496365A (en) 1992-07-02 1996-03-05 Sgro; Jean-Claude Autoexpandable vascular endoprosthesis
US5306294A (en) 1992-08-05 1994-04-26 Ultrasonic Sensing And Monitoring Systems, Inc. Stent construction of rolled configuration
US5366473A (en) 1992-08-18 1994-11-22 Ultrasonic Sensing And Monitoring Systems, Inc. Method and apparatus for applying vascular grafts
US5382261A (en) 1992-09-01 1995-01-17 Expandable Grafts Partnership Method and apparatus for occluding vessels
US5484444A (en) 1992-10-31 1996-01-16 Schneider (Europe) A.G. Device for the implantation of self-expanding endoprostheses
US5342348A (en) 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5423849A (en) 1993-01-15 1995-06-13 Target Therapeutics, Inc. Vasoocclusion device containing radiopaque fibers
US5306261A (en) 1993-01-22 1994-04-26 Misonix, Inc. Catheter with collapsible wire guide
US5480423A (en) 1993-05-20 1996-01-02 Boston Scientific Corporation Prosthesis delivery
US5549635A (en) 1994-01-24 1996-08-27 Solar, Rita & Gaterud, Ltd. Non-deformable self-expanding parallel flow endovascular stent and deployment apparatus therefore
US5549663A (en) 1994-03-09 1996-08-27 Cordis Corporation Endoprosthesis having graft member and exposed welded end junctions, method and procedure
US5556413A (en) 1994-03-11 1996-09-17 Advanced Cardiovascular Systems, Inc. Coiled stent with locking ends
US5449373A (en) 1994-03-17 1995-09-12 Medinol Ltd. Articulated stent
US5458605A (en) 1994-04-04 1995-10-17 Advanced Cardiovascular Systems, Inc. Coiled reinforced retractable sleeve for stent delivery catheter
US5540701A (en) 1994-05-20 1996-07-30 Hugh Sharkey Passive fixation anastomosis method and device
EP0686379B1 (en) 1994-06-08 2000-08-09 Cardiovascular Concepts, Inc. Vascular graft
US5522881A (en) 1994-06-28 1996-06-04 Meadox Medicals, Inc. Implantable tubular prosthesis having integral cuffs
US5509902A (en) 1994-07-25 1996-04-23 Raulerson; J. Daniel Subcutaneous catheter stabilizing devices and methods for securing a catheter using the same
US5575816A (en) 1994-08-12 1996-11-19 Meadox Medicals, Inc. High strength and high density intraluminal wire stent
US5545210A (en) 1994-09-22 1996-08-13 Advanced Coronary Technology, Inc. Method of implanting a permanent shape memory alloy stent
US5591197A (en) 1995-03-14 1997-01-07 Advanced Cardiovascular Systems, Inc. Expandable stent forming projecting barbs and method for deploying
US5554180A (en) 1995-07-07 1996-09-10 Aeroquip Corporation Intraluminal stenting graft
US5607442A (en) 1995-11-13 1997-03-04 Isostent, Inc. Stent with improved radiopacity and appearance characteristics
DE19617823A1 (en) 1996-05-03 1997-11-13 Sitomed Medizintechnik Vertrie Vascular prosthesis for coronary use

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Cragg, A.H., et al., "Nitinol intravascular stent: Results of preclinical evaluation" Radiology (1993) 189:775-778.
Cragg, A.H., et al., "Percutaneous femoropopliteal graft placement" Journal of Vascular and Interventional Radiology (1993) 4:445-463.
Cragg, A.H., et al., "Percutaneous femoropopliteal graft placement" Radiology (1993) 187(3):643-648.
Cragg, A.H., et al., Nitinol intravascular stent: Results of preclinical evaluation Radiology (1993) 189:775 778. *
Cragg, A.H., et al., Percutaneous femoropopliteal graft placement Journal of Vascular and Interventional Radiology (1993) 4:445 463. *
Cragg, A.H., et al., Percutaneous femoropopliteal graft placement Radiology (1993) 187(3):643 648. *
Laborde et al., "Intraluminal Bypass of Abdominal Aortic Aneurysm: Feasibilty Study"; Radiology 1992; 184: 185-190.
Laborde et al., Intraluminal Bypass of Abdominal Aortic Aneurysm: Feasibilty Study ; Radiology 1992; 184: 185 190. *
MinTec Minimally Invasive Technologies Product Brochure for the Craggstent and Cragg EndoPro System 1, 4 pages total. *
MinTec™ Minimally Invasive Technologies Product Brochure for the Craggstent and Cragg EndoPro System 1, 4 pages total.
Product Brochure for Cook Z Stents, Gianturco Rosch Biliary Design, Cook , A Cook Groups Company, P.O. Box 489, Bloomington, IN, 47402, U.S.A., 4 pages total. *
Product Brochure for Cook-Z™ Stents, Gianturco-Rosch Biliary Design, Cook®, A Cook Groups Company, P.O. Box 489, Bloomington, IN, 47402, U.S.A., 4 pages total.
Product Brochure for Palmaz Balloon Expandable Stent, Johnson & Johnson Interventional Systems, 40 Technology Drive, P.O. Box 4917, Warren, NJ, 07059, 2 pages total. *
Product Brochure for Palmaz™ Balloon-Expandable Stent, Johnson & Johnson Interventional Systems, 40 Technology Drive, P.O. Box 4917, Warren, NJ, 07059, 2 pages total.
Schneider (USA) Inc., Pfizer Hospital Products Group, 5905 Nathan Lane, Minneapolis, Minnesota, 55442, Product Brochure for Catheters, Guidewires, and Stents, 2 pages total. *

Cited By (496)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040193251A1 (en) * 1994-08-12 2004-09-30 Meadox Medicals, Inc. Nested stent
US8092512B2 (en) * 1994-08-12 2012-01-10 Boston Scientific Scimed, Inc. Nested stent
US20020040238A1 (en) * 1994-08-12 2002-04-04 Meadox Medicals, Inc. High strength and high density intraluminal wire stent
US6517570B1 (en) 1994-08-31 2003-02-11 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US6331188B1 (en) 1994-08-31 2001-12-18 Gore Enterprise Holdings, Inc. Exterior supported self-expanding stent-graft
US8623065B2 (en) 1994-08-31 2014-01-07 W. L. Gore & Associates, Inc. Exterior supported self-expanding stent-graft
US6613072B2 (en) 1994-09-08 2003-09-02 Gore Enterprise Holdings, Inc. Procedures for introducing stents and stent-grafts
US7939000B2 (en) 1995-03-10 2011-05-10 Bard Peripheral Vascular, Inc. Methods for making an encapsulated stent and intraluminal delivery thereof
US8337650B2 (en) 1995-03-10 2012-12-25 Bard Peripheral Vascular, Inc. Methods for making a supported graft
US6758858B2 (en) 1995-03-10 2004-07-06 Bard Peripheral Vascular, Inc. Diametrically adaptable encapsulated stent and methods for deployment thereof
US6790226B2 (en) 1995-03-10 2004-09-14 Bard Peripheral Vascular, Inc. Endoluminal prosthesis with support wire
US8617441B2 (en) 1995-03-10 2013-12-31 Bard Peripheral Vascular, Inc. Methods for making an encapsulated stent
US6797217B2 (en) 1995-03-10 2004-09-28 Bard Peripheral Vascular, Inc. Methods for making encapsulated stent-grafts
US8647458B2 (en) 1995-03-10 2014-02-11 Bard Peripheral Vascular, Inc. Methods for making a supported graft
US6361637B2 (en) 1995-12-14 2002-03-26 Gore Enterprise Holdings, Inc. Method of making a kink resistant stent-graft
US6352553B1 (en) 1995-12-14 2002-03-05 Gore Enterprise Holdings, Inc. Stent-graft deployment apparatus and method
US6520986B2 (en) 1995-12-14 2003-02-18 Gore Enterprise Holdings, Inc. Kink resistant stent-graft
US8323328B2 (en) 1995-12-14 2012-12-04 W. L. Gore & Associates, Inc. Kink resistant stent-graft
US6878161B2 (en) * 1996-01-05 2005-04-12 Medtronic Vascular, Inc. Stent graft loading and deployment device and method
US20020177890A1 (en) * 1996-01-05 2002-11-28 Lenker Jay A. Stent graft loading and deployment device and method
US6544249B1 (en) * 1996-11-29 2003-04-08 The Lions Eye Institute Of Western Australia Incorporated Biological microfistula tube and implantation method and apparatus
US6551350B1 (en) 1996-12-23 2003-04-22 Gore Enterprise Holdings, Inc. Kink resistant bifurcated prosthesis
US6352561B1 (en) 1996-12-23 2002-03-05 W. L. Gore & Associates Implant deployment apparatus
US7682380B2 (en) 1996-12-23 2010-03-23 Gore Enterprise Holdings, Inc. Kink-resistant bifurcated prosthesis
US6723120B2 (en) 1997-04-15 2004-04-20 Advanced Cardiovascular Systems, Inc. Medicated porous metal prosthesis
US7699890B2 (en) 1997-04-15 2010-04-20 Advanced Cardiovascular Systems, Inc. Medicated porous metal prosthesis and a method of making the same
US20070282427A1 (en) * 1997-04-15 2007-12-06 Yan John Y Medicated Porous Metal Prosthesis And A Method Of Making The Same
US8172897B2 (en) 1997-04-15 2012-05-08 Advanced Cardiovascular Systems, Inc. Polymer and metal composite implantable medical devices
US7931931B2 (en) 1997-04-15 2011-04-26 Advanced Cardiovascular Systems, Inc. Medicated porous metal prosthesis and a method of making the same
US10028851B2 (en) 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US8007529B2 (en) 1997-04-15 2011-08-30 Advanced Cardiovascular Systems, Inc. Medicated porous metal prosthesis
US6497671B2 (en) * 1997-12-05 2002-12-24 Micrus Corporation Coated superelastic stent
US20030144731A1 (en) * 1998-02-05 2003-07-31 Medtronic, Inc. Radially-expandable stent and delivery system
US6613079B1 (en) * 1998-02-05 2003-09-02 Medtronic, Inc. Radially-expandable stent with controllable force profile
US6533807B2 (en) 1998-02-05 2003-03-18 Medtronic, Inc. Radially-expandable stent and delivery system
US10548750B2 (en) 1998-02-09 2020-02-04 Trivascular, Inc. Endovascular graft
US8801769B2 (en) 1998-02-09 2014-08-12 Trivascular, Inc. Endovascular graft
US8361136B2 (en) 1998-02-09 2013-01-29 Trivascular, Inc. Endovascular graft
US9867727B2 (en) 1998-02-09 2018-01-16 Trivascular, Inc. Endovascular graft
US8118858B2 (en) 1998-03-05 2012-02-21 Boston Scientific Scimed, Inc. Intraluminal stent
US8764815B2 (en) 1998-03-05 2014-07-01 Boston Scientific Scimed, Inc. Intraluminal stent
US20110015721A1 (en) * 1998-03-05 2011-01-20 Boston Scientific Scimed, Inc. Intraluminal Stent
US9925074B2 (en) 1999-02-01 2018-03-27 Board Of Regents, The University Of Texas System Plain woven stents
US8876880B2 (en) 1999-02-01 2014-11-04 Board Of Regents, The University Of Texas System Plain woven stents
US8974516B2 (en) 1999-02-01 2015-03-10 Board Of Regents, The University Of Texas System Plain woven stents
US8414635B2 (en) 1999-02-01 2013-04-09 Idev Technologies, Inc. Plain woven stents
US10213328B2 (en) 1999-02-02 2019-02-26 Bard Peripheral Vascular, Inc. Partial encapsulation of stents
US8617337B2 (en) 1999-02-02 2013-12-31 Bard Peripheral Vascular, Inc. Partial encapsulation of stents
US8771217B2 (en) 1999-04-26 2014-07-08 Glaukos Corporation Shunt device and method for treating ocular disorders
US9492320B2 (en) 1999-04-26 2016-11-15 Glaukos Corporation Shunt device and method for treating ocular disorders
US9827143B2 (en) 1999-04-26 2017-11-28 Glaukos Corporation Shunt device and method for treating ocular disorders
US7850637B2 (en) 1999-04-26 2010-12-14 Glaukos Corporation Shunt device and method for treating glaucoma
US10492950B2 (en) 1999-04-26 2019-12-03 Glaukos Corporation Shunt device and method for treating ocular disorders
US8388568B2 (en) 1999-04-26 2013-03-05 Glaukos Corporation Shunt device and method for treating ocular disorders
US8152752B2 (en) 1999-04-26 2012-04-10 Glaukos Corporation Shunt device and method for treating glaucoma
US10568762B2 (en) 1999-04-26 2020-02-25 Glaukos Corporation Stent for treating ocular disorders
US20040024446A1 (en) * 1999-07-02 2004-02-05 Scimed Life Systems, Inc. Helically formed stent/graft assembly
US8586125B2 (en) 1999-09-03 2013-11-19 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6602280B2 (en) 2000-02-02 2003-08-05 Trivascular, Inc. Delivery system and method for expandable intracorporeal device
US8808219B2 (en) 2000-04-14 2014-08-19 Glaukos Corporation Implant delivery device and methods thereof for treatment of ocular disorders
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6780164B2 (en) 2000-04-14 2004-08-24 Glaukos Corporation L-shaped implant with bi-directional flow
US8333742B2 (en) 2000-04-14 2012-12-18 Glaukos Corporation Method of delivering an implant for treating an ocular disorder
US8348877B2 (en) 2000-04-14 2013-01-08 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US7867205B2 (en) 2000-04-14 2011-01-11 Glaukos Corporation Method of delivering an implant for treating an ocular disorder
US8273050B2 (en) 2000-04-14 2012-09-25 Glaukos Corporation Ocular implant with anchor and therapeutic agent
US8801648B2 (en) 2000-04-14 2014-08-12 Glaukos Corporation Ocular implant with anchor and methods thereof
US8814820B2 (en) 2000-04-14 2014-08-26 Glaukos Corporation Ocular implant with therapeutic agent and methods thereof
US9789001B2 (en) 2000-04-14 2017-10-17 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US20030181848A1 (en) * 2000-04-14 2003-09-25 Bergheim Olav B. Implant with drug coating
US9993368B2 (en) 2000-04-14 2018-06-12 Glaukos Corporation System and method for treating an ocular disorder
US10485702B2 (en) 2000-04-14 2019-11-26 Glaukos Corporation System and method for treating an ocular disorder
US9066782B2 (en) 2000-04-14 2015-06-30 Dose Medical Corporation Ocular implant with therapeutic agents and methods thereof
US6451050B1 (en) * 2000-04-28 2002-09-17 Cardiovasc, Inc. Stent graft and method
US7335314B2 (en) 2000-09-28 2008-02-26 Advanced Cardiovascular Systems Inc. Method of making an implantable medical device
US20050033412A1 (en) * 2000-09-28 2005-02-10 Wu Steven Z. Method of making an implantable medical device
US6805898B1 (en) 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
US6770089B1 (en) * 2000-12-28 2004-08-03 Advanced Cardiovascular Systems, Inc. Hybrid stent fabrication using metal rings and polymeric links
US20050171595A1 (en) * 2001-03-06 2005-08-04 Feldman Marc D. Method and apparatus for stent deployment with enhanced delivery of bioactive agents
US7238199B2 (en) 2001-03-06 2007-07-03 The Board Of Regents Of The University Of Texas System Method and apparatus for stent deployment with enhanced delivery of bioactive agents
US7637936B2 (en) 2001-04-06 2009-12-29 Boston Scientific Scimed, Inc. Stent design
US8062244B2 (en) 2001-04-07 2011-11-22 Glaukos Corporation Self-trephining implant and methods thereof for treatment of ocular disorders
US7857782B2 (en) 2001-04-07 2010-12-28 Glaukos Corporation Ocular implant delivery system and method thereof
US8118768B2 (en) 2001-04-07 2012-02-21 Dose Medical Corporation Drug eluting ocular implant with anchor and methods thereof
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US10828473B2 (en) 2001-04-07 2020-11-10 Glaukos Corporation Ocular implant delivery system and methods thereof
US9572963B2 (en) 2001-04-07 2017-02-21 Glaukos Corporation Ocular disorder treatment methods and systems
US8579846B2 (en) 2001-04-07 2013-11-12 Glaukos Corporation Ocular implant systems
US9155654B2 (en) 2001-04-07 2015-10-13 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US9987472B2 (en) 2001-04-07 2018-06-05 Glaukos Corporation Ocular implant delivery systems
US8075511B2 (en) 2001-04-07 2011-12-13 Glaukos Corporation System for treating ocular disorders and methods thereof
US6761733B2 (en) 2001-04-11 2004-07-13 Trivascular, Inc. Delivery system and method for bifurcated endovascular graft
US6733521B2 (en) 2001-04-11 2004-05-11 Trivascular, Inc. Delivery system and method for endovascular graft
US8142364B2 (en) 2001-05-02 2012-03-27 Dose Medical Corporation Method of monitoring intraocular pressure and treating an ocular disorder
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
US6551352B2 (en) 2001-05-03 2003-04-22 Bionx Implants, Inc. Method for attaching axial filaments to a self expanding stent
WO2002089706A1 (en) * 2001-05-03 2002-11-14 Bionx Implants, Inc. Method for attaching axial filaments to a self expanding stent
US8337445B2 (en) 2001-05-03 2012-12-25 Glaukos Corporation Ocular implant with double anchor mechanism
US7918815B2 (en) 2001-05-22 2011-04-05 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US7691078B2 (en) 2001-05-22 2010-04-06 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20050187510A1 (en) * 2001-06-01 2005-08-25 Mcweeney John O. Compressible ureteral stent for comfort
US6887215B2 (en) 2001-06-01 2005-05-03 Boston Scientific Scimed, Inc. Compressible ureteral stent for comfort
US10285856B2 (en) 2001-08-28 2019-05-14 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US9561131B2 (en) 2001-08-28 2017-02-07 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US7879079B2 (en) 2001-08-28 2011-02-01 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US8257427B2 (en) 2001-09-11 2012-09-04 J.W. Medical Systems, Ltd. Expandable stent
US6790223B2 (en) 2001-09-21 2004-09-14 Scimed Life Systems, Inc. Delivering a uretheral stent
US9326876B2 (en) 2001-12-03 2016-05-03 J.W. Medical Systems Ltd. Apparatus and methods for delivery of multiple distributed stents
US8177831B2 (en) 2001-12-03 2012-05-15 Xtent, Inc. Stent delivery apparatus and method
US7892274B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US8083788B2 (en) 2001-12-03 2011-12-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US8080048B2 (en) 2001-12-03 2011-12-20 Xtent, Inc. Stent delivery for bifurcated vessels
US8702781B2 (en) 2001-12-03 2014-04-22 J.W. Medical Systems Ltd. Apparatus and methods for delivery of multiple distributed stents
US8070789B2 (en) 2001-12-03 2011-12-06 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US8016870B2 (en) 2001-12-03 2011-09-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US7938852B2 (en) 2001-12-03 2011-05-10 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
US8956398B2 (en) 2001-12-03 2015-02-17 J.W. Medical Systems Ltd. Custom length stent apparatus
US8016871B2 (en) 2001-12-03 2011-09-13 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US8574282B2 (en) 2001-12-03 2013-11-05 J.W. Medical Systems Ltd. Apparatus and methods for delivery of braided prostheses
US6599319B2 (en) * 2001-12-14 2003-07-29 Celanese Advanced Materials, Inc. Prosthetic ligament
US7766954B2 (en) 2001-12-20 2010-08-03 Trivascular2, Inc. Advanced endovascular graft
US8864814B2 (en) 2001-12-20 2014-10-21 Trivascular, Inc. Method of delivering advanced endovascular graft and system
US8241346B2 (en) 2001-12-20 2012-08-14 Trivascular, Inc. Endovascular graft and method of delivery
US20030212449A1 (en) * 2001-12-28 2003-11-13 Cox Daniel L. Hybrid stent
WO2003057077A1 (en) * 2001-12-28 2003-07-17 Advanced Cardiovascular Systems, Inc. Hybrid stent
US9220632B2 (en) 2002-03-07 2015-12-29 Glaukos Corporation Fluid infusion methods for ocular disorder treatment
US8617094B2 (en) 2002-03-07 2013-12-31 Glaukos Corporation Fluid infusion methods for glaucoma treatment
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US8882781B2 (en) 2002-03-15 2014-11-11 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US10485701B2 (en) 2002-04-08 2019-11-26 Glaukos Corporation Devices and methods for glaucoma treatment
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US7879001B2 (en) 2002-04-08 2011-02-01 Glaukos Corporation Devices and methods for treatment of ocular disorders
US9597230B2 (en) 2002-04-08 2017-03-21 Glaukos Corporation Devices and methods for glaucoma treatment
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US7207111B2 (en) 2002-04-18 2007-04-24 Ormco Corporation Method of manufacturing an endodontic instrument
US20060014480A1 (en) * 2002-04-18 2006-01-19 Ormco Corporation Method of manufacturing a dental instrument
US20040171333A1 (en) * 2002-04-18 2004-09-02 Ormco Corporaiton Method of manufacturing an endodontic instrument
US7779542B2 (en) 2002-04-18 2010-08-24 Ormco Corporation Method of manufacturing a dental instrument
US6783438B2 (en) 2002-04-18 2004-08-31 Ormco Corporation Method of manufacturing an endodontic instrument
US6805706B2 (en) 2002-08-15 2004-10-19 Gmp Cardiac Care, Inc. Stent-graft with rails
US8007459B2 (en) 2002-09-21 2011-08-30 Glaukos Corporation Ocular implant with anchoring mechanism and multiple outlets
US20060052861A1 (en) * 2002-12-24 2006-03-09 Novostent Corporation Vascular prothesis having interdigitating edges and methods of use
US7901448B2 (en) 2002-12-24 2011-03-08 Novostent Corporation Vascular prothesis having interdigitating edges and methods of use
US8740968B2 (en) 2003-01-17 2014-06-03 J.W. Medical Systems Ltd. Multiple independent nested stent structures and methods for their preparation and deployment
US8282680B2 (en) 2003-01-17 2012-10-09 J. W. Medical Systems Ltd. Multiple independent nested stent structures and methods for their preparation and deployment
US7367989B2 (en) 2003-02-27 2008-05-06 Scimed Life Systems, Inc. Rotating balloon expandable sheath bifurcation delivery
US7314480B2 (en) 2003-02-27 2008-01-01 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery
US20040215320A1 (en) * 2003-04-25 2004-10-28 James Machek Integral stent graft
US7789979B2 (en) 2003-05-02 2010-09-07 Gore Enterprise Holdings, Inc. Shape memory alloy articles with improved fatigue performance and methods therefor
US8177927B2 (en) 2003-05-02 2012-05-15 W. L. Gore & Associates, Inc. Method of making shape memory alloy articles with improved fatigue performance
US20040216814A1 (en) * 2003-05-02 2004-11-04 Dooley Bret A. Shape memory alloy articles with improved fatigue performance and methods therefore
US7811393B2 (en) 2003-05-02 2010-10-12 Gore Enterprise Holdings, Inc. Shape memory alloy articles with improved fatigue performance and methods therefor
US8709177B2 (en) 2003-05-02 2014-04-29 W. L. Gore & Associates, Inc. Shape memory alloy articles with improved fatigue performance and methods therefore
US20070088426A1 (en) * 2003-05-02 2007-04-19 Dooley Bert A Shape memory alloy articles with improved fatigue performance and methods therefore
US20100319815A1 (en) * 2003-05-02 2010-12-23 Dooley Bret A Method of making shape memory alloy articles with improved fatigue performance
US8216396B2 (en) 2003-05-02 2012-07-10 W. L. Gore & Associates, Inc. Shape memory alloy articles with improved fatigue performance and methods therefor
US7651529B2 (en) 2003-05-09 2010-01-26 Boston Scientific Scimed, Inc. Stricture retractor
US20040243215A1 (en) * 2003-05-27 2004-12-02 Kristoff Nelson Staged deployment endograft
US7101390B2 (en) * 2003-05-27 2006-09-05 Scimed Life Systems, Inc. Staged deployment endograft
US7297156B2 (en) * 2003-05-27 2007-11-20 Boston Scientific Corporation Staged deployment endograft
US20060229703A1 (en) * 2003-05-27 2006-10-12 Kristoff Nelson Staged deployment endograft
US7918881B2 (en) 2003-06-09 2011-04-05 Xtent, Inc. Stent deployment systems and methods
US8784472B2 (en) 2003-08-15 2014-07-22 Boston Scientific Scimed, Inc. Clutch driven stent delivery system
EP1518518A2 (en) * 2003-09-25 2005-03-30 Karel Volenec Stent designed to stop esophageal variceal bleeding
EP1518518A3 (en) * 2003-09-25 2005-04-13 Karel Volenec Stent designed to stop esophageal variceal bleeding
US7056337B2 (en) 2003-10-21 2006-06-06 Cook Incorporated Natural tissue stent
US20050085898A1 (en) * 2003-10-21 2005-04-21 Cook Incorporated. Natural tissue stent
WO2005039445A3 (en) * 2003-10-23 2005-07-21 James C Peacock Iii Stent-graft assembly formed insitu
US20060259125A1 (en) * 2003-10-23 2006-11-16 Peacock James C Iii System and method for forming composite stent-graft assembly in-situ
WO2005039445A2 (en) * 2003-10-23 2005-05-06 Peacock James C Iii Stent-graft assembly formed insitu
US8052912B2 (en) 2003-12-01 2011-11-08 Advanced Cardiovascular Systems, Inc. Temperature controlled crimping
US20050118344A1 (en) * 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US8585747B2 (en) 2003-12-23 2013-11-19 J.W. Medical Systems Ltd. Devices and methods for controlling and indicating the length of an interventional element
US9566179B2 (en) 2003-12-23 2017-02-14 J.W. Medical Systems Ltd. Devices and methods for controlling and indicating the length of an interventional element
US7686841B2 (en) 2003-12-29 2010-03-30 Boston Scientific Scimed, Inc. Rotating balloon expandable sheath bifurcation delivery system
US7922753B2 (en) 2004-01-13 2011-04-12 Boston Scientific Scimed, Inc. Bifurcated stent delivery system
US7803178B2 (en) 2004-01-30 2010-09-28 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
US8267989B2 (en) 2004-01-30 2012-09-18 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
EP2332493A1 (en) 2004-01-30 2011-06-15 TriVascular, Inc. Inflatable porous implants and methods for drug delivery
US8012192B2 (en) 2004-02-18 2011-09-06 Boston Scientific Scimed, Inc. Multi-stent delivery system
US7225518B2 (en) 2004-02-23 2007-06-05 Boston Scientific Scimed, Inc. Apparatus for crimping a stent assembly
US8333784B2 (en) 2004-02-24 2012-12-18 Boston Scientific Scimed, Inc. Rotatable catheter assembly
US7744619B2 (en) 2004-02-24 2010-06-29 Boston Scientific Scimed, Inc. Rotatable catheter assembly
US7922740B2 (en) 2004-02-24 2011-04-12 Boston Scientific Scimed, Inc. Rotatable catheter assembly
US8460358B2 (en) 2004-03-30 2013-06-11 J.W. Medical Systems, Ltd. Rapid exchange interventional devices and methods
US9050205B2 (en) 2004-05-25 2015-06-09 Covidien Lp Methods and apparatus for luminal stenting
US8623067B2 (en) 2004-05-25 2014-01-07 Covidien Lp Methods and apparatus for luminal stenting
US9125659B2 (en) 2004-05-25 2015-09-08 Covidien Lp Flexible vascular occluding device
US10004618B2 (en) 2004-05-25 2018-06-26 Covidien Lp Methods and apparatus for luminal stenting
US9801744B2 (en) 2004-05-25 2017-10-31 Covidien Lp Methods and apparatus for luminal stenting
US9393021B2 (en) 2004-05-25 2016-07-19 Covidien Lp Flexible vascular occluding device
US11771433B2 (en) 2004-05-25 2023-10-03 Covidien Lp Flexible vascular occluding device
US10765542B2 (en) 2004-05-25 2020-09-08 Covidien Lp Methods and apparatus for luminal stenting
US9855047B2 (en) 2004-05-25 2018-01-02 Covidien Lp Flexible vascular occluding device
US10918389B2 (en) 2004-05-25 2021-02-16 Covidien Lp Flexible vascular occluding device
US8617234B2 (en) 2004-05-25 2013-12-31 Covidien Lp Flexible vascular occluding device
US8628564B2 (en) 2004-05-25 2014-01-14 Covidien Lp Methods and apparatus for luminal stenting
US9295568B2 (en) 2004-05-25 2016-03-29 Covidien Lp Methods and apparatus for luminal stenting
US9700448B2 (en) 2004-06-28 2017-07-11 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8986362B2 (en) 2004-06-28 2015-03-24 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US7641681B2 (en) 2004-12-28 2010-01-05 Boston Scientific Scimed, Inc. Low profile stent-graft attachment
US20060142840A1 (en) * 2004-12-28 2006-06-29 Scimed Life Systems, Inc. Low profile stent-graft attachment
US20060149364A1 (en) * 2004-12-31 2006-07-06 Steven Walak Low profile vascular graft
US9592137B2 (en) 2005-04-04 2017-03-14 Flexible Stenting Solutions, Inc. Flexible stent
US7803180B2 (en) 2005-04-04 2010-09-28 Flexible Stenting Solutions, Inc. Flexible stent
US8652193B2 (en) 2005-05-09 2014-02-18 Angiomed Gmbh & Co. Medizintechnik Kg Implant delivery device
US20100049003A1 (en) * 2005-06-24 2010-02-25 Levy Elad I Expandable surgical site access system
WO2007002392A3 (en) * 2005-06-24 2007-05-10 Zimmer Spine Inc Expandable surgical site access system
WO2007002392A2 (en) * 2005-06-24 2007-01-04 Power Ten, Llc Expandable surgical site access system
US20070073375A1 (en) * 2005-09-23 2007-03-29 Boston Scientific Scimed, Inc. Secured stent delivery system
US7670365B2 (en) * 2005-09-23 2010-03-02 BostonScientific Scimed, Inc. Secured stent delivery system
US9579260B2 (en) 2005-10-13 2017-02-28 DePuy Synthes Products, Inc. Drug-impregnated encasement
US8900620B2 (en) 2005-10-13 2014-12-02 DePuy Synthes Products, LLC Drug-impregnated encasement
US20080262630A1 (en) * 2005-10-13 2008-10-23 Synthes (U.S.A. Drug-Impregnated Encasement
US10814112B2 (en) 2005-10-13 2020-10-27 DePuy Synthes Products, Inc. Drug-impregnated encasement
US20070129786A1 (en) * 2005-10-14 2007-06-07 Bradley Beach Helical stent
US8956400B2 (en) 2005-10-14 2015-02-17 Flexible Stenting Solutions, Inc. Helical stent
US7723422B2 (en) 2005-12-23 2010-05-25 Boston Scientific Scimed, Inc. Functionalized block copolymers
US20070149690A1 (en) * 2005-12-23 2007-06-28 Boston Scientific Scimed, Inc. Functionalized block copolymers
US10433988B2 (en) 2006-02-22 2019-10-08 Covidien Lp Stents having radiopaque mesh
US11382777B2 (en) 2006-02-22 2022-07-12 Covidien Lp Stents having radiopaque mesh
US9610181B2 (en) 2006-02-22 2017-04-04 Covidien Lp Stents having radiopaque mesh
US9320590B2 (en) 2006-02-22 2016-04-26 Covidien Lp Stents having radiopaque mesh
US9883957B2 (en) 2006-03-20 2018-02-06 J.W. Medical Systems Ltd. Apparatus and methods for deployment of linked prosthetic segments
US8652198B2 (en) 2006-03-20 2014-02-18 J.W. Medical Systems Ltd. Apparatus and methods for deployment of linked prosthetic segments
US9636254B2 (en) 2006-06-30 2017-05-02 Aquesys, Inc. Systems for reducing pressure in an organ
US20100121248A1 (en) * 2006-06-30 2010-05-13 Aquesys, Inc. Apparatus for reducing pressure in an organ
US20100119696A1 (en) * 2006-06-30 2010-05-13 Aquesys, Inc. Manufacture of an organ implant
US10085884B2 (en) 2006-06-30 2018-10-02 Aquesys, Inc. Intraocular devices
US10603163B2 (en) 2006-09-25 2020-03-31 Spirox, Inc. Nasal implant introduced through a non-surgical injection technique
US9408729B2 (en) 2006-10-22 2016-08-09 Idev Technologies, Inc. Secured strand end devices
US8419788B2 (en) 2006-10-22 2013-04-16 Idev Technologies, Inc. Secured strand end devices
US8966733B2 (en) 2006-10-22 2015-03-03 Idev Technologies, Inc. Secured strand end devices
US8739382B2 (en) 2006-10-22 2014-06-03 Idev Technologies, Inc. Secured strand end devices
US9895242B2 (en) 2006-10-22 2018-02-20 Idev Technologies, Inc. Secured strand end devices
US10470902B2 (en) 2006-10-22 2019-11-12 Idev Technologies, Inc. Secured strand end devices
US9149374B2 (en) 2006-10-22 2015-10-06 Idev Technologies, Inc. Methods for manufacturing secured strand end devices
US9585776B2 (en) 2006-10-22 2017-03-07 Idev Technologies, Inc. Secured strand end devices
US9408730B2 (en) 2006-10-22 2016-08-09 Idev Technologies, Inc. Secured strand end devices
US9629736B2 (en) 2006-10-22 2017-04-25 Idev Technologies, Inc. Secured strand end devices
US10828195B2 (en) 2006-11-10 2020-11-10 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US8506515B2 (en) 2006-11-10 2013-08-13 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US9962290B2 (en) 2006-11-10 2018-05-08 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US9622888B2 (en) 2006-11-16 2017-04-18 W. L. Gore & Associates, Inc. Stent having flexibly connected adjacent stent elements
US10456281B2 (en) 2006-11-16 2019-10-29 W.L. Gore & Associates, Inc. Stent having flexibly connected adjacent stent elements
US9457133B2 (en) 2007-02-20 2016-10-04 J.W. Medical Systems Ltd. Thermo-mechanically controlled implants and methods of use
US8980297B2 (en) 2007-02-20 2015-03-17 J.W. Medical Systems Ltd. Thermo-mechanically controlled implants and methods of use
US8623070B2 (en) 2007-03-08 2014-01-07 Thomas O. Bales Tapered helical stent and method for manufacturing the stent
US9339404B2 (en) 2007-03-22 2016-05-17 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8372131B2 (en) 2007-07-16 2013-02-12 Power Ten , LLC Surgical site access system and deployment device for same
US8500794B2 (en) 2007-08-02 2013-08-06 Flexible Stenting Solutions, Inc. Flexible stent
US8066755B2 (en) 2007-09-26 2011-11-29 Trivascular, Inc. System and method of pivoted stent deployment
US8226701B2 (en) 2007-09-26 2012-07-24 Trivascular, Inc. Stent and delivery system for deployment thereof
US8663309B2 (en) 2007-09-26 2014-03-04 Trivascular, Inc. Asymmetric stent apparatus and method
US10682222B2 (en) 2007-10-04 2020-06-16 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
US10159557B2 (en) 2007-10-04 2018-12-25 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
US8083789B2 (en) 2007-11-16 2011-12-27 Trivascular, Inc. Securement assembly and method for expandable endovascular device
US8328861B2 (en) 2007-11-16 2012-12-11 Trivascular, Inc. Delivery system and method for bifurcated graft
US20090143760A1 (en) * 2007-11-30 2009-06-04 Jacques Van Dam Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder
US9486219B2 (en) 2007-11-30 2016-11-08 Treus Medical, Inc. Biliary shunts, delivery systems, methods of using the same and kits therefor
US9282968B2 (en) 2007-11-30 2016-03-15 Treus Medical, Inc. Applicator for endoscopic treatment of biliary disease
US11103372B2 (en) 2008-01-11 2021-08-31 W. L. Gore & Associates, Inc. Stent having adjacent elements connected by flexible webs
US9943428B2 (en) 2008-01-11 2018-04-17 W. L. Gore & Associates, Inc. Stent having adjacent elements connected by flexible webs
US11865020B2 (en) 2008-01-11 2024-01-09 W. L. Gore & Associates, Inc. Stent having adjacent elements connected by flexible webs
US8926688B2 (en) 2008-01-11 2015-01-06 W. L. Gore & Assoc. Inc. Stent having adjacent elements connected by flexible webs
US8196279B2 (en) 2008-02-27 2012-06-12 C. R. Bard, Inc. Stent-graft covering process
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
US8333003B2 (en) 2008-05-19 2012-12-18 Boston Scientific Scimed, Inc. Bifurcation stent crimping systems and methods
US8133199B2 (en) 2008-08-27 2012-03-13 Boston Scientific Scimed, Inc. Electroactive polymer activation system for a medical device
US9730821B2 (en) 2008-09-25 2017-08-15 Advanced Bifurcation Systems, Inc. Methods and systems for treating a bifurcation with provisional side branch stenting
US10610391B2 (en) 2008-09-25 2020-04-07 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
US11426297B2 (en) 2008-09-25 2022-08-30 Advanced Bifurcation Systems Inc. Selective stent crimping
US10918506B2 (en) 2008-09-25 2021-02-16 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
US8828071B2 (en) 2008-09-25 2014-09-09 Advanced Bifurcation Systems, Inc. Methods and systems for ostial stenting of a bifurcation
US11000392B2 (en) 2008-09-25 2021-05-11 Advanced Bifurcation Systems Inc. Partially crimped stent
US11298252B2 (en) 2008-09-25 2022-04-12 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
US10219927B2 (en) 2008-09-25 2019-03-05 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation
US8795347B2 (en) 2008-09-25 2014-08-05 Advanced Bifurcation Systems, Inc. Methods and systems for treating a bifurcation with provisional side branch stenting
US9855158B2 (en) 2008-09-25 2018-01-02 Advanced Bifurcation Systems, Inc. Stent alignment during treatment of a bifurcation
US10219926B2 (en) 2008-09-25 2019-03-05 Advanced Bifurcation Systems Inc. Selective stent crimping
US11839562B2 (en) 2008-09-25 2023-12-12 Advanced Bifurcation Systems Inc. Partially crimped stent
US8808347B2 (en) 2008-09-25 2014-08-19 Advanced Bifurcation Systems, Inc. Stent alignment during treatment of a bifurcation
US8979917B2 (en) 2008-09-25 2015-03-17 Advanced Bifurcation Systems, Inc. System and methods for treating a bifurcation
US8769796B2 (en) 2008-09-25 2014-07-08 Advanced Bifurcation Systems, Inc. Selective stent crimping
US9737424B2 (en) 2008-09-25 2017-08-22 Advanced Bifurcation Systems, Inc. Partially crimped stent
US11857442B2 (en) 2008-09-25 2024-01-02 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation
US9724218B2 (en) 2008-09-25 2017-08-08 Advanced Bifurcation Systems, Inc. Methods and systems for ostial stenting of a bifurcation
US20100094394A1 (en) * 2008-10-06 2010-04-15 Bradley Beach Reconstrainable stent delivery system
US9149376B2 (en) 2008-10-06 2015-10-06 Cordis Corporation Reconstrainable stent delivery system
US10010438B2 (en) 2008-10-06 2018-07-03 Flexible Stenting Solutions, Inc. Reconstrainable stent delivery system
US20100094447A1 (en) * 2008-10-09 2010-04-15 Seiko Epson Corporation Operation sequence creating apparatus, method for controlling same, and program
US11806265B2 (en) 2008-11-19 2023-11-07 Spirox, Inc. Apparatus and methods for correcting nasal valve collapse
US9597220B2 (en) 2008-11-19 2017-03-21 Spirox, Inc. Apparatus and methods for correcting nasal valve collapse
US10786383B2 (en) 2008-11-19 2020-09-29 Spirox, Inc. Apparatus and methods for correcting nasal valve collapse
US20100286760A1 (en) * 2009-04-24 2010-11-11 Bradley Beach Flexible devices
US9901347B2 (en) 2009-05-29 2018-02-27 Terus Medical, Inc. Biliary shunts, delivery systems, and methods of using the same
US10660751B2 (en) 2009-12-08 2020-05-26 Cardiovalve Ltd. Prosthetic heart valve with upper skirt
US10548726B2 (en) 2009-12-08 2020-02-04 Cardiovalve Ltd. Rotation-based anchoring of an implant
US11351026B2 (en) 2009-12-08 2022-06-07 Cardiovalve Ltd. Rotation-based anchoring of an implant
US11141268B2 (en) 2009-12-08 2021-10-12 Cardiovalve Ltd. Prosthetic heart valve with upper and lower skirts
US11839541B2 (en) 2009-12-08 2023-12-12 Cardiovalve Ltd. Prosthetic heart valve with upper skirt
US9788941B2 (en) 2010-03-10 2017-10-17 Mitraltech Ltd. Axially-shortening prosthetic valve
US11109964B2 (en) 2010-03-10 2021-09-07 Cardiovalve Ltd. Axially-shortening prosthetic valve
US9763657B2 (en) 2010-07-21 2017-09-19 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US10925595B2 (en) 2010-07-21 2021-02-23 Cardiovalve Ltd. Valve prosthesis configured for deployment in annular spacer
US11426155B2 (en) 2010-07-21 2022-08-30 Cardiovalve Ltd. Helical anchor implantation
US11653910B2 (en) 2010-07-21 2023-05-23 Cardiovalve Ltd. Helical anchor implantation
US10531872B2 (en) 2010-07-21 2020-01-14 Cardiovalve Ltd. Valve prosthesis configured for deployment in annular spacer
US10512456B2 (en) 2010-07-21 2019-12-24 Cardiovalve Ltd. Techniques for percutaneous mitral valve replacement and sealing
US9283116B2 (en) 2010-11-15 2016-03-15 Aquesys, Inc. Intraocular shunt deployment device
US8852256B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for intraocular shunt placement
US8308701B2 (en) 2010-11-15 2012-11-13 Aquesys, Inc. Methods for deploying intraocular shunts
US8974511B2 (en) 2010-11-15 2015-03-10 Aquesys, Inc. Methods for treating closed angle glaucoma
US9980854B2 (en) 2010-11-15 2018-05-29 Aquesys, Inc. Shunt placement through the sclera
US8585629B2 (en) 2010-11-15 2013-11-19 Aquesys, Inc. Systems for deploying intraocular shunts
US9877866B2 (en) 2010-11-15 2018-01-30 Aquesys, Inc. Intraocular shunt placement
US10004638B2 (en) 2010-11-15 2018-06-26 Aquesys, Inc. Intraocular shunt delivery
US8663303B2 (en) 2010-11-15 2014-03-04 Aquesys, Inc. Methods for deploying an intraocular shunt from a deployment device and into an eye
US8721702B2 (en) 2010-11-15 2014-05-13 Aquesys, Inc. Intraocular shunt deployment devices
US8758290B2 (en) 2010-11-15 2014-06-24 Aquesys, Inc. Devices and methods for implanting a shunt in the suprachoroidal space
US10940040B2 (en) 2010-11-15 2021-03-09 Aquesys, Inc. Intraocular shunt placement
US9393153B2 (en) 2010-11-15 2016-07-19 Aquesys, Inc. Methods for intraocular shunt placement
US9693901B2 (en) 2010-11-15 2017-07-04 Aquesys, Inc. Shunt placement through the sclera
US9326891B2 (en) 2010-11-15 2016-05-03 Aquesys, Inc. Methods for deploying intraocular shunts
US10307293B2 (en) 2010-11-15 2019-06-04 Aquesys, Inc. Methods for intraocular shunt placement
US9017276B2 (en) 2010-11-15 2015-04-28 Aquesys, Inc. Shunt placement through the sclera
US8801766B2 (en) 2010-11-15 2014-08-12 Aquesys, Inc. Devices for deploying intraocular shunts
US8828070B2 (en) 2010-11-15 2014-09-09 Aquesys, Inc. Devices for deploying intraocular shunts
US8852137B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for implanting a soft gel shunt in the suprachoroidal space
US9095411B2 (en) 2010-11-15 2015-08-04 Aquesys, Inc. Devices for deploying intraocular shunts
US9192516B2 (en) 2010-11-15 2015-11-24 Aquesys, Inc. Intraocular shunt placement
US10842671B2 (en) 2010-11-15 2020-11-24 Aquesys, Inc. Intraocular shunt placement in the suprachoroidal space
US10285832B2 (en) 2011-02-08 2019-05-14 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation with a fully crimped stent
US9254210B2 (en) 2011-02-08 2016-02-09 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
US11484424B2 (en) 2011-02-08 2022-11-01 Advanced Bifurcation Systems Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
US10406010B2 (en) 2011-02-08 2019-09-10 Advanced Bifurcation Systems Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
US11717428B2 (en) 2011-02-08 2023-08-08 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation with a fully crimped stent
US11000393B2 (en) 2011-02-08 2021-05-11 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation with a fully crimped stent
US9364356B2 (en) 2011-02-08 2016-06-14 Advanced Bifurcation System, Inc. System and methods for treating a bifurcation with a fully crimped stent
US11690712B2 (en) 2011-08-05 2023-07-04 Cardiovalve Ltd. Clip-secured implant for heart valve
US10376361B2 (en) 2011-08-05 2019-08-13 Cardiovalve Ltd. Techniques for percutaneous mitral valve replacement and sealing
US10245143B2 (en) 2011-08-05 2019-04-02 Cardiovalve Ltd. Techniques for percutaneous mitral valve replacement and sealing
US10226341B2 (en) 2011-08-05 2019-03-12 Cardiovalve Ltd. Implant for heart valve
US11291547B2 (en) 2011-08-05 2022-04-05 Cardiovalve Ltd. Leaflet clip with collars
US11291545B2 (en) 2011-08-05 2022-04-05 Cardiovalve Ltd. Implant for heart valve
US11291546B2 (en) 2011-08-05 2022-04-05 Cardiovalve Ltd. Leaflet clip with collars
US11344410B2 (en) 2011-08-05 2022-05-31 Cardiovalve Ltd. Implant for heart valve
US10702385B2 (en) 2011-08-05 2020-07-07 Cardiovalve Ltd. Implant for heart valve
US20140324164A1 (en) * 2011-08-05 2014-10-30 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US10695173B2 (en) 2011-08-05 2020-06-30 Cardiovalve Ltd. Techniques for percutaneous mitral valve replacement and sealing
US9387078B2 (en) 2011-08-05 2016-07-12 Mitraltech Ltd. Percutaneous mitral valve replacement and sealing
US11369469B2 (en) 2011-08-05 2022-06-28 Cardiovalve Ltd. Method for use at a heart valve
US11517436B2 (en) 2011-08-05 2022-12-06 Cardiovalve Ltd. Implant for heart valve
US11517429B2 (en) 2011-08-05 2022-12-06 Cardiovalve Ltd. Apparatus for use at a heart valve
US11864995B2 (en) 2011-08-05 2024-01-09 Cardiovalve Ltd. Implant for heart valve
US11363951B2 (en) 2011-09-13 2022-06-21 Glaukos Corporation Intraocular physiological sensor
US8852136B2 (en) 2011-12-08 2014-10-07 Aquesys, Inc. Methods for placing a shunt into the intra-scleral space
US10314743B2 (en) 2011-12-08 2019-06-11 Aquesys, Inc. Intraocular shunt manufacture
US9592154B2 (en) 2011-12-08 2017-03-14 Aquesys, Inc. Intraocular shunt manufacture
US9113994B2 (en) 2011-12-08 2015-08-25 Aquesys, Inc. Intraocular shunt manufacture
US9883969B2 (en) 2011-12-08 2018-02-06 Aquesys, Inc. Intrascleral shunt placement
US9271869B2 (en) 2011-12-08 2016-03-01 Aquesys, Inc. Intrascleral shunt placement
US8765210B2 (en) 2011-12-08 2014-07-01 Aquesys, Inc. Systems and methods for making gelatin shunts
US10080682B2 (en) 2011-12-08 2018-09-25 Aquesys, Inc. Intrascleral shunt placement
US9095413B2 (en) 2011-12-08 2015-08-04 Aquesys, Inc. Intraocular shunt manufacture
US10617653B2 (en) 2011-12-28 2020-04-14 DePuy Synthes Products, Inc. Films and methods of manufacture
US9381683B2 (en) 2011-12-28 2016-07-05 DePuy Synthes Products, Inc. Films and methods of manufacture
US10695203B2 (en) * 2012-02-14 2020-06-30 W. L. Gore & Associates, Inc. Endoprosthesis having aligned legs for ease of cannulation
US20130211501A1 (en) * 2012-02-14 2013-08-15 W. L. Gore & Associates, Inc. Endoprosthesis having aligned legs for ease of cannulation
US9687371B2 (en) * 2012-02-14 2017-06-27 W. L. Gore & Associates, Inc. Endoprosthesis having aligned legs for ease of cannulation
US10195063B2 (en) 2012-02-14 2019-02-05 W. L. Gore & Associates, Inc. Endoprosthesis having aligned legs for ease of cannulation
US11672682B2 (en) 2012-02-14 2023-06-13 W. L. Gore & Associates, Inc. Endoprosthesis having aligned legs for ease of cannulation
US10271989B2 (en) 2012-03-26 2019-04-30 Glaukos Corporation System and method for delivering multiple ocular implants
US11197780B2 (en) 2012-03-26 2021-12-14 Glaukos Corporation System and method for delivering multiple ocular implants
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
US9066825B2 (en) 2012-05-14 2015-06-30 C.R. Bard, Inc. Uniformly expandable stent
US10588765B2 (en) 2012-05-14 2020-03-17 C. R. Bard, Inc. Uniformly expandable stent
US9114001B2 (en) 2012-10-30 2015-08-25 Covidien Lp Systems for attaining a predetermined porosity of a vascular device
US9301831B2 (en) 2012-10-30 2016-04-05 Covidien Lp Methods for attaining a predetermined porosity of a vascular device
US9907643B2 (en) 2012-10-30 2018-03-06 Covidien Lp Systems for attaining a predetermined porosity of a vascular device
US10206798B2 (en) 2012-10-31 2019-02-19 Covidien Lp Methods and systems for increasing a density of a region of a vascular device
US9452070B2 (en) 2012-10-31 2016-09-27 Covidien Lp Methods and systems for increasing a density of a region of a vascular device
US10952878B2 (en) 2012-10-31 2021-03-23 Covidien Lp Methods and systems for increasing a density of a region of a vascular device
US9943427B2 (en) 2012-11-06 2018-04-17 Covidien Lp Shaped occluding devices and methods of using the same
US10500040B2 (en) 2012-11-13 2019-12-10 Cardiovalve Ltd. Percutaneously-deliverable dual-frame valve
US9498332B2 (en) 2012-11-13 2016-11-22 Mitraltech Ltd. Percutaneously-deliverable mechanical valve
US10045845B2 (en) 2012-11-13 2018-08-14 Mitraltech Ltd. Percutaneously-deliverable mechanical valve
US11135059B2 (en) 2013-01-24 2021-10-05 Cardiovalve Ltd. Prosthetic valve and upstream support therefor
US10835377B2 (en) 2013-01-24 2020-11-17 Cardiovalve Ltd. Rolled prosthetic valve support
US9681952B2 (en) 2013-01-24 2017-06-20 Mitraltech Ltd. Anchoring of prosthetic valve supports
US10631982B2 (en) 2013-01-24 2020-04-28 Cardiovale Ltd. Prosthetic valve and upstream support therefor
US11844691B2 (en) 2013-01-24 2023-12-19 Cardiovalve Ltd. Partially-covered prosthetic valves
US9561122B2 (en) 2013-02-05 2017-02-07 Covidien Lp Vascular device for aneurysm treatment and providing blood flow into a perforator vessel
US9157174B2 (en) 2013-02-05 2015-10-13 Covidien Lp Vascular device for aneurysm treatment and providing blood flow into a perforator vessel
US10159600B2 (en) 2013-02-19 2018-12-25 Aquesys, Inc. Adjustable intraocular flow regulation
US9125723B2 (en) 2013-02-19 2015-09-08 Aquesys, Inc. Adjustable glaucoma implant
US10195078B2 (en) 2013-02-19 2019-02-05 Aquesys, Inc. Adjustable intraocular flow regulation
US10195079B2 (en) 2013-02-19 2019-02-05 Aquesys, Inc. Adjustable intraocular implant
US9610195B2 (en) 2013-02-27 2017-04-04 Aquesys, Inc. Intraocular shunt implantation methods and devices
US10524959B2 (en) 2013-02-27 2020-01-07 Aquesys, Inc. Intraocular shunt implantation methods and devices
US11890186B2 (en) 2013-02-27 2024-02-06 Spirox, Inc. Nasal implants and systems and methods of use
US9480594B2 (en) 2013-02-27 2016-11-01 Spirox, Inc. Nasal implants and systems and methods of use
US10588740B2 (en) 2013-02-27 2020-03-17 Spirox, Inc . Nasal implants and systems and methods of use
USD723165S1 (en) 2013-03-12 2015-02-24 C. R. Bard, Inc. Stent
US10849558B2 (en) 2013-03-13 2020-12-01 Glaukos Corporation Intraocular physiological sensor
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US10285853B2 (en) 2013-03-15 2019-05-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US11559430B2 (en) 2013-03-15 2023-01-24 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US11523938B2 (en) 2013-03-15 2022-12-13 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US10188551B2 (en) 2013-03-15 2019-01-29 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10500304B2 (en) 2013-06-21 2019-12-10 DePuy Synthes Products, Inc. Films and methods of manufacture
US11298264B2 (en) 2013-06-28 2022-04-12 Aquesys, Inc. Intraocular shunt implantation
US10369048B2 (en) 2013-06-28 2019-08-06 Aquesys, Inc. Intraocular shunt implantation
US9808373B2 (en) 2013-06-28 2017-11-07 Aquesys, Inc. Intraocular shunt implantation
US9585790B2 (en) 2013-11-14 2017-03-07 Aquesys, Inc. Intraocular shunt inserter
US10653555B2 (en) 2013-11-14 2020-05-19 Aquesys, Inc. Intraocular shunt insertion techniques
US10470928B2 (en) 2013-11-14 2019-11-12 Aquesys, Inc. Intraocular shunt inserter
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10492908B2 (en) 2014-07-30 2019-12-03 Cardiovalve Ltd. Anchoring of a prosthetic valve
US10980631B2 (en) 2014-08-26 2021-04-20 Spirox, Inc. Nasal implants and systems and method of use
US10398545B2 (en) 2014-08-26 2019-09-03 Spirox, Inc. Nasal implants and systems and method of use
US11857444B2 (en) 2014-11-26 2024-01-02 W. L. Gore & Associates, Inc. Balloon expandable endoprosthesis
US10299948B2 (en) 2014-11-26 2019-05-28 W. L. Gore & Associates, Inc. Balloon expandable endoprosthesis
US11285029B2 (en) 2014-11-26 2022-03-29 W. L. Gore & Associates, Inc. Balloon expandable endoprosthesis
US10543116B2 (en) 2014-11-26 2020-01-28 W. L. Gore & Associates, Inc. Balloon expandable endoprosthesis
US10206801B2 (en) * 2014-12-29 2019-02-19 Cook Medical Technologies Llc Trigger wire arrangements for endografts
US20160184116A1 (en) * 2014-12-29 2016-06-30 Cook Medical Technologies Llc Trigger wire arrangements for endografts
US10507105B2 (en) 2015-02-05 2019-12-17 Cardiovalve Ltd. Prosthetic valve with tissue anchors free from lateral interconnections
US11793635B2 (en) 2015-02-05 2023-10-24 Cardiovalve Ltd. Prosthetic valve with angularly offset frames
US11534298B2 (en) 2015-02-05 2022-12-27 Cardiovalve Ltd. Prosthetic valve with s-shaped tissue anchors
US10357360B2 (en) 2015-02-05 2019-07-23 Cardiovalve Ltd. Prosthetic valve with aligned inner and outer frames
US10667908B2 (en) 2015-02-05 2020-06-02 Cardiovalve Ltd. Prosthetic valve with S-shaped tissue anchors
US10463488B2 (en) 2015-02-05 2019-11-05 Cardiovalve Ltd. Prosthetic valve with separably-deployable valve body and tissue anchors
US9974651B2 (en) 2015-02-05 2018-05-22 Mitral Tech Ltd. Prosthetic valve with axially-sliding frames
US10973636B2 (en) 2015-02-05 2021-04-13 Cardiovalve Ltd. Prosthetic valve with tissue anchors free from lateral interconnections
US10463487B2 (en) 2015-02-05 2019-11-05 Cardiovalve Ltd. Prosthetic valve delivery system with independently-movable capsule portions
US10695177B2 (en) 2015-02-05 2020-06-30 Cardiovalve Ltd. Prosthetic valve with aligned inner and outer frames
US10390952B2 (en) 2015-02-05 2019-08-27 Cardiovalve Ltd. Prosthetic valve with flexible tissue anchor portions
US10449047B2 (en) 2015-02-05 2019-10-22 Cardiovalve Ltd. Prosthetic heart valve with compressible frames
US10722360B2 (en) 2015-02-05 2020-07-28 Cardiovalve Ltd. Prosthetic valve with radially-deflectable tissue anchors
US10918481B2 (en) 2015-02-05 2021-02-16 Cardiovalve Ltd. Techniques for deployment of a prosthetic valve
US11801135B2 (en) 2015-02-05 2023-10-31 Cardiovalve Ltd. Techniques for deployment of a prosthetic valve
US10849748B2 (en) 2015-02-05 2020-12-01 Cardiovalve Ltd. Prosthetic valve delivery system with independently-movable capsule portions
US11793638B2 (en) 2015-02-05 2023-10-24 Cardiovalve Ltd. Prosthetic valve with pivoting tissue anchor portions
US10426610B2 (en) 2015-02-05 2019-10-01 Cardiovalve Ltd. Prosthetic valve with radially-deflectable tissue anchors
US10736742B2 (en) 2015-02-05 2020-08-11 Cardiovalve Ltd. Prosthetic valve with atrial arms
US10524903B2 (en) 2015-02-05 2020-01-07 Cardiovalve Ltd. Prosthetic valve with aligned inner and outer frames
US10682227B2 (en) 2015-02-05 2020-06-16 Cardiovalve Ltd. Prosthetic valve with pivoting tissue anchor portions
US10758344B2 (en) 2015-02-05 2020-09-01 Cardiovalve Ltd. Prosthetic valve with angularly offset frames
US10888422B2 (en) 2015-02-05 2021-01-12 Cardiovalve Ltd. Prosthetic valve with flexible tissue anchor portions
US11672658B2 (en) 2015-02-05 2023-06-13 Cardiovalve Ltd. Prosthetic valve with aligned inner and outer frames
US10864078B2 (en) 2015-02-05 2020-12-15 Cardiovalve Ltd. Prosthetic valve with separably-deployable valve body and tissue anchors
US11612517B2 (en) 2015-06-03 2023-03-28 Aquesys, Inc. Ab externo intraocular shunt placement
US10463537B2 (en) 2015-06-03 2019-11-05 Aquesys Inc. Ab externo intraocular shunt placement
US10470927B2 (en) 2015-06-03 2019-11-12 Aquesys, Inc. AB externo intraocular shunt placement
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11737865B2 (en) 2015-09-25 2023-08-29 Spirox, Inc. Nasal implants and systems and method of use
US10993800B2 (en) 2015-09-25 2021-05-04 Spirox, Inc. Nasal implants and systems and method of use
US11298117B2 (en) 2016-02-16 2022-04-12 Cardiovalve Ltd. Techniques for providing a replacement valve and transseptal communication
US10531866B2 (en) 2016-02-16 2020-01-14 Cardiovalve Ltd. Techniques for providing a replacement valve and transseptal communication
US10987133B2 (en) 2016-05-02 2021-04-27 Entellus Medical, Inc. Nasal valve implants and methods of implanting the same
US11779481B2 (en) 2016-05-25 2023-10-10 W. L. Gore & Associates, Inc. Controlled endoprosthesis balloon expansion
US10568752B2 (en) 2016-05-25 2020-02-25 W. L. Gore & Associates, Inc. Controlled endoprosthesis balloon expansion
US10667947B2 (en) 2016-06-02 2020-06-02 Aquesys, Inc. Intraocular drug delivery
US10856975B2 (en) 2016-08-10 2020-12-08 Cardiovalve Ltd. Prosthetic valve with concentric frames
USD800908S1 (en) 2016-08-10 2017-10-24 Mitraltech Ltd. Prosthetic valve element
US11779458B2 (en) 2016-08-10 2023-10-10 Cardiovalve Ltd. Prosthetic valve with leaflet connectors
US10335264B2 (en) * 2017-03-10 2019-07-02 Byung Choo Moon Vascular graft
US11793633B2 (en) 2017-08-03 2023-10-24 Cardiovalve Ltd. Prosthetic heart valve
USD841813S1 (en) 2017-08-03 2019-02-26 Cardiovalve Ltd. Prosthetic heart valve element
US11571298B2 (en) 2017-08-03 2023-02-07 Cardiovalve Ltd. Prosthetic valve with appendages
US11246704B2 (en) 2017-08-03 2022-02-15 Cardiovalve Ltd. Prosthetic heart valve
USD841812S1 (en) 2017-08-03 2019-02-26 Cardiovalve Ltd. Prosthetic heart valve element
US10537426B2 (en) 2017-08-03 2020-01-21 Cardiovalve Ltd. Prosthetic heart valve
US10575948B2 (en) 2017-08-03 2020-03-03 Cardiovalve Ltd. Prosthetic heart valve
US10654230B2 (en) 2017-08-28 2020-05-19 The Boeing Company Methods of forming a cored composite laminate
US10888421B2 (en) 2017-09-19 2021-01-12 Cardiovalve Ltd. Prosthetic heart valve with pouch
US11116625B2 (en) 2017-09-28 2021-09-14 Glaukos Corporation Apparatus and method for controlling placement of intraocular implants
US11246753B2 (en) 2017-11-08 2022-02-15 Aquesys, Inc. Manually adjustable intraocular flow regulation
US11382746B2 (en) 2017-12-13 2022-07-12 Cardiovalve Ltd. Prosthetic valve and delivery tool therefor
US11872131B2 (en) 2017-12-13 2024-01-16 Cardiovalve Ltd. Prosthetic valve and delivery tool therefor
US11872124B2 (en) 2018-01-10 2024-01-16 Cardiovalve Ltd. Temperature-control during crimping of an implant
US11633277B2 (en) 2018-01-10 2023-04-25 Cardiovalve Ltd. Temperature-control during crimping of an implant
US10952898B2 (en) 2018-03-09 2021-03-23 Aquesys, Inc. Intraocular shunt inserter
US11135089B2 (en) 2018-03-09 2021-10-05 Aquesys, Inc. Intraocular shunt inserter
EP3622922A1 (en) 2018-09-13 2020-03-18 ETH Zürich Self-expandable stent, method and device to produce the self-expandable stent
WO2020052870A1 (en) 2018-09-13 2020-03-19 Eth Zurich Self-expandable stent, method and device to produce the self-expandable stent
US11931071B2 (en) 2021-03-28 2024-03-19 Entellus Medical, Inc. Nasal valve implants and methods of implanting the same

Also Published As

Publication number Publication date
US5876432A (en) 1999-03-02

Similar Documents

Publication Publication Date Title
US6165210A (en) Self-expandable helical intravascular stent and stent-graft
US6017362A (en) Folding self-expandable intravascular stent
EP0754016B1 (en) Self-expandable stent and stent-graft
US6015429A (en) Procedures for introducing stents and stent-grafts
US8623065B2 (en) Exterior supported self-expanding stent-graft
AU783826B2 (en) Spider silk covered stent
US20020156523A1 (en) Exterior supported self-expanding stent-graft
US5556414A (en) Composite intraluminal graft
EP0689805B1 (en) Bistable luminal graft endoprostheses
US20060122691A1 (en) Hybrid stent
EP1263348B1 (en) Intraluminal prosthesis
WO1996021404A1 (en) Kink-resistant stent-graft
WO1996021404A9 (en) Kink-resistant stent-graft

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROGRAFT MEDICAL, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RHEE, WOONZA;MCCULLOUGH, KIMBERLY A.;REEL/FRAME:007041/0234;SIGNING DATES FROM 19940603 TO 19940606

Owner name: PROGRAFT MEDICAL, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAU, LILIP;MARONEY, CHARLES THOMAS;HARTIGAN, WILLIAM M.;REEL/FRAME:007041/0230

Effective date: 19940615

AS Assignment

Owner name: GORE ENTERPRISE HOLDINGS, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROGRAFT MEDICAL, INC.;REEL/FRAME:010450/0097

Effective date: 19980424

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: W. L. GORE & ASSOCIATES, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GORE ENTERPRISE HOLDINGS, INC.;REEL/FRAME:027906/0508

Effective date: 20120130

FPAY Fee payment

Year of fee payment: 12